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ABSTRACT 
Oxidative stress is a key pathophysiological mechanism contributing to the 
selective degeneration of dopaminergic neurons in Parkinson’s disease. 
Unraveling the molecular mechanisms underlying various stages of oxidative 
neuronal damage is critical to better understanding the diseases and 
developing new treatment modalities.  We previously showed that protein 
kinase C delta (PKCδ) proteolytic activation during the late stages of 
oxidative stress is a key proapoptotic signaling mechanism that contributes to 
oxidative damage in Parkinson's disease (PD) models.  The time course 
studies revealed that PKCδ activation precedes apoptotic cell death and that 
cells resisted early insults of oxidative damage, suggesting that some intrinsic 
compensatory response protects neurons from early oxidative insult.  In this 
study, we identified that protein kinase D1 (PKD1) functions as a key anti-
apoptotic kinase to protect neuronal cells against early stages of oxidative 
stress.  Exposure of dopaminergic neuronal cells to H2O2 and 6-OHDA 
induced PKD1 activation loop (PKD1S744/748) phosphorylation long before 
induction of neuronal cell death.  Blockade of PKCδ cleavage, PKCδ 
knockdown or overexpression of a cleavage-resistant PKCδ mutant 
effectively attenuated PKD1 activation, indicating that PKCδ proteolytic 
activation regulates PKD1 phosphorylation.  Furthermore, the PKCδ catalytic 
fragment, but not the regulatory fragment, increased PKD1 activation, 
confirming PKCδ activity modulates PKD1 activation.  We also identified that 
phosphorylation of S916 at the C-terminal is a preceding event required for 
PKD1 activation loop phosphorylation.  Importantly, negative modulation of 
PKD1 by the RNAi knockdown or overexpression of PKD1S916A phospho-
defective mutants augmented oxidative stress-induced apoptosis, while 
positive modulation of PKD1 by the overexpression of full length PKD1 or 
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constitutively active PKD1 plasmids attenuated oxidative stress-induced 
apoptosis, suggesting an anti-apoptotic role for PKD1 during oxidative 
neuronal injury.  
 
Since we showed the importance of PKD1 activation in cell culture models of 
Parkinson’s disease, we further proceeded to characterize PKD1 signal 
transduction involved in a pre-clinical model of Parkinson’s disease.  
Exposure of dopaminergic neuronal cells or primary mesencephalic neurons 
to MPP+ induced PKD1 activation loop (PKD1S744/748) phosphorylation and 
activation. PKD1 is activated and translocates to the nucleus in the nigral 
dopaminergic neurons of mice exposed to acute MPTP treatment.  Inhibiton 
of PKCδ activation by siRNA knockdown or DEVD-fmk prevented PKD1 
activation during MPP+ treatment in dopaminergic neuronal cells. To further 
validate this finding, we used the PKCδ knock-out (PKCδ -/-) mouse model. 
PKD1 was not activated in the nigral dopaminergic neurons of PKCδ knock-
out (PKCδ -/-) mice exposed to acute MPTP treatment.  Earlier we reported 
that Fyn kinase regulates PKCδ in dopaminergic cells.  So we used a Fyn 
knockout (Fyn -/-) mouse model to test the hypothesis that Fyn kinase acts as 
an upstream regulator of PKCδ-PKD1 signaling in PD. PKD1 was not 
activated in nigral dopaminergic neurons of Fyn knockout (Fyn -/-) mice 
exposed to acute MPTP treatment.    We also identified that phosphorylation 
of S916 at the C-terminal occurs in nigral dopaminergic neurons of mice 
exposed to MPTP and S916 phosphorylation  does not occur in (PKCδ -/-) 
mice, confirming PKCδ’s tight control over PKD1 activation.  Further, 
dopaminergic neurons co-treated with the PKD1 inhibitor kbNB 142-70 and 
exposed to MPP+ exacerbated neuronal death, confirming the survival role of 
PKD1. Consistent with other results, PKD1 was activated in the nigral 
dopaminergic neurons of human post-mortem PD brains. Having confirmed 
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that positive modulation of PKD1 can be a novel neuroprotective strategy, we 
took a translational approach by developing PKD1 activator and 
characterizing the protective function in pre-clinical models of Parkinson’s 
disease.  Positive genetic modulation of PKD1 by overexpression of 
constitutively active PKD1 protected against MPP+-induced toxicity.  
Pharmacological activation by rosiglitazone protected against while inhibition 
by kbNB 142-70 exacerbated MPP+ and 6-OHDA toxicity in cell culture PD 
models. Peptides were rationally designed and screened for their ability to 
activate PKD1 using various screening methods. Peptide AK-P4 was 
identified to activate PKD1 specifically and protect against MPP+ and 6-
OHDA in both N27 cells and primary mesencephalic neurons. Further, AK-P4 
tagged with the TAT sequence (AK-P4T) delivered using intravenous 
injections activated PKD1 in mice. The neuroprotective effects of AK-P4T 
were tested using the subchronic MPTP mouse model. Co-treatment with AK-
P4T restored the neurotransmitter levels and the behavioral and locomotor 
activities of the MPTP treated mice significantly.   
 
Collectively, we show that PKD1 is regulated in a Fyn- PKCδ dependent 
manner and represents a novel intrinsic protective response in counteracting 
early stage oxidative damage in PD. Further, we demonstrate that the 
rationally designed PKD1 activator peptide AK-P4T positively modulated 
PKD1 and protected against neurodegeneration in the pre-clinical models of 
PD. Overall, that positive modulation of PKD1 by AK-P4T suggests its 
promise as a potential therapeutic agent against PD.
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CHAPTER 1: GENERAL INTRODUCTION 
Dissertation organization 
An Alternative thesis format is used for this thesis, which includes modified 
versions of manuscripts either published or to be submitted for publication. 
The thesis contains a general introduction, four research papers, a general 
conclusion, and an acknowledgement. References for each individual section 
are listed at the end of corresponding chapters, except for the background 
and literature review: references for these are listed following the general 
conclusion. The general introduction (Chapter I) outlines the current 
knowledge of the Parkinson’s disease etiology and therapies and covers the 
overview of the research objective. Background and literature review I 
provide background information on Parkinson’s disease, current available 
symptomatic / protective strategies and the novel signal transduction therapy 
approaches. Background and literature review II of the chapter summarizes 
the role of Protein Kinase D1 (PKD1) in different cell signaling process, 
functions and various disease pathologies.  Chapter II “Protein Kinase D1 
(PKD1) activation mediates a compensatory protective response during early 
stages of oxidative stress-induced neuronal degeneration” is a research 
paper published in the journal Molecular Neurodegeneration (6:43, 2011). 
Chapter III “Protein Kinase D1 (PKD1) activation protects against 
dopaminergic neuronal degeneration induced by Parkinsonian specific 
toxicant 6-OHDA” has been submitted to the journal BBA-Biochimica et 
Biophysica Acta. Chapter IV “Fyn-PKCδ Signaling Regulates the Anti-
Apoptotic PKD1 in Experimental Models of Parkinson’s disease” is a research 
paper to be submitted to PLOS ONE and chapter V “Rationally designed 
peptide based PKD1 activator protects against neurodegeneration in pre-
clinical models of Parkinson’s disease” will be submitted for publication in 
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Science Translational Medicine. This dissertation contains the experimental 
results obtained by the author during his Ph.D study under the supervision of 
his major professor, Dr.Anumantha G. Kanthsamy. 
 
Introduction 
Parkinson’s disease is a major neurodegenerative disorder affecting over a 
million Americans with an annual cost of several billion dollars. Current 
treatment approaches available for PD are symptomatic and fail to prevent 
the progression of the neurodegenerative process.  The currently available 
drugs are limited in their effectiveness to either slow or stop the progressive 
neurodegenerative processes in PD, largely due to the lack of mechanistic 
insights into the selective dopaminergic degenerative process.  Experimental 
findings from cell cultures, animal models, and humans indicate that oxidative 
stress and apoptosis may contribute to the pathophysiological processes 
underlying many neurodegenerative diseases including Parkinon’s disease 
(2) (3) (4) (5) (6).  Our understanding of oxidative damage induced 
neurodegeneration has increased over recent years.   Oxidative stress 
induced apoptosis is a continual cell death process involving multiple stages 
and signaling molecules and generally can be divided into two distinct 
phases; the early stage where ROS initiation occur and the late stages where 
irreversible oxidative damage leads to cell death (7) (8). 
Most current investigations of signaling in neurodegenerative disorders have 
primarily focused on signaling pathways that are activated only during cell 
death. We have earlier explored one such pro-apoptotic pathway mediated by 
PKCδ cleavage in dopaminergic neurons (8-10).  But the compensatory 
responses against oxidative damage remain largely unexplored.  Recently, 
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we unravelled a novel compensatory protective mechanism in dopaminergic 
neurons mediated by protein kinase D1 (PKD1).  This review will provide an 
overview about PKD1, its mode of activation and functional significance 
during oxidative damage as this might lead to a novel and alternative 
translational approaches to treat neurodegeneration. 
Background and Literature Review 1 
Parkinson’s disease and therapeutic options 
Parkinson’s disease (PD) is a progressive neurodegenerative disorder that is 
characterized by the loss of dopaminergic neurons in the substantia nigra 
pars compacta (SNpc) region of the mid-brain.  Cardinal PD symptoms range 
from resting tremors, bradykinesia (slowness of movements), akinesia 
(difficulty in initiating movements) rigidity and facial palsy (11).  Non-Motor 
symptoms include speech abnormalities, sleep abnormalities, constipation, 
olfactory dysfunction, depression/ cognitive impairment (12).  Parkinson’s 
disease process occurs through numerous stages of , as described by Braak 
et al., (13, 14). In stages 1-2 the presence of PD related inclusions are mainly 
confined to the IX/X motor nucleus or the reticular zone (medulla oblongata). 
In stages 3-4 the pathology spreads to the upper and lower brain stem but is 
not co-existent with cortical inclusion bodies and finally in the stages 5-6 
there is severe involvement of neo-cortex along with frontal and temporal 
lobes.  Some non-motor symptoms like speech sleep disorder, and olfactory 
dysfunctions, might antedate the appearance of motor symptoms while 
cognitive impairment can follow the motor symptoms during the late stages.  
But the progression is not linear and can be faster with mild impairment and 
slower with marked impairment. Two subtypes have been recently noted; one 
tremor dominant form occuring in younger patients of age around 45 years 
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and another form dominant with rigidity, abnormal gait and postural instability 
occuring in older patients of age greater than 55 (15). Parkinson’s disease is 
idiopathic and can be multifactorial with both genetic and environmental 
causes can contribute to the disease progression but the exact cause of this 
pathology remains unclear (16). Although numerous genetic mutations have 
been associated with familial Parkinsonism (17) (18), these mutations are 
only unique to the familial cases and account for less than 5-10% of the PD 
occurences.  Mutations have been found in some important genes like α-
synuclein, parkin and DJ1.  2- 3% of early onset and 50 % of late onset 
shows mutation in these genes.  Some of the other genes which are 
associated with PD include PINK1, LRRK2, EIF4G1 etc.  Environmental 
causes also have been 
proposed.  The 
environmental 
chemical toxicants like 
maneb, paraquat, 
rotenone and MPTP 
have been shown to 
lead to 
neurodegenerative pathology not only in animal and cellular models but also 
in human subjects (19) (20) (21). Basal ganglia in the mid brain, comprises of 
the striatum (sub divided into the caudate nucleus/putamen or neostriatum 
and the ventral striatum), the external (GPe) and internal (GPi) pallidal 
segments, the subthalamic nucleus and the substantia nigra (made up of the 
pars compacta-SNpc and the pars reticulata-SNpr). Striatal nuclei and the 
output basal ganglia connections are sub-divided into two pathways referred 
to as the direct pathway made up of GPi, SNpr and the indirect pathway 
(GABAergic neurons- Enkephalin) made up of GPe segment , further 
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connecting the GPi/SNpr via the subthalamic nucleus (STN) (22). The direct 
and the indirect pathways collectively function to exert an inhibitory effect on 
the basal ganglia inhibitory output to the thalamo cortical pathway. Dopamine 
acts via a net inhibitory effect (D2 receptors) over the indirect pathway and a 
excitatory effect on the direct pathway to maintain the smoothness of motion 
(23) (24). Dopamine (DA) is a neurotransmitter that is synthesized from the 
amino acid tyrosine by the rate limiting tyrosine hydroxylase (TH).  Tyrosine is 
first converted to L-3, 4-dihydroxyphenylalanine (L-DOPA) by TH and 
decarboxylated to DA by the aromatic L-amino acid decarboxylase (AADC) 
(25).  Dopamine can be converted to Noradrenaline (NE) by dopamine-β-
hydroxylase or it can be sequestered into synaptic vesicles by vesicular 
monoamine transporter (VMAT).  Vesicles fuse with the synaptic membrane 
and release DA into the synaptic cleft, where it acts on various dopamine 
receptors and initiate different signaling mechanisms.  Excess DA is removed 
from the synaptic cleft through re-uptake process by the dopamine 
transporter (DAT).  Dopamine (DA) homeostasis is critically dependent on the 
dopamine transporter (DAT) located in the nerve terminals (26). Chemical 
compounds that are structurally similar to DA exhibit similar uptake Vmax via 
the transporter system into the dopaminergic system. 
There are four major brain dopaminergic pathways in the mid-brain; nigro-
striatal, mesolimbic, mesocortical and the tuberoinfundibular (27). 
Nigrostriatal pathways arise from the dopamine producing neuronal cell 
bodies of the SNpc and act to inhibit the release of excitatory cholinergic 
neurotransmitters from the striatum via the Gs linked D2 receptors. The 
extreme loss of the dopaminergic neurons in the substantia nigra (>50%) and 
the striatum (>70%) in turn leads to the development of motor symptoms 
seen in Parkinson’s disease. In addition to the loss of dopaminergic neurons 
the major pathological features of PD are the dystrophic neuritis termed 
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“Lewy neuritis” (LN) and cytoplasmic inclusion bodies referred to as “Lewy 
bodies”. 
Many environmental factors are linked to neurodegenerative but none of 
these factors have been proved to be the cause of the disease.  1,2,3,6-
methyl-phenyl-tetrahydropyridine (MPTP) a potent neurotoxin was identified 
to induce Parkinsonian like pathology (28) MPTP is a byproduct of a synthetic 
meperedine derivative and can get oxidized to pyridinium ion (MPP+) which is 
neurotoxic as it acts as an inhibitor of the complex I of the mitochondrial 
respiratory chain and mediating oxidative damage and apoptosis  (29). A 
majority of the toxins like rotenone, paraquat and MPTP which induce the 
clinical and pathological features similar to PD have been demonstrated to be 
a potent mitochondrial complex I enzyme inhibitors (20) (30) (31).  
Furthermore oxidative stress induced mitochondrial dysfunction and 
bioenergetic crisis was demonstrated in PD post mortem brain studies (32) 
(33).  Current tretament options are mostly symptomatic and donot slow 
down the progression of PD. 
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Parkinon’s disease therapy 
The therapeutic options for medical management of PD have increased 
through the years.  The treatment is mostly symptomatic and can be 
dopaminergic and non-dopaminergic based.  Current successful 
pharmacological therapeutic measures have been the administration of the 
dopamine precursor drug levadopa {Eadie, 1995 #4}.  Eventhough Levadopa 
administration has been successful in treating Parkinsonian symptoms, the 
prolonged administration can cause some motor system side-effects like 
aggravated forms of dyskinesias on the disease (34) (35). Promising results 
from preclinical studies showed that dopamine agonists can be a treatment 
for PD.  Patients treated with dopamine agonists pramipexole and ropinirole 
for example showed significantly lower reduction of F-DOPA uptake 
compared to levodopa treatment.  Eventhough, there is reduced decline of 
radiotracer, it did not translate clinically as motor function of levodopa- treated 
patients were better than those treated with dopamine agonists. 
Glutamate antagonists 
Research on pathophysiology of PD has shown dysfunctional mitochondria 
and reduced complex I stimulating increased glutamatergic activity and 
making the dopaminergic neurons vulnerable in neurodegeneration.  Pre-
clinical studies have shown that N-methyl-d-aspartate (NMDA) receptor 
antagonists blocking the activation of NMDA receptors by glutamate have 
antiparkinsonian effects and potentiate the effect of dopamine on striatal 
function.  Studies on riluzole, a glutamate antagonists show neuroprotective 
effects in animal models of PD.  In clincial trials on PD patients, the authors 
concluded that riluzole does not show superiority over placebo on disease 
progression or to alleviate the symptoms (36) (37) (38) (1) 
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Monoamine oxidase inhibitors 
Oxidative stress was considered an important contributor to 
neurodegeneration in PD.  Use of MPTP toxicity model and its blockade by 
MAO-B inhibitors in pre-clinical models, MAO-B inhibitor was probed for its 
neuroprotective effects.  For example one of the selective inhibitor of MAO-B 
rasagiline was tested in PD patients.  Early treatmnet of rasagiline proved to 
be efficacious in PD patients eventhough there is a criticism about the 
methadology of the trial (36) (37) (38) (1) 
Neurotrophic factors 
Neurotrophic factors which help survival of dopaminergic neurons in 
substantia nigra, has been proposed as a potential treatment for PD.  Glial 
cell line-derived neurotrophic factor (GDNF) has been demonstrated to have 
neuroprotective affects on nigral dopaminergic neurons.  A randomized trial 
compared the effects of monthly intracerebroventricular administration of 
placebo and recombinant GDNF in patients suffering from advanced PD.  
The study was not effective and possible reason being that did not reach its 
intended targets.  A randomized, trial in PD patients recieving bilateral 
continuous intraputaminal infusion of GNDF or placebo via 
intraparenchymatous catheters stereotactically targeted to the posterior 
dorsal putamen showed some beneficial effect of but did not translate into a 
significant clinical improvement of motor function (36) (37) (38) (1). 
Antioxidants and Bioenergetics 
Mitochondrial dysfunction and oxidative stress have long been implicated as 
pathophysiological mechanisms of dopaminergic neuronal loss in PD.  First 
evidence emerged from observations that abuse of 1-methyl-4-phenyl-
1,2,3,4-tetrahydropyridine (MPTP), whose active metabolite 1-methyl-4-
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phenyl-pyridine (MPP+) is an inhibitor of the mitochondrial complex I can 
induce irreversible parkinsonian condition.  Further studies in postmortem 
brain of patients suffering from idiopathic PD have shown reduction in 
mitochondrial complex I activity indicating a role of mitochondrial dysfunction 
in the pathogenesis of PD. 
Coenzyme Q10 (CoQ10) is an antioxidant and an essential cofactor in the 
mitochondrial respiratory chain.  Previous Studies have shown reduced levels 
of CoQ10 in PD patients.  In the Coenzyme Q10 Evaluation-2 (QE2) study, 
treatment with CoQ10 showed significant benefit for PD patients.  Based on 
this observation a randomized trial examining CoQ10 in phase III trials to 
evaluate the putative disease-modifying effects were performed.  The study 
indicated that CoQ10 could be considered for evaluation in future trials.  
Future studies with larger cohorts and longer treatment periods are required 
to examine the neuroprotective effects of CoQ10  (36) (37) (38) (1). 
Another pharmacological approach to increase bioenergetics in PD was using 
dietary supplement creatine, which plays an important role in mitochondrial 
energy production. Creatine is converted to phosphocreatine to transfer 
phosphoryl groups in mitochondrial ATP synthesis and buffering intracellular 
energy stores.  In two separate clinical trials the results were conflicting and 
require a well designed trial to probe creatines’s protective effects. 
Alpha-tocopherol or vitamin E, another antioxidant, has also been 
investigated, but showed conflicting results like creatine.  Current drugs 
active in clinical trials are given below in the table. 
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Based on the success of kinase modulators in cancer along with more light 
on the cellular and molecular pathways, focus to develop a ‘signal 
transduction therapy’ has increased for PD to offer neuroprotection.  The 
following sections will focus on i) recent advances in the mitochondrial 
apoptotic process and ii) current advances in signal transduction therapy 
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targeting the apoptotic process to prevent dopaminergic degeneration for 
neuroprotection. 
Oxidative damage induced apoptosis in neurodegeneration 
Studies in human PD brain tissues indicate the role of apoptosis in  
neurodegeneration.  TUNEL (terminal dUTP nick-end labeling) staining a 
measurment for DNA fragmentation gives some evidence for the occurrence 
of apoptosis in post-mortem tissues.  Studies done in cellular and animal 
models also conclusively show that neurodegeneration occurs through 
apoptosis. 
Apoptosis can be divided into two groups as the extrinsic or death ligand 
mediated pathway and the intrinsic or the mitochondrial pathway of apoptosis 
(Vila and Przedborski 2003). The extrinsic pathway utilizes the recruitment of 
cell-surface death receptors like Fas/CD95 which has Fas-Ligand as a ligand 
and the tumor necrosis factor receptor-1 (TNFR-1) having TNF-α as a ligand 
(Wallach et al. 1999).  Caspase family of enzymes potentiates and regulates 
apoptotic signaling.  These enzymes have specificity for aspartic acid on the 
N-terminal side of the substrate containing a specific pentapeptide sequence 
(QACXG).  Caspase activation involves the proteolytic cleavage of the 
enzyme to a large subunit (p17-p20) and a small sub-unit (p10-p12) which 
form self heterodimers and leading to active form of the enzyme. Based on 
type of activity in cells the caspases can be broadly classified into two main 
groups; initiator caspases (that regulate effector caspases as caspases 1, 2, 
4, 5, 8, 9, and 10) and the effector caspases (that execute apoptosis as 
caspases 3, 6, 7, and 14). Once the extrinsic pathway is activated, adaptor 
proteins will recruit caspase-8 and then in turn activate effector caspase-3 
directly. Caspase-8 can also cleave Bid (a BH3-only member of the B-cell 
leukemia/lymphoma 2 [Bcl-2] family of proteins) ((39) (40).  Since mediation 
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of apoptosis through mitochondrial dysfunction has been described as one of 
the major causes of neurodegenerative disorders (41) (42) , this section will 
focus on mitochondrial apoptosis. 
During the early stage, the oxidative stress leads to an oxidant/ anti-oxidant 
homeostatic imbalance and mitochondrial dysfunction resulting in the 
formation of mitochondrial permeability transition pore (mtTP), cytochrome C 
release and caspase-3 activation. In the late stage, considerable fraction of 
mitochondria is affected resulting in bioenergetic crisis, overegeneration of 
ROS, DNA fragmentation and neuronal death. 
The inner membrane of the mitochondrion forms Ca++ channels between the 
mitochondrial matrix and the cytosol which are known as permeability 
transition pores (PTPs) (43). Cytochrome c is released from the mitochondria 
through permeability transition pores (PTPs). Once cytochrome c is released, 
it forms a large dATP/ATP dependent complex with an adapter protein Apaf-1 
and the pro-caspase-9 which is referred to as the apoptosome and is a 
primary initiator factor of downstream apoptotic cascade. Caspase-9 further 
activates caspase-3 through proteolytic cleavage (44). 
Release of proteins and enzymes from the mitochondria is closely monitored 
by Bcl-2 family of proteins (McDonnell et al. 1996; Reed 1996; Blandino and 
Strano 1997).  Bcl2 family can be divided into the pro-apoptotic members and 
the anti-apoptotic members.  Bak and Bax regulate cytochrome c release 
from the inner mitochondrial membrane (Lutter et al. 2000; Kuwana et al. 
2002). Bcl2 has been shown to affect protection by inhibiting intracellular free 
radicals, and increasing buffering ability of excess Ca++ in the mitochondria 
(Kane et al. 1993; Ellerby et al. 1996; Zhu et al. 2000). 
13 
 
Many protein kinases that signal for both neuronal survival and death are 
activated at both stages. 
Signal transduction therapy 
Cell death kinases 
Recent advances in drug discovery have lead to novel signal transduction 
therapies for many diseases and disorders.  Current signal transduction 
therapies in PD mainly focus on developing inhibitors against cell death (2) 
(3) (4) (5) (6).  The cell survival kinases mediate compensatory responses 
by activating many anti-oxidant, anti-apoptotic signaling cascades and try to 
maintain the oxidant/ anti-oxidant homeostatic balance.  But the failure to 
counteract the oxidative damage and the persistent generation of ROS 
results in apoptosis mediated by cell death kinases. 
Some of the cell death kinases involved in the execution of apoptosis 
includes PKCδ, JNK, MLK, ASK1, MAPK etc.  Sustained or delayed 
activation of ERK promoted cell death and neuronal degeneration (45-48).  
Activation of JNK almost exclusively leads to cell death (49).  ASK1 activation 
sensitizes the neurons to cell death (50). MLK family of kinases acts as an 
upstream activator of the pro-apoptotic JNK in the apoptotic cascade (51).  
PKCδ cleavage sensitizes the neurons to death in pe-clinical models of 
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neurodegeneration (6).  These cell death kinases have also been shown to 
relay specifically the ROS generated during mitochondrial dyfunction. 
Mutations in kinases like DJ, LRRK2, Parkin, PINK1, α-synuclein have also 
been assosciated with Parkinson’s disease.  Parkin, PINK1, DJ1 has been 
linked to mitochondrial biogenesis, energy production and neuroprotection. 
Therapeutic interventions developed against some of these major cell death 
kinases including JNK, GSK, MLK, MAPK, havenot progressed to the 
treatment stage (45-48). For example, the mixed lineage kinase inhibitor 
CEP-1347 failed to stop or slow down PD progression in clinical trials (52).  
One of the hypothesis given for the failure was that the therapeutic strategy of 
inhibiting kinases involved in cell death execution might be too late to stop 
neurodegeneration in addition to the complex signal transduction process 
(53).  This has resulted in revaluating the scientific thinking to develop 
alternative approaches through better understanding of the 
neurodegeneration signaling mechanisms. 
Compensatory protective responses 
One of the alternative hypotheses is neuroprotection through modulating the 
survival factors.  Some of the key compensatory responses are the anti-
oxidant factors GSH, α-tocopherol, SOD, GPX which resist the early stage 
ROS generation; anti-apoptotic BCl2 family of proteins that resist the 
formation of permebaility transistion pore is the second layer of defense 
against cell death during the intermediate stage; the late stage anti-apoptotic 
defenses are mediated by anti-apoptotic proteins like IAP family members 
and chaperones like HSPs.  Several HSPs (for example, HSP27, HSP70 and 
HSP90) act as specific anti-apoptotic factors during the late stages after 
casapse-3 activation.  This occurs through multiple mechanisms, including: 
15 
 
apoptosome inhibition, blockage of endonucleases from mitochondria 
release, cytosolic endonucleases sequestration, preventing protein 
aggregation and inhibition of mitochondrial DNase activity.  In line with these 
observations, brain-targeted overexpression of HSPs conferred 
neuroprotection.  The members of the inhibitor of apoptosis protein (IAP) 
family act as an endogenous defense against excessive caspase activation.  
In-vivo overexpression of the IAPs including NAIP, IAPs 1 and 2 had reduced 
CNS tissue damage (54). 
Unlike the cell survival kinases the key protein kinases that mediate 
protective compensatory responses to counteract oxidative damage in 
Parkinson’s disease are still largley unexplored.  So far only AKT is known to 
offer neuroprotection is (54).  Recently, we identified an oxidant/anti-oxidant 
signal transduction circuit in the progression of PD.  PKD1 activation acts as 
a cell survival switch in the circuit and protect against early oxidative damage 
but deactivated during the late stages which co-relates with dopaminergic 
degeneration (55).  Our studies in PD models have shown that positive 
modulation of PKD1 protects against dopaminergic degeneration (55). 
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Background and Literature Review 2 
Different Roles of Protein Kinase D1 (PKD1) 
Protein kinase D1 (PKD) belongs to the CAMK family of kinases and has a 
molecular weight of 110kDa.  PKD family consists of three related 
serinserine/threonine kinases PKD1, PKD2 and PKD3.  PKD1 has a 
regulatory fragment and a catalytic fragment.  The regulatory fragment 
consists of two cysteine rich domains (cys I, cys II) and the pleckstrin 
homology domain (PH). The regulatory domain has an inhibitory effect on the 
catalytic (56, 57). PKD was first identified in both mouse and human by two 
different labs (58) (59) and can be activated by phosphorylation at the dual 
serine residues (ser 744/748) in the kinase domain by different PKCs 
depending upon the cellular type and stimuli (59, 60). For example, 
PKCtheta and PKCepsilon can increase PKD1 activation loop 
phosphorylation and activation in kidney cell lines (61) (62).  PKCeta and 
PKCdelta can bind to the PH domain and phosphorylate the activation loop of 
PKD1 in COS-7 and HeLa cells   (63, 64). PKD1 activation has recently been 
shown to play a role in multiple signaling functions including proliferation, 
cytoskeletal reorganization, Golgi function, immune function, and cell survival 
in many non-neuronal cell models (65-69). PKD1 has been shown to 
regulate various cell signaling molecules and pathways including ERK1/2, 
JNK pathways (70-72), effector enzymes like MnSOD that scavenge ROS 
(68) (64), transcriptional regulators including NF-κB and MEF2 (73) (74),  
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stress responsive chaperones like HSP27 (75), and some members of the 
HDAC family (68, 76, 77).  Recently, PKD1 was recognized as an important 
mitochondrial ROS sensor that translocates to the nucleus to switch on cell 
survival mechanisms (64). 
PKD are distributed intracellularly in the cytosol, Golgi and mitochondria.  The 
PKD1 translocation and activation requires involvment of different domains.  
Cysteine rich domain 1 (C2) helps in translocation of PKD1 to the Golgi 
apparatus. Cysteine rich domain 2 (C2) is required for diacyl glycerol binding 
and Gαq binding. Once activated by PKCs through activation loop 
phosphorylation in the cytosol or mitochondria, PKD translocates to nucleus 
and activates many transcription factors (**).  Cysteine rich domain 2 (C2) is 
required for nuclear import whereas PH domain is required for nuclear export 
(65-69, 78). 
PKD1 mode of activation 
PKD1 gets activated in response to various stimuli including growth factors, 
phorbhol esters, G-protein coupled receptors, genotoxic stress and oxidative 
stress.  The mode of activation also depends on the context of PKD1’s 
multiple signaling functions including proliferation, cell survival, cell death, 
cytoskeletal reorganization, golgi function and immune function in many non-
neuronal cell models (65-69). 
PKD1 activation methods can be classified into four major ones: 
GPCR Signaling 
Multiple Stimuli including mitogenic neuropeptides and growth factors such as 
bombesin, vasopressin, endothelin, bradykinin, and platelet-derived growth 
factor activate PKD1.  Rozengurt et al showed that DAG production during 
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external stimuli causes PKC activation which can further interact with PKD1 
PH domain to relieve PH domain autoinhibition and transphosphorylate at the 
activation loop serine residue S744 and S748 resulting in PKD1 activation.  
All four novel PKC isoforms have been implicated in activation of PKD1.  
PKCε and PKCη strongly induced PKD1 activation in COS-7 cells.  Classical 
PKC member PKCα was also implicated in PKD1 activation.  PKD cysteine 
rich domains bind with DAG;C2 is specific to plasma membrane translocation 
while C1 is specific to translocation to golgi outer membrane (64, 78-81) 
Oxidative stress specific Src-Ab1-PKC pathway 
Storz et al showed that during oxidative stress in HeLa cells PKD1 act as a 
mitochondrial specific oxidative stress sensor.  PKD1 and PKCδ are recruited 
to mitochondrial membrane through PLD1 mediated DAG signaling. Further, 
the C-abl kinase phosphorylates at PKD1 Y 469 residue opening up the 
kinase through a conformational change; this creates a binding site at PKD1 
C1a domain for the PKCδ C2 domain to bind and phosphorylate the 
activation loop  S744/S748 residues and C-src is found to be the upstream 
regulator of this process .  Activated PKD1 cause nuclear translocation of NF-
κB and further induce expression of mitochondrial MnSOD which scavenge 
ROS (64, 78-81). 
Proteolytic activation of PKD1 
Häussermanna et al showed that PKD1 can generate a 62 kD fragment 
persistently active catalytic fragment when exposed to stimuli like TNF alpha, 
beta-D-arabinofuranosylcytosine (ara-C),1 2-O-tetradecanoylphorbol-13-
acetate (TPA), bryostatin 1 or cycloheximide.  Further PKD1 was cleaved by 
calpain in response to arachidonic acid treatment (82). 
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Together, PKD1 can persistently get activated in response to proteolytic 
cleavage. 
PKD1 activation by proteolytically activated PKCδ catalytic fragment (PKCδ-
CF) 
We identified that 
proteolytically activated 
PKCδ (PKCδ – CF) 
activates protein kinase D1 
(PKD1) by phosphorylating 
the activation loop 
(PKD1S744/748) in 
dopaminergic neuronal cells 
exposed to oxidative stress.  
We identified that 
phosphorylation of S916 at 
the C-terminal and not Y469 
is a preceding event 
required for PKD1 activation 
loop phosphorylation.  We 
also found that 
phosphorylation of S916 is 
dependent on PKCδ.  Previously we have shown that proteolytically activated 
PKCδ (PKCδ – CF) act as an oxidative stress sensor.  This unique method of 
activation is specific in neuronal injury suggesting a protective compensatory 
role for PKD1 during oxidative stress (55). 
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PKD1 Signal transduction 
Cytoskeletal organization and cellular motility 
Lamellipodia are believed to be the motor required for polarized cellular 
migration and movement in mammalian cells (Yamaguchi & Condeelis, 
2007). Actin depolymerization contributes to this cellular movement.  Cofilin is 
a family of proteins that can depolymeraize actin filaments.  Phosphorylation 
of cofilin phosphorylation suppresses cell motility whereas cofilin 
dephosphorylation by protein phosphatase, SSH1L, restores cell motility. 
SSH1L posphorylation by PKD1 contributes eventually to the disruption of 
SSH1L from phospho-cofilin and thereby regulating Lamellipodia cell 
movement and migration.  PKD1 phosphorylates the Ras effector RIN1 to 
inhibit F-actin remodelling and cell motility (81) (83)  
In many cancers including prostate, breast and stomach there is a 
downregulation of PKD1 and E-cadherin (84).  PKD1 phosphorylation of the 
E-cadherin results in the inhibition of motility. PKD1 also regulate E-cadherin 
gene expression and downregulate mesenchymal protein expression. 
Therefor, Reduced PKD1 function decreases E-cadherin function and 
expression but promotes mesenchymal gene expression contributing to 
cancer (81). 
PKD1 phosphorylates the transcription factor SNAIL, leading to the de-
repression of E-cadherin in prostate tumours and cell lines.  Further, PKD1 
overexpression decreased tumour development in a xenograft model (81). 
Golgi Function: 
PKD kinases especially PKD2 and PKD3 regulate the fission of vesicles that 
carry protein and lipid cargo from the trans-golgi network (TGN) to the plasma 
membrane in HeLa cells.  The enzyme PI4KIIIβ located in the golgi apparatus 
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is activated by PKD.  PI4KIIIβ phosphorylates phosphatidyl inositol to 
generate PI4P which is an important lipid mediator for vesicular trafficking.  
For example PI4P act as a docking site for some lipid and sterol transfer 
proteins that delivers ceramide (CERT) and cholestrol (OSBP) to Golgi 
membranes.  Both ceramide and cholestrol are required for further 
downstream signaling events and for packaging/budding in TGN (85, 86) 
Gβ1γ2 subunits of heterotrimeric G-proteins bind Golgi membranes and 
further activate PKD, which is a downstream target which further promotes 
golgi vesicle fission and delivery of secreted proteins to the plasma 
membrane (65).  
PKD1 regulates insulin secretion by increasing Golgi fission in β-cells (87). 
Active, Golgi-associated PKDs are detected in hippocampal neurons (88). 
Transcriptional regulation: 
Histone deacetylases regulate gene transcription by repression through 
chromatin remodelling, recruitment of co-repressors, deacetylation etc.  
PKD1 phosphorylates HDAC5 and promote nuclear export of HDACs thus 
de-repressing MEF2-mediated transcription. Phosphorylation of HDAC5 by 
PKD1 also de-represses Nkx2-5-mediated. 
In endothelial cells PKD activation by VEGF stimulates PLCγ and HDAC7 
phosphorylation leading to MEF2 dependent transcriptional regulation and 
angiogenesis. 
PKD1 phosphorylates HDAC7 and promote nuclear export of HDAC7 thus 
de-repressing RUNX-mediated transcription and bone formation when 
stimulated by bone morphogenetic proteins. 
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Immune Functions: 
C. elegans lacking DKF-2A, a PKD1 homologue are vulnerable to human and 
C. elegans bacterial pathogens.  TPA-1, a PKCδ homologue regulates DKF-
2A activation.  DKF-2A activates PMK-1, a p38α MAPK homologue which is 
essential for induction of most of the immune function genes.  Signaling 
through T cell receptor activates PKD1 and increases SAPK/JNK/NF-kappa B 
activation through hematopoietic progenitor kinase (HPK1) activation in 
Jurkat T cells.  PKD1 may auguments T cell adhesion.  Also during T-cell 
receptor stimulation, CD4 and CD8 co-receptors expression occurs in 
response to RhoA induced PKD1 activation (89). On  theother hand; T-cell-
receptor β-chain expression is downregulated by cytoplasmic PKD1.  B cell 
receptor stimulation activates PKD1 through CD40 and TRAF2 binding.  PKC 
is activated through COS-7 cells and lymphocytes.  Mast cell IgE receptor 
stimulation also activates PKD1   (84). 
PKD is a major oxidative stress sensor and the role of PKD1 in oxidative 
signaling will be detailed in the following section. 
PKD1 and oxidative stress signaling 
PKD predominantly act as a cell survival kinase during oxidative stress.  
During oxidative stress in HeLa cells PKD1 and PKCδ are recruited to 
mitochondrial membrane through PLD1 mediated DAG signaling.  Further, 
the C-abl kinase phosphorylates at PKD1 Y 469 residue opening up the 
kinase through a conformational change; this creates a binding site at PKD1 
C1a domain for the PKCδ C2 domain to bind and phosphorylate the 
activation loop  S744/S748 residues and C-src is found to be the upstream 
regulator of this process. Activated PKD1 cause nuclear translocation of NF-
κB and further induce expression of mitochondrial MnSOD which scavenge 
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ROS. This C-Src/ C-Abl/ PKCδ/ PKD1 signalling module leads to NF-κB-
mediated transcription of pro-survival genes in Hela cells (64, 68). 
In HeLa cells PKD might affect apoptosis through regulation of JNK.  In 
response to apoptotic signals, mitochondria release hydrogen peroxide and 
nitric oxide (NO).  During oxidative stress NO is produced by mitochondrial 
NO synthase. Which inhibit complex III electron transfer to increase 
superoxide and hydrogen peroxide production. JNK is activated during this 
process and downregulate the antiapoptotic proteins Bcl-2 and Bcl-XL and 
mediates opening of the membrane transition pore and the voltage-
dependent anion channel (VDAC) through phosphorylation which results in 
apoptotic signaling through Ca2+ release, cytochrome C release and 
caspases activation. PKD can form a complex with JNK and supresses JNK 
activation in some cancer cells (70) 
PKD can mediate NF-κB activation and inactivates p38 MAPK and regulates 
cell survival in oxidative stress-induced intestinal epithelial cell injury.  
Further, PKD1WT attenuated MKK3/6 phosphorylation to downregulate p38 
MAPK in this cell lines.ROS also induce cytoskeletal reorganization that 
induce RhoA and Rho kinase (ROCK) activation.  ROCK further activates Src 
and PKC signaling resulting in activation of PKD1–NF-κB signalling. In 
pancreatic β cells, early induction of the antiapoptotic and anti-inflammatory 
gene TNFAIP3/A20 during stress is controlled by PKD1 activation. PKD1 
induces A20 promoter activity and causes A20’s negative feedback regulation 
of NF-κB signaling (81). 
Role of PKD1 in various disease pathologies 
Decreased function of PKD1as a cause in disease pathologies 
 
24 
 
Breast cancer 
PKD1 protein decreased in human breast-cancer tissue arrays in invasive 
and metastatic ductal carcinomas (90, 91). PKD1 over expression in invasive 
breast-cancer cells decreased migration and invasion.  Activating PKD1 
downregulates matrix metalloproteases (MMPs) and decreases cell migration 
and invasion . Thus, restoring PKD1 expression or activation can reduce 
migration and metastasis of breast tumour cells. 
Prostate cancer 
Analysis of human prostate tumour samples revealed correlations between 
decreased PKD1 and E-cadherin mRNA levels.  PKD1 phosphorylation of the 
E-cadherin results in the inhibition of motility  (84). PKD1 also regulate E-
cadherin gene expression and downregulate mesenchymal protein 
expression. Therefore, Reduced PKD1 function decreases E-cadherin 
function and expression but promotes mesenchymal gene expression 
contributing to cancer.  PKD1 phosphorylates the transcription factor SNAIL, 
leading to the de-repression of E-cadherin in prostate tumours and cell lines.  
Further, PKD1 overexpression decreased tumour development in a xenograft 
model. PKD1 downregulates androgen receptor (AR) function and prostate 
cancer cell proliferation. 
Together, PKDs can decrease cell motility by phosphorylating SSH1L, 
cortactin, E-cadherin, SNAIL and RIN1, or decreasing MMP expression. 
Stomach cancer 
PKD1 levels are decreased in primary gastric tumors cell lines due to the 
hypermethylation of the PKD1 promoter region. Methylation of PKD1 
promoter increases with ageing.  Knockdown of PKD1 increased migration 
and invasion in gastric cancer cells. 
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The following view has been put forth; the presence of PKD1 may enhance 
survival and proliferation and necessary for early stage tumor promotion 
events.  But silencing of PKD1 may allow tumor progression into invasive 
stages and metastasis. 
Diabetes 
PKD1 enhances glucose-dependent insulin secretion by increasing Golgi 
fission in β-cells.  This PKD1 activation is negatively modulated by p38δ MAP 
kinase by phosphorylation.  Disruption of the p38δ gene in mice persistently 
activates PKD1 which regulates insulin and glucose levels   (87) . 
The M3 acetylcholine (ACh) receptor promotes insulin release from 
pancreatic β-cells and PKD1 act as a key downstream effector to enhance 
glucose-dependent insulin secretion.  PKD1 activation and ACh-augmented 
insulin secretion are suppressed in cells overexpressing phosphorylation-
deficient M3 receptors. 
PKD1 regulates insulin release and homeostatic regulation of glucose 
metabolism (81). 
Increased function of PKD1 as a cause in disease pathologies 
Pancreatic cancer 
PKD1 might play a role in pancreatic cancer cells.  There is an increase in 
expression of activated PKD1/2 in pancreatic cancer tissue microarrays. 
In pancreatic cancer cell lines, PKD1 overexpression led to increased cell 
proliferation rate through upregulation of survivin and FLICE-inhibitory protein 
(c-FLIPL).  PKD activation stimulated DNA synthesis and mitogenic signaling 
in human pancreatic cancer. PKD1 phosphorylated Hsp27 which is linked to 
cytoskeleton rearrangement, cell mobility, cell survival, and proliferation and 
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has increased expression in many types of cancer. PKD inhibitor 
CRT0066101 reduced tumor (92).  
Skin cancer 
PKD has been found to promote hyperproliferative disorders of the skin (92). 
Lung cancer and lymphoma 
Very little is known about the role of PKD in small cell lung cancer (SCLC). 
One study has shown that the PKC/PKD signaling pathway exists in the 
SCLC cell lines H69, H345, and H510 and that PKD can be activated by 
phorbol esters and bombesin in these cells. To date, there have been no 
reports on PKD expression and distribution in actual human tumor samples 
(92). 
Angiogenesis 
In endothelial cells PKD activation by VEGF stimulates PLCγ and HDAC7 
phosphorylation leading to MEF2 dependent transcriptional regulation and 
angiogenesis.  HDAC7-regulates endothelial-cell migration, tube formation 
and genesis of capillaries (92). 
Cardiac hypertrophy 
Cardiac hypertrophy is the response to conditions like hypertension, heart 
muscle injury (myocardial infarction), or neurohormones.  PKD1 activates 
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MEF2.  MEF2 recruits co-activators increases Ca2+ release and energy 
metabolism.  This results in hypertrophy, and eventually heart failure.  Further 
activated CAMTA2–Nkx2-5 complex drives cardiac gene transcription, 
promoting hypertrophy along with MEF2.  (Fielitz et al, 2008) 
Skeletal muscles 
Muscle fatigue is caused by a decline of muscle performance with activity due 
to reasons including failure of excitation-contraction, coupling, metabolism 
alteration and reactive oxygen species.  PKD1 induces expression of slow-
twitch contractile proteins that mediate muscle endurance through HDAC5 
phosphorylation and MEF2 activation (93). 
PKD1 mediates myocardial excitation–contraction coupling and 
phosphorylates troponin I reducing the Ca2+ sensitivity of myofibres and 
diminishes twitch amplitude. Bone morphogenetic proteins promote bone 
formation and improve skeletal function.  HDAC7 repression of RUNX binding 
is released by PKD1 phosphorylation of HDAC7 (81). 
PKD1 in CNS 
The PKD is involved in protein sorting and packaging in TGN vesicles of 
dendrites (94) (88). Neuronal polarity and post-synaptic functions are 
regulated by this function.  Any change to PKD activity also causes change in 
dendritic branching.  Reduction in PKD levels increases the endocytosis of 
dendritic-membrane proteins (94).  Together the study show that PKDs 
regulates cell polarity and dendritic specialization by playing an essential part 
in protein sorting, packaging and targeting in the TGN and suppress 
endocytosis of dendritic membrane proteins. 
PKD1 phosphorylates KI220, a transmembrane scaffold protein at the plasma 
membrane which regulates neuronal development, morphogenesis and 
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polarity.  It also modulates phosphorylation of proteins like MAP1 and 
stathmin.  Autophosphorylation of PKD1 Ser 916 is shown to be important for 
transporting KI220 from the TGN to the plasma membrane . 
PKD plays a very important role in associative learning in C.elegans.  C. 
elegans detects and chemotactic towards Na+ but pre-incubation with Na+ 
during starvation results in Na+ avoidance.  Caenorhabditis elegans gene, 
dkf-2 (PKD homolog), encodes DKF-2A which is present mainly in intestine, 
and DKF-2B which is mainly found in neurons.  DKF-2B is expressed in 
neurons responsible for Na+ chemotaxis and learning   (92). dkf-2 gene 
disruption has no effect on Na+ chemotaxis, but supresses Na+-dependent 
learning.  Restoring Dkf-2 function brings back learning in dkf-2 null animals.  
Interestingly, EGL-8, a PLCβ homologue and TPA-1, a PKCδ homologue act 
as upstream regulators of both DKF-2B and DKF-2A in C.Elegans (92). The 
study demonstrate that PKD help enable learning and behavioral plasticity by 
transducing and integrating signals from environment to both neurons and 
intestine and thereby regulating a crucial neuronal function. 
Metabotropic glutamate receptors (mGluRs) regulate strength and plasticity 
of synaptic connections in the brain.  In hippocampal cultures, mGluR5 
stimulation results in PKD phosphorylation at Ser-916 residue. 
Protease-activated receptor 2 is activated during inflammation and injury.  
PKD isoforms are expressed in primary sensory neurons that are responsible 
for mediating inflammation and pain transmission function.  PAR(2) agonists 
activate PKD isoforms in HEK293 cells and DRG neurons.  And PKD 
activation is considered to be an important signaling cascade in protease-
induced activation of nociceptive neurons and can be an important new target 
for antiinflammatory and analgesic therapies. 
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Tachykinins stimulate NK(3) receptors and contribute to excitatory 
transmission in primary afferent neurons (IPANs) in small intestine.  Protein 
kinase C (PKC), - Protein kinase D (PKD) signal transduction are found to 
propagate the signal. 
In drospohila, PKD1 disruption resulted in tissue loss, wing defects and 
degeneration of the retina.  This confirms that PKD is involved in 
developmental function in Drosophila. 
PKD1 plays a prominent role in neuonal polarity, learning signal transmission 
etc.  But PKD1‘s role in neurodegeneration remains relatively unknown.  
Recently it was reported that protein kinase D (PKD) act as early marker of 
neuronal DNA damage.  PKD-activation was detected during genotoxic stress 
and ataxia telangiectasia-mutated (ATM) activation.  The study also showed 
that PKD stimulation was very specific to DNA.  These results were also 
replicated in- vivo, in rats where injection of DNA-toxin etoposide showed 
increased activation of PKD.  
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Our in-vitro and in-vivo results demonstrate that the PKD1-mediated 
protective mechanism is a constituent of a novel signal transduction circuit 
that regulates cell survival and cell death during various stages of oxidative 
stress in dopaminergic neuronal system.  A detailed comparative analysis of 
PKCδ proteolytic activation, PKD1 activation loop phosphorylation and the 
extent of cell death during oxidative stress revealed an interesting functional 
relationship between activation of kinases and regulation of cell death.  
Comparison of PKD1 activation and cytotoxicity shows that PKD1 activation 
is maximal during the early oxidative stress stage when no measurable 
cytotoxicity is noted.  Interestingly, when PKD1 activation begins to decline at 
the end of the early stage, cell death begins to occur.  Also, the level of PKCδ 
proteolytic activation directly correlates with the extent of cell death at the 
later stage of oxidative stress. As depicted in the scheme, in the early stages 
of oxidative insult, PKCδ acts as an oxidative stress sensor/regulator and 
activates the survival switch PKD1 against oxidative damage.  However, 
prolonged oxidative insult creates a homeostatic imbalance, causing 
deactivation / switching OFF of PKD1 and persistent proteolytic activation of 
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PKCδ, the death switch contributes to extensive neuronal damage.  We 
previously showed a parallel proapoptotic mechanism involving translocation 
of PKCδ catalytic fragments to the mitochondria, resulting in a persistent 
increase in caspase-3 dependent PKCδ proteolytic cleavage via a positive 
feedback loop mechanism. Our results suggest that positive modulation of 
the PKD1-mediated protective mechanism against oxidative damage in 
dopaminergic neurons may provide novel neuroprotective strategies for 
treatment of PD (55). 
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Chapter II: Protein Kinase D1 (PKD1) activation mediates 
a compensatory protective response during early stages 
of oxidative stress-induced neuronal degeneration  
A paper published in Molecular Neurodegeneration 2011 6:43. 
Arunkumar Asaithambi, Arthi Kanthasamy, Hariharan Saminathan, 
Vellareddy Anantharam and Anumantha G. Kanthasamy 
Abstract 
Background 
Oxidative stress is a key pathophysiological mechanism contributing to 
degenerative processes in many neurodegenerative diseases and therefore, 
unraveling molecular mechanisms underlying various stages of oxidative 
neuronal damage is critical to better understanding the diseases and 
developing new treatment modalities.  We previously showed that protein 
kinase C delta (PKCδ) proteolytic activation during the late stages of 
oxidative stress is a key proapoptotic signaling mechanism that contributes to 
oxidative damage in Parkinson's disease (PD) models.  The time course 
studies revealed that PKCδ activation precedes apoptotic cell death and that 
cells resisted early insults of oxidative damage, suggesting that some intrinsic 
compensatory response protects neurons from early oxidative insult.  
Therefore, the purpose of the present study was to characterize protective 
signaling pathways in dopaminergic neurons during early stages of oxidative 
stress.  
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Results  
Herein, we identify that protein kinase D1 (PKD1) functions as a key anti-
apoptotic kinase to protect neuronal cells against early stages of oxidative 
stress.  Exposure of dopaminergic neuronal cells to H2O2 or 6-OHDA induced 
PKD1 activation loop (PKD1S744/748) phosphorylation long before induction 
of neuronal cell death.  Blockade of PKCδ cleavage, PKCδ knockdown or 
overexpression of a cleavage-resistant PKCδ mutant effectively attenuated 
PKD1 activation, indicating that PKCδ proteolytic activation regulates PKD1 
phosphorylation.  Furthermore, the PKCδ catalytic fragment, but not the 
regulatory fragment, increased PKD1 activation, confirming PKCδ activity 
modulates PKD1 activation.  We also identified that phosphorylation of S916 
at the C-terminal is a preceding event required for PKD1 activation loop 
phosphorylation.  Importantly, negative modulation of PKD1 by the RNAi 
knockdown or overexpression of PKD1S916A phospho-defective mutants 
augmented oxidative stress-induced apoptosis, while positive modulation of 
PKD1 by the overexpression of full length PKD1 or constitutively active PKD1 
plasmids attenuated oxidative stress-induced apoptosis, suggesting an anti-
apoptotic role for PKD1 during oxidative neuronal injury.  
 
Conclusion 
Collectively, our results demonstrate that PKCδ-dependent activation of 
PKD1 represents a novel intrinsic protective response in counteracting early 
stage oxidative damage in neuronal cells.  Our results suggest that positive 
modulation of the PKD1-mediated compensatory protective mechanism 
against oxidative damage in dopaminergic neurons may provide novel 
neuroprotective strategies for treatment of PD. 
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Introduction 
Oxidative stress-induced neuronal damage has been implicated in many 
neurodegenerative disorders including Parkinson’s disease (PD), Alzheimer’s 
diseases, ALS, Huntington’s diseases and stroke  (1), (2), (3) (4) (5) (6) (7).  
Neuronal cells maintain an oxidant/antioxidant homeostatic balance, and any 
breach in redox homeostasis causes excessive ROS production, resulting in 
oxidative damage (8) (9) (10).  Oxidative stress triggers apoptosis through 
activation of many signaling molecules including kinases and proteases (11) 
(12) (13) (14) (15), and the roles of these signaling molecules in 
dopaminergic cell death are being actively investigated.  Recently, we 
demonstrated that the proteolytic activation of PKCδ, a novel PKC family 
member, mediates apoptosis in cell culture and animal models of PD (15) 
(16) (17) (18) (19).  
 
PKCδ can be activated by membrane translocation, phosphorylation, or 
proteolytic cleavage by caspase-3, leading to persistently active catalytic 
fragments.  We previously showed that various oxidative stressors like H2O2, 
MPP+ and 6-OHDA induce PKCδ cleavage to increase the kinase activity and 
apoptosis in dopaminergic cells  (20) (15) (21) (16).  The time course studies 
revealed that the pro-apoptotic proteolytic activation of PKCδ occurs well 
before apoptotic cell death, and that cells resist early oxidative damage, 
suggesting that some key intrinsic compensatory responses protect neurons 
from the initial oxidative insult.  Therefore, we speculated that the persistently 
active catalytic fragment of PKCδ might have other functions during the early 
stages of oxidative stress, and so we further explored downstream signaling 
mechanisms.  
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Protein kinase D1 (PKD1) is a calcium/calmodulin-dependent member of the 
CAMK kinase family and can be activated by dual phosphorylation of seine 
residues (Ser 744/748) in the catalytic domain by different PKCs, depending 
upon the cellular type and stimuli (22-24).  PKD1 is activated in response to 
multiple stimuli including growth factors, phorbol esters, G-protein coupled 
receptors, genotoxic stress and oxidative stress (25-28).  In non-neuronal 
cells, PKD1 activation has been shown to play a role in diverse cellular 
functions including proliferation, cytoskeletal reorganization, golgi function 
and immune response (27, 29-32).  PKD1 has been shown to regulate 
various cell signaling molecules and pathways including ERK1/2, JNK 
pathways (33-35), effector enzymes like MnSOD that scavenge ROS (31) 
(36), transcriptional regulators including NF-κB and MEF2 (37) (38),  stress 
responsive chaperones like HSP27 (39), and some members of the HDAC 
family (26, 31, 40).  Recently, PKD1 was recognized as an important 
mitochondrial ROS sensor that translocates to the nucleus to switch on cell 
survival mechanisms (36).  Also, PKD1 activation loop phosphorylation has 
been shown as an early marker of sympathetic neuronal DNA damage (41).  
In neuronal models, PKD1 regulates trafficking of dendritic membrane 
proteins to maintain neuronal polarity and synaptic plasticity (42).  
While many biological functions of PKD1 are beginning to emerge, the role of 
PKD1 in the brain, specifically in the nigral dopaminergic system, remains 
unknown.  The relationship between PKD1 signaling and neurodegeneration 
has not yet been examined in a single study.  Herein, we demonstrate that 
PKD1 closely interacts with PKCδ and serves as a key compensatory 
protective mechanism in dopaminergic neuronal cells during the early stages 
of oxidative insult.  
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Materials and Methods: 
Cell Culture  
The immortalized rat mesencephalic dopaminergic neuronal cell line (N27) 
was a kind gift from Dr. Kedar N. Prasad (University of Colorado Health 
Sciences Center, Denver, CO).  N27 cells were grown in RPMI 1640 medium 
containing 10% fetal bovine serum, 2 mm l-glutamine, 50 units of penicillin, 
and 50 μg/ml streptomycin. Cells were maintained in a humidified 
atmosphere of 5% CO2 at 37 °C, as described previously (16).  N27 cells are 
used widely as a cell culture model for PD (20) (15) (21) (16, 43). 
 
Primary mesencephalic neuronal culture  
Primary mesencephalic neuronal cultures were prepared from the ventral 
mesencephalon of gestational 16- to 18-day-old mouse embryos, as 
described earlier (44).  Tissues were dissected from E16 to E18 mouse 
embryos maintained in ice cold Ca2+-free Hanks' balanced salt solution and 
then dissociated in Hanks' balanced salt solution containing trypsin-0.25% 
EDTA for 30 min at 37°C.  The dissociated cells were then plated at equal 
density (0.5 × 106 cells) on 12 mm coverslips precoated with 0.1 mg/ml poly-
D-lysine.  Cultures were maintained in neurobasal medium fortified with B-27 
supplements, 500 μM l-glutamine, 100 IU/ml penicillin, and 100 μg/ml 
streptomycin (Invitrogen).  The cells were maintained in a humidified CO2 
incubator (5% CO2 and 37°C). Half of the culture medium was replaced 
every 2 days.  Approximately 6- to 7-day-old cultures were used for 
experiments.  Primary mesencephalic dopaminergic neuronal cells were 
exposed to 10 μM for 1 h.  
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Treatment Paradigm 
N27 cells were exposed to H2O2 (100 μm) for 0–4 h at 37°C. Primary neurons 
were exposed to H2O2 (10 μm) for 1 h.  Cell lysates were used for Western 
blotting and immunoprecipitation studies.  Untreated cells were grown in the 
complete medium and used as the experimental control. 
 
Cytotoxicity Assays  
 Cell death was determined using the Sytox green cytotoxicity assay, after 
exposing the N27 cells to H2O2 (100 μm), as described previously.  This 
cytotoxicity assay was optimized for a multiwell format, which is more efficient 
and sensitive than other cytotoxicity measurements (45) (46).  Briefly, N27 
cells were grown in 24-well cell culture plates at 100,000 cells per well and 
treated with H2O2 (100 μm) and 1 μm Sytox green fluorescent dye.  The 
Sytox green assay allows dead cells to be viewed directly under a  
fluorescence microscope, as well as quantitatively measured with a 
fluorescence microplate reader (excitation 485 nm; emission 538 nm) 
(Biotek). Phase contrast and fluorescent images were taken after H2O2 
exposure with a NIKON TE2000 microscope, and pictures were captured with 
a SPOT digital camera.  
 
ROS Generation Assay  
 ROS generation was monitored by CM-DCFDA dye, as described previously 
(15, 47).  This is a non-fluorescent dye in its reduced form, but after oxidation 
in the cells, the acetate group is removed by cellular esterases, resulting in 
fluorescence.  N27 cells were seeded in 48-well plates at a confluence of 
40,000 cells / well for 24 h. First, cells were loaded with 10µM CM-DCFDA 
dye (Invitrogen) at 37°C for 1 h in the dark.  Cells were then treated with H2O2 
in Hanks' balanced salt solution (HBSS) and the fluorescence of the cells was 
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measured using the synergy 2 fluorescence plate reader (Biotek) at various 
time points (excitation 485 nm; emission 538 nm). 
 
Immunocytochemistry    
 The primary mesencephalic neurons or N27 cells after H2O2 treatment were 
fixed with 4% paraformaldehyde and processed for immunocytochemical 
staining.  First, nonspecific sites were blocked with 2% bovine serum 
albumin, 0.5% Triton and 0.05% Tween-20 in phosphate-buffered saline 
(PBS) for 20 min.  The cells then were incubated with antibodies directed 
against TH, native PKD1 and PKD1-pS744/S748 in PBS containing 1% BSA 
at 4°C overnight, followed by incubation with Alexa 488 and Alexa 568 
conjugated secondary antibodies in PBS containing 1% BSA. Secondary 
antibody treatments were followed by incubation with Hoechst 33342 dye for 
5 min at room temperature to stain the nucleus.  The coverslips containing 
stained cells were washed with PBS, mounted on slides, and viewed under a 
Nikon inverted fluorescence microscope (model TE-2000U; Nikon, Tokyo, 
Japan).  Both fluorescence and confocal images were captured with a SPOT 
digital camera (Diagnostic Instruments, Inc., Sterling Heights, MI). 
 
Western Blot Analysis  
Cells were lysed in either modified RIPA buffer or M-PER buffer (Thermo 
Scientific) for Western blot, immunoprecipitation and kinase assays.  Lysates 
containing equal amounts of protein were loaded in each lane and separated 
on 10-12% SDS-PAGE, as described previously (Kaul et al., 2003).  PKD1 
polyclonal (1:1000), PKCδ polyclonal (1: 1000), PKD1-pS744/S748 (1:1000), 
PKD1-pS916 (1:1000), PKD1-pY469 (1:1000), - and β-actin (1:10000) 
antibodies were used to blot the membranes. IR dye-800 conjugated anti-
rabbit (1:5000) and Alexa Fluor 680 conjugated anti-mouse (1:10000) were 
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used for antibody detection with the Odyssey IR Imaging system (LICOR), as 
previously described. 
 
PKCδ Kinase Assay 
Immunoprecipitation and PKCδ kinase assay were performed as described 
earlier (15).  After cell lysis, cell were immunoprecipitated using a polyclonal 
PKCδ rabbit antibody and protein A Sepharose, and washed three times with 
PKCδ kinase buffer (40 mM Tris (pH 7.4), 20 mM MgCl2, 20 μM ATP, 2.5 mM 
CaCl2).  The reaction was started by adding 20 μl of buffer containing 0.4 mg 
histone and 5 μCi of [γ-32P]ATP (4,500 Ci/mM).  After incubation for 10 min at 
30°C, SDS loading buffer (2X) was added to the samples to terminate the 
reaction.  The reaction products were separated on SDS-PAGE (12%), and 
the H1-phosphorylated bands were detected using a phosphoimager (Fujifilm 
FLA-5100) and quantified with MultiGauge V3.0 software. 
 
Protein Kinase D1 Kinase Assay  
 The cells were exposed to H2O2 (100 μM) for 1 h and cell lysates were 
immunoprecipitated, as previously reported, with native PKD1 antibody 
(Santa Cruz).  The kinase reaction was carried out at room temperature for 
20 min after adding 10 μl of kinase substrate mix (0.1 mM ATP + 10 µci  [γ-
32P] ATP + 2 ug Syntide 2 peptide substrate in kinase buffer).  Kinase buffer 
contains 20 mM Tris  pH 7.5, 10 mM MgCl2, and 1 mM DTT.  The samples 
were centrifuged to terminate the kinase reaction, and the supernatants 
containing the phosphorylated peptide were applied as spots to P81 
phosphocellulose squares (Whatmann).  The papers were washed four times 
with 0.75% phosphoric acid and once with acetone and dried, and activity 
was determined by liquid scintillation counting.  The samples were also 
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loaded on a SDS-PAGE and probed for native PKD1 to determine equal 
loading. 
 
DNA Fragmentation Assay    
DNA fragmentation was measured using the Cell Death Detection ELISA 
Plus assay kit (Roche), for the detection of early apoptotic death, as 
described previously (15, 47).  After 100μm H2O2 treatment, the cells were 
spun down at 200×g for 5 min and washed once with PBS.  Then cells were 
lysed with lysis buffer provided with the kit.  After lysis, the samples were 
spun down at 10,000 rpm for 10 min to collect the supernatant that was used 
to measure DNA fragmentation.  The supernatants were further dispensed 
into the microtiter plates coated with streptavidin containing HRP-conjugated 
antibody cocktail that can detect the nucleosomes. After 2 h incubation, the 
HRP substrate provided in the kit was added.  Measurements were taken in a 
Synergy 2 multiwell plate reader at 405 nm, with 490 nm as a reference 
reading.  
 
Transient and Stable Transfections  
cDNA encoding PKCδ catalytic fragment (PKCδ-CF), PKCδ regulatory 
fragment (PKCδ-RF) and PKCδ caspase-resistant mutant (PKCδ-CRM) 
(PKCδD327A) from the pEGFPN1 vector were subcloned into the lentiviral 
expression vector plenti6/V5-d-TOPO in our lab (herein referred to as V5-
PKCδ-CF, V5-PKCδ-RF, V5-PKCδ-CRM) (15, 48).  ViraPower Lentiviral 
Expression System (Invitrogen) was used to establish stable transfections of 
a caspase-resistant mutant of PKCδD327A (48).  Full-length human PKD1 
plasmid (PKD1-FL), PKD1 activation loop, active PKD1S744E/S748E (PKD1-CA) 
and PKD1S916A mutants were obtained from Addgene, Inc. (49) (50) (37).  
Electroporation was carried out with an Amaxa Nucleofector transfector 
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instrument, as per the manufacturer's protocol.  The transfected cells were 
then transferred to T-75 flasks or 6-well plates as desired and allowed to 
grow for a 24 h period before the treatment.  
 
RNAi 
PKCδ-siRNA was prepared by an in vitro transcription method, as described 
previously (20).  PKCδ-siRNA effectively suppressed  > 80% of PKCδ protein 
expression levels within 24 h post-transfection.  Predesigned PKD1-siRNA 
was purchased from IDT, Inc. PKD1-siRNA effectively suppressed  > 80% of 
PKD1 protein expression levels after 36 h post-transfection.  N27 cells (50–
70% confluence) were transfected with siRNA duplexes using an Amaxa 
Nucleofector kit (Amaxa), as described in our  previous study (20). 
 
Statistical Analysis 
Data analysis was performed using Prism 3.0 software (GraphPad Software, 
San Diego, CA). Bonferroni's multiple comparison testing was used to find 
the significant differences between treatment and control groups.  Differences 
with p < 0.05, p < 0.01, and p < 0.001 were considered significantly different 
from n≥6 from two or more independent experiments, and are indicated in the 
figures.  
 
Results 
Role of PKC cleavage in the early stages of H2O2-induced oxidative 
stress in dopaminergic neuronal cells 
H2O2 is a common oxidative insult used to probe various cellular signaling 
pathways in different cell types including neuronal cells (15, 51, 52).  We 
have already demonstrated that H2O2 causes dose- and time-dependent 
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cytotoxicity, DNA fragmentation and cell death in the dopaminergic neuronal 
N27 cell model (15).  In order to determine the interrelationship between 
PKC proteolytic cleavage and oxidative stress-induced cell death, we 
examined the time course of PKC proteolytic activation and cell death.  As 
shown in Fig 1A, generation of ROS occurs as early as 1 h after H2O2 
treatment. Cytotoxicity begins between 90 and 120 min (Fig 1B). PKC 
proteolytic cleavage and the kinase activity increases during the early stage 
of H2O2 exposure at 60 min (Fig 1C, D).  Comparison of PKC proteolytic 
activation and cytotoxicity at 60 min revealed that PKC proteolytic activation 
occurs during the early stages of oxidative stress preceding cell death (Fig 
1E).  There was no cell death during this intermediate period between ROS 
generation and PKC proteolytic activation.  PKC knockdown by RNAi 
almost completely blocked the cell death induced by H2O2 at 120 min of 
treatment, demonstrating the pro-apoptotic function performed by PKC in 
N27 cells (Fig 1F).  Importantly, a significant lag period between induction of 
cell death and PKC proteolytic activation was observed.  This interesting 
observation prompted a search for cell signaling mechanisms associated with 
a compensatory protective response involving PKC proteolytic activation 
during early stages of oxidative stress.  
 
Oxidative stress induces phosphorylation and activation of PKD1 in a 
time-dependent manner 
We hypothesized that the proteolytically cleaved PKC might activate other 
downstream cell survival signaling molecules to counteract the early stage of 
oxidative insult.  To test this hypothesis, we first used a bioinformatic 
approach to search for a key pro-survival molecule that interacts with PKC.  
Scansite Motif Scanner software (53) predicted that out of all the PKCs, only 
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PKC can phosphorylate the protein kinase D1 (PKD1) activation loop ser 
residue at high stringency search  (additional file 1).  Further literature review 
indicated that PKD1 is an oxidative stress-responsive kinase that can be 
activated by phosphorylation at the activation loop (S744/S748) in non-
neuronal models (22-25, 54).  This encouraged us to look further for the 
expression and activation of PKD1 in dopaminergic neuronal cells. 
Immunocytochemical staining showed abundant expression of PKD1 in N27 
dopaminergic cells, as visualized by confocal and fluorescence microscopy 
(Fig 2A), which is similar to the expression pattern of PKC in this cell type.  
Importantly, PKD1 is also highly expressed in primary tyrosine hydroxylase 
(TH) positive dopaminergic neurons obtained from mouse substantia nigra in 
the cytosolic region (Fig 2B).  
 
To determine if oxidative stress can induce PKD1 Ser 744/Ser 748 
phosphorylation in the activation loop, we examined the ability of H2O2 to 
induce time-dependent PKD1 activation loop phosphorylation in N27 
dopaminergic cells.  As shown in Fig 2C, 100 μM H2O2 induced transient 
PKD1 activation loop phosphorylation corresponding to the 120 kDa band 
starting at around 30 min, peaking at 60 min and returning to control levels 
after 90 min, with native protein levels remaining the same.  We also 
observed a second band around 100 kDa, which might correspond to the 
other isoform, PKD2.  According to the manufacturers (Cell Signaling 
Technology), the phospho-specific antibody can also detect PKD2 Ser 
706/Ser 710 phosphorylation because of the conserved activation loop 
residues between PKD isoforms.  However, the PKD2 activation loop 
phosphorylation does not follow the transient pattern of activation observed 
with PKD1 (Fig 2C). Furthermore, the activation loop phosphorylation of 
PKD1 increased the PKD1 kinase activity, as measured by a [32P] kinase 
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assay using Syntide 2 substrate (Fig 2D).  Collectively, these results 
demonstrate that oxidative stress activates PKD1 at early stages through 
phosphorylation of the dual phospho sites pS744/pS748.  
 
Oxidative stress-induced PKD1 activation depends on PKCδ  
To further determine whether PKC regulates PKD1, we used both 
pharmacological and genetic approaches to suppress the PKC and then 
measured the level of PKD1 activation.  Treatment of N27 cells with the 
PKC inhibitor rottlerin (1μM) completely suppressed H2O2 -induced PKD1 
activation (Fig 3A), suggesting a potential role of PKC in PKD1 activation.  
Next, we used the PKC-specific siRNA to knockdown PKC and then 
probed for PKC expression and PKD1 phosphorylation.  PKC knockdown 
completely attenuated PKD1 activation loop phosphorylation except for the 
bottom band, corresponding to 100 kDa PKD2 (Fig 3B).  Furthermore, PKD1 
activity was measured by [32P] kinase assay in PKC knockdown samples.  
The suppression in PKC expression completely attenuated PKD1 activation 
during H2O2 -mediated oxidative stress, confirming that PKC is indeed 
involved in PKD1 activation (Fig 3C).  To show the specificity of PKC in 
PKD1 activation in neuronal models, we used PKCα siRNA and then 
measured PKD1 activation loop phosphorylation (additional file 2).  
Knockdown of PKCα did not attenuate PKD1 activation loop phosphorylation, 
further demonstrating the specificity of PKC-mediated PKD1 
phosphorylation in dopaminergic neuronal models. 
 
 
 
45 
 
The constitutively active catalytic fragment of PKCδ mediates PKD1 
activation 
Time course analysis of PKC proteolytic cleavage and PKD1 activation 
revealed that the onset of proteolytic activation of PKC coincides with the 
maximal activation of PKD1 at 60 min following H2O2-induced oxidative stress 
(Fig 4A).  Previously, we had shown that caspase-3 inhibitor z-DEVD-fmk and 
pan caspase inhibitor ZVAD-fmk attenuate H2O2-induced proteolytic 
activation of PKC
activated PKC contributes to PKD1 activation.  As shown in Fig 4B, co-
treatment with z-DEVD-fmk and ZVAD-fmk for 1 h significantly blocked H2O2-
induced activation loop phosphorylation of PKD1 as well as proteolytic 
2O2-induced activation loop 
phosphorylation of PKD2 was not affected in the presence of these caspase 
inhibitors.  To further confirm the role of proteolytically activated PKC in 
PKD1 activation, we used N27 cells stably expressing the PKC cleavage-
resistant mutant PKCδD327A (PKC-CRM).  H2O2 treatment in PKC-CRM 
cells significantly attenuated PKD1 phosphorylation, confirming that the 
proteolytically cleaved PKC  contributes to PKD1 phosphorylation during 
early stages of oxidative stress (Fig 4C).  To further support this observation, 
we separately over-expressed the PKC catalytic fragment (V5-PKC-CF) 
and PKC regulatory fragment (V5-PKC-RF) using a lentiviral vector 
(plenti6/V5-D-TOPO) in N27 cells and then evaluated for activation of PKD1.  
Interestingly, V5-PKC-CF over-expressing cells had increased PKD1 
phosphorylation, while V5-PKC-RF over-expressing cells did not increase 
phospho-PKD1 levels (Fig 4D).  Collectively, these results demonstrate that 
the constitutively active catalytic fragment of PKCδ mediates PKD1 activation 
loop phosphorylation. 
46 
 
 
PKD1 activation functions as an anti-apoptotic protective mechanism 
against oxidative stress 
We previously reported that proteolytically activated PKC (PKC-CF) 
mediates apoptosis in neurotoxicity models (15, 19, 55) and therefore, we 
initially hypothesized that PKC proteolytic cleavage-dependent activation of 
PKD1 may have a proapoptotic function.  Surprisingly, PKD1 knockdown 
siRNA significantly augmented H2O2 -induced cell death at 2 h, as measured 
by Sytox cell death assay (Fig 5A).  PKD1 knockdown increased cell death by 
nearly twofold compared to control groups during H2O2 treatment, indicating a 
pro-survival role for PKD1 against oxidative stress (Fig 5B).  Visualization of 
PKD1 knockdown cells by phase contrast and fluorescence microscopy 
further confirmed that PKD1 knockdown cells are more sensitive than non-
specific control cells to H2O2-induced cytotoxicity (Fig 5C and D).  We further 
measured the H2O2 -induced apoptosis in PKD1 knockdown cells by DNA 
fragmentation ELISA assay at  
3 h.  The results showed an increase in DNA fragmentation in the PKD1 
knockdown group, as compared to the non-specific siRNA control group, 
further confirming the anti-apoptotic role of PKD1 in dopaminergic cells (Fig 
5E).  
 
PKD1 C-terminal Ser 916 phosphorylation precedes PKD1 Ser 744/Ser 
748 activation loop phosphorylation during oxidative stress 
We also characterized the sequential mechanisms of PKD1 activation in 
dopaminergic neuronal cells.  We investigated the other two key 
phosphorylation sites of PKD1, Tyr 469 and Ser 916. As shown in Fig 6A 
H2O2-induces transient phosphorylation of PKD1 Ser 916 in a time-dependent 
manner.  The data suggests that PKD1 C-terminal Ser 916 was rapidly 
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phosphorylated as early as 10 min after H2O2 treatment continues to increase 
up to 90 min and decreases at 150 min (Fig 6A).  The phospho PKD1-pS916 
antibody detects a doublet PKD1 band.  On the other hand, H2O2 failed to 
induce PKD1-tyr 469 phosphorylation in N27 dopaminergic cells (Fig 6A).  
Our results are consistent with a previous study suggesting that PKD1 tyr 469 
phosphorylation does not occur in H2O2-treated Swiss 3T3 cells (56).  
Similarly, it was shown that Vasopressin a GPCR agonist can activates PKD1 
in Swiss 3T3 cells [30].  Since H2O2 did not phosphorylate tyr 469, we used 
desmopressin, a synthetic analogue of vasopressin to induce tyr 469 
phosphorylation.  Exposure of N27 dopaminergic cells to the positive control 
desmopressin induced tyr 469 phosphorylation (Fig 6B).  To further evaluate 
the involvement of PKD1 Ser 916 phosphorylation in PKD1 activation, we 
overexpressed the PKD1S916A mutant and PKD1WT plasmids in dopaminergic 
cells and then stimulated the cells with H2O2.  Overexpression of PKD1
S916A 
mutant blocked PKD1 activation loop phosphorylation (Fig 6C), suggesting 
that Ser 916 phosphorylation is an early event that has to occur prior to PKD1 
activation loop phosphorylation. Furthermore, knockdown of PKC attenuated 
PKD1S916 phosphorylation, demonstrating that this is PKC dependent (Fig 
6D).  Together, these results suggest that PKD1 Ser 744/Ser 748 activation 
loop phosphorylation is intrinsically regulated by PKC via C-terminal 
phosphorylation of PKD1 Ser916.  
 
PKD1 activation acts as a protective compensatory mechanism during 
early stages of oxidative stress 
To understand the relationship between PKCδ/PKD1 activation and neuronal 
cell death during oxidative stress, we quantified the PKCδ/PKD1 activation 
profile from the Western blots and then compared them with the profile of 
neuronal cell death during H2O2-induced oxidative stress.  As shown in Fig 
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7A, PKD1 was activated at the early stages of oxidative insult and no 
measurable cell death was observed until PKD1 activation started declining 
to basal levels.  Alternatively, PKCδ activation was concomitantly increased 
along with H2O2 -induced cytotoxic cell death at the later stage of oxidative 
stress.  Thus, the inverse correlation of PKD1 activation with cytotoxicity 
suggests that PKD1 activation may act as a compensatory protective 
response during early stages of oxidative insult.  To test this hypothesis, we 
first overexpressed the full-length human PKD1 (PKD1WT) in N27 cells and 
then examined the H2O2 -induced cytotoxicity.  As anticipated, PKD1
WT 
overexpression protected the dopaminergic cells against oxidative stress-
induced cytotoxicity at 2 h (Fig 7B).  In order to establish the pro-survival 
function of PKD1 activation, we examined whether overexpression of the 
PKD1S916A phosphorylation defective mutant exacerbated H2O2 -induced 
neuronal cell death.  As shown in Fig 7C, overexpression of the PKD1S916A 
phosphorylation defective mutant exacerbated H2O2 -induced cytotoxic cell 
death as early as 90 minutes, compared to vector overexpressing cells.  To 
further confirm our hypothesis that PKD1 activation loop phosphorylation acts 
as an early protective compensatory response, we overexpressed the 
activation loop active plasmid (PKD1S744E/S748E), where the replacement of 
serine with glutamate makes the kinase constitutively active (50), and 
cytotoxicity was monitored  for up to 3h following H2O2 treatment (Fig 7D).  
The constitutively active PKD1 mutants tremendously suppressed the 
cytotoxicity, even during late stages of oxidative insult, indicating that PKD1 
activation is a very significant early protective compensatory mechanism in 
dopaminergic cells.  Collectively, these results demonstrate that PKD1 is a 
cell survival kinase that is activated during the early stages of oxidative stress 
to protect against cytotoxicity in dopaminergic cell models. 
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Activated PKD1 translocates to nucleus during oxidative stress in cell 
culture models of neurodegeneration 
We also performed immunocytochemical staining to examine the subcellular 
localization of activated PKD1 during oxidative stress. Activated PKD1 
(PKD1pS744/pS748) (green) co-localized with the nuclear Hoechst stain 
(blue) at 1 h during H2O2 -induced oxidative stress in N27 cells, as visualized 
by fluorescence microscopy (Fig 8A).  These results indicate that activated 
PKD1 translocates to the nucleus of dopaminergic neuronal cells to carry out 
cell repair and survival functions.   
 
Furthermore, we examined oxidative stress-induced PKD1 activation in 
primary mesencephalic dopaminergic neurons.  Mouse primary 
mesencephalic neuronal cultures were treated with a low dose of 10 µM H2O2 
to induce oxidative stress and then subcellular localization of PKD1activation 
was monitored by TH/PKD1 double immunolabeling.  Activated PKD1 (red) 
(PKD1 pS744/pS748) co-localized (pink) with the nuclear Hoechst stain 
(blue) following H2O2 treatment in primary mesencephalic neurons staining 
for TH (green), as visualized by fluorescence microscopy (Fig 8B).  We also 
examined the activation profile of PKD1 pS916 C-terminal phosphorylation. 
PKD1pS916 (red) was localized (pink/yellow) in both cytosol and nucleus of 
TH +ve primary mesencephalic neurons staining for green during H2O2 -
induced oxidative stress (Fig 8C).   
 
Parkinsonian-specific toxicant causes PKD1 activation 
Activation of this signaling pathway was also tested using the parkinsonian-
specific toxicant 6-OHDA.  We treated N27 cells with 100 µM 6-OHDA and 
performed a time-course analysis for 1, 3, and 6 h.  PKD1 activation started 
as early as 1 h and continued until 3 h before reaching control levels at 
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around 6 h (Fig. 9).  This further confirmed the involvement of PKD1 signaling 
during parkinsonian-specific oxidative insult. 
 
Discussion 
The present study reveals a novel protective compensatory signaling 
mechanism via PKCδ-PKD1 molecular interaction in dopaminergic neuronal 
cells.  Through our collective results, we report for the first time four key 
findings in a dopaminergic neuronal model pertinent to oxidative stress-
mediated neurodegenerative processes: (i) A proteolytically activated 
catalytic PKCδ fragment (PKCδ-CF)  phosphorylates and activates protein 
kinase D1 (PKD1); (ii) PKD1 activation counteracts early stage oxidative 
damage and protects dopaminergic neuronal cells from cytotoxicity; (iii) 
PKCδ-dependent phosphorylation of ser 916 residue precedes ser 744/ser 
748; (iv) PKCδ - PKD1 crosstalk tightly regulates cell survival and cell death 
to maintain cellular homeostasis in response to oxidative damage.  The 
elucidation of this compensatory signal transduction mechanism in 
neurodegenerative diseases may enhance understanding of degenerative 
processes and lead to development of novel treatment modalities. 
 
H2O2-induced cytotoxicity causes apoptosis in neuronal and non-neuronal 
cells (15, 51, 52, 57). Generally, oxidative stress-induced apoptosis can be 
classified into early and late stages. DNA fragmentation occurs in the late 
stage of apoptosis and is preceded by ROS generation, mitochondrial 
dysfunction and caspase-3 activation and membrane phosphatidyl exposure 
(10) (55).  In neurodegenerative disorders, especially PD, the signaling 
mechanisms that contribute to increased vulnerability of dopaminergic 
neurons to oxidative damage are still under investigation. Most current 
research focuses on cell death mechanisms in dopaminergic neurons.  Some 
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of the signaling kinases responsible for cell death mechanisms in PD include 
JNK, MLK, MAPK, LRRK2, etc. (58-61).  Earlier, the involvement of a novel 
biochemical mechanism for cell death in dopaminergic neurons through 
caspase-mediated proteolytic activation of PKCδ was demonstrated (15) (16) 
(17) (18) (19).  The high levels of persistently active PKCδ catalytic fragment 
mediate apoptosis during oxidative stress in both cell culture and animal 
models of PD (15) (16) (17) (18) (19).  We also have shown in our earlier 
study that a positive feedback loop exists during the late stages of oxidative 
stress, where the persistently active PKCδ catalytic fragment translocates to 
the mitochondria to promote cytochrome C release and apoptosis (16, 17, 
62). 
We previously demonstrated proteolytic activation of PKCδ occurs during the 
early stages of oxidative stress, even before cell death can occur, and 
coincides with the initiation of mitochondrial ROS generation/caspase-3 
activation in dopaminergic neurons (15) (17).  Thus, we speculated that 
proteolytically activated PKCδ might play a regulatory role during the early 
stages of apoptosis. Previous research suggests the presence of a variety of 
protective compensatory mechanisms that counteract the early oxidative 
insult (8) (9) (10).  Since we observed in our present study a significant lag 
time before induction of cell death during the early stages of oxidative stress 
(Fig 1B), we hypothesize that proteolytically activated PKCδ might sense the 
extent of oxidative damage and act as a homeostatic regulator in response to 
oxidative stress, modulating cell survival and cell death mechanisms through 
interactions with protective signaling molecules. 
Protein kinase D1 (PKD1) is emerging as an important signaling molecule 
associated with oxidative stress in non-neuronal cell lines (31) (35, 36).  
Studies have shown that oxidative stress increases PKD1 activation loop 
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phosphorylation (pS744/pS748) via full length PKCs, including PKCδ, in non-
neuronal models (37, 63-66).  However, the functions of PKD1 during 
oxidative stress-induced neurodegeneration have not been studied 
previously.  In the present study, we report that cleaved active PKCδ 
phosphorylates the activation loop of PKD1 and activates the kinase during 
the early stages of H2O2 -induced oxidative stress in dopaminergic neuronal 
cells.  We also observed a similar activation pattern for PKD1 and PKCδ 
during oxidative stress caused by the parkinsonian-specific toxicant 6-OHDA 
(Fig. 9).  To our knowledge, this is the first report of a novel cell survival/cell 
death signal regulation by the cleaved catalytic fragment of PKCδ at two 
different stages of apoptosis based on the extent of oxidative damage.  
 
PKD1 is mainly activated by a diacylglycerol-dependent PKCs mechanism 
(22, 67) or by PKD1 cleavage (68-70).  A recent study shows that PKD1 auto-
inhibition is released through phosphorylation at the Y463 site in the 
regulatory domain, leading to the activation loop phosphorylation by PKCδ full 
length (PKCδ-FL) in Hela cells (24).  PKD1 is in a closed conformation during 
the resting stage, with the regulatory fragment having an autoinhibitory effect 
on the catalytic fragment (54, 71).  Multiple phosphorylation sites on PKD1 
seem to be important for its activation loop phosphorylation, depending on 
the cell types and stimuli.  In human cancer cell lines, PKD1 can be 
phosphorylated at multiple sites including Y463, S910 (corresponding to 
murine Y469, S916) (24, 72).  Phosphorylation of Ser 916 (murine) 
autophosphorylation site correlated with PKD1 activation loop 
phosphorylation (65, 73).  During oxidative stress in non-neuronal models, 
Tyr 469 is phosphorylated by upstream kinases, which results in release of 
the Pleckstrin homology (PH) domain autoinhibition prior to activation loop 
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phosphorylation; this mechanism does not involve C-terminus Ser 916 
phosphorylation (24, 37).  In our dopaminergic neuronal models, oxidative 
stress failed to induce PKD1 Tyr 469 phosphorylation (Fig. 6A), whereas 
PKD1 Tyr 469 phosphorylation was induced by the positive control 
desmopressin (Fig. 6B).  Our results demonstrate that the mechanism of 
PKD1 activation in dopaminergic neurons is distinct from the mechanisms in 
other non-neuronal models.  We demonstrate that S916 phosphorylation, but 
not Tyr 469 phosphorylation, is a preceding event that occurs and is required 
for PKD1ser744/Ser748 activation loop phosphorylation (Fig. 6).  Our data 
suggest that Ser 916 phosphorylation on the C-terminal of PKD1 may open 
the conformation for full activation of the kinase through activation loop 
phosphorylation during oxidative stress in dopaminergic neurons. A detailed 
comparative analysis of PKCδ proteolytic activation, PKD1 activation loop 
phosphorylation and the extent of cell death during oxidative stress revealed 
an interesting functional relationship between activation of kinases and 
regulation of cell death.  Comparison of PKD1 activation and cytotoxicity 
shows that PKD1 activation is maximal during the early oxidative stress stage 
when no measurable cytotoxicity is noted (Fig 7A).  Interestingly, when PKD1 
activation begins to decline at the end of the early stage, cell death begins to 
occur.  Also, the level of PKCδ proteolytic activation directly correlates with 
the extent of cell death at the later stage of oxidative stress.  When the 
constitutively active PKD1 mutant (PKD1S744E/S748E) is overexpressed, 
dopaminergic  cells are resistant to H2O2 -induced neurotoxicity, even during 
the late stages of oxidative stress (Fig 7D), which is consistent with our 
hypothesis that PKD1 activation protects against oxidative damage.  The 
downstream signaling mechanisms of PKD1 activation in dopaminergic 
neuronal cells are not known. PKD1 translocates to the nucleus and 
regulates phosphorylation of HDACs and various transcription factors in 
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various non-neuronal cell lines including B cell, cardiomyocytes & oestoblasts  
(31) (23) (40, 74).  PKD1 translocation to the nucleus after activation in 
dopaminergic neurons is also noted in the present study (Fig. 8), suggesting 
that nuclear translocation of PKD1 may activate key cell survival transcription 
factors and genes.  Thus, we suggest that PKD1 functions as a cell survival 
switch and turns ‘ON’ a protective compensatory mechanism in dopaminergic 
neurons.  Studies are underway to characterize the downstream protective 
response of PKD1 signaling in nigral dopaminergic neurons. 
 
Conclusions 
Our results demonstrate that the PKD1-mediated protective mechanism is a 
novel signal transduction pathway that regulates cell survival and cell death 
during various stages of oxidative stress in dopaminergic neuronal cells.  As 
depicted in Fig. 10, in the early stages of oxidative insult, PKCδ acts as an 
oxidative stress sensor/regulator and activates PKD1, which serves as a key 
compensatory protective mechanism against oxidative damage.  However, 
prolonged oxidative insult creates a homeostatic imbalance, causing 
deactivation of PKD1 and persistent proteolytic activation of PKC that 
contribute to extensive neuronal damage.  We previously showed a parallel 
proapoptotic mechanism involving translocation of PKCδ catalytic fragments 
to the mitochondria, resulting in a persistent increase in caspase-3 dependent 
PKCδ proteolytic cleavage via a positive feedback loop mechanism (16, 17, 
62).  Our results suggest that positive modulation of the PKD1-mediated 
protective mechanism against oxidative damage in dopaminergic neurons 
may provide novel neuroprotective strategies for treatment of PD.  
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Figure legends 
Figure 1. Relationship between PKCδ proteolytic activation and cell 
death during initial stages of H2O2 -induced oxidative stress in N27 
dopaminergic neuronal cell model. 
N27 dopaminergic cells were treated with H2O2 (100 µM) for 0-180 min and 
assayed for ROS generation using DCFDA dye (A) and for cytotoxicity using 
Sytox green dye (B).  Non-linear regression graph from two or more 
independent experiments (n=6-8).  PKCδ cleavage was monitored by 
Western blot in a time dependent manner for 0 - 90 min in N27 dopaminergic 
cells treated with H2O2  (100 µM) (C).  N27 dopaminergic cells were treated 
with H2O2  (100 µM)  for  0, 30 or 60 minutes and PKCδ kinase activity was 
measured using [32P] kinase assay; the bands were quantified for the graph 
(D).  Data quantified from B and C were used to generate a bar graph and 
were compared with cytotoxicity and PKCδ cleavage following H2O2 exposure 
for 60 min. **, p<0.01 as indicated by two-way ANOVA analysis using 
Bonferroni post test (E).  N27 cells were transfected with 1 μM PKCδ siRNA 
and non-specific siRNA for 24 h and treated with 100 μM H2O2 and monitored 
for cytotoxicity using Sytox green dye, which showed significant protection 
from oxidative stress. ***, p<0.001 denotes significant difference between 
non-specific siRNA- H2O2 and PKCδ siRNA H2O2-treated groups from two or 
more independent experiments (n= 6-8).  Statistics were performed by one-
way ANOVA analysis using Bonferroni post test (F).  
 
Figure 2. PKD1 is highly expressed in dopaminergic neurons and 
activated during initial stages of H2O2 -induced oxidative stress  
Immunofluorescence analysis of N27 dopaminergic cells stained for native 
PKD1 using fluorescence and confocal microscopy.  Nuclei were stained with 
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Hoechst dye (A).  Primary dopaminergic neurons staining for tyrosine 
hydroxylase (TH) obtained from the mouse substantia nigral region show co-
localization of native PKD1 with TH. TH – Green, PKD1 native – Red, 
Nucleus – Blue, Yellow -Merge. Nuclei were stained with Hoechst dye (B).  
N27 dopaminergic neuronal cells were treated with or without H2O2 (100 µM)  
for  30, 60 or 90 min and probed for PKD1 activation loop phosphorylation 
pS744/pS748 and native PKD1 expression (C).  N27 cells were treated with 
or without H2O2 (100 µM) and PKD1 kinase activity was measured by [
32P] 
kinase assay using syntide 2 substrate at 60 min (D).  *, p<0.05 denotes 
significant difference between untreated and H2O2 -treated groups.  
Figure 3. PKCδ dependent phosphorylation of PKD1 activation loop. 
N27 dopaminergic cells were treated with H2O2 (100 μM) with or without 1 μM 
rottlerin, and the lysates were probed for PKD1 activation phosphorylation 
(A).  N27 dopaminergic cells were transfected with 1 μM PKCδ siRNA and 
non-specific siRNA and monitored for PKCδ protein expression and PKD1 
activation loop phosphorylation after H2O2  treatment (B)  and PKD1 kinase 
activity assay was performed.  **, p<0.01 denotes significant difference 
between NS-siRNA-H2O2
 and PKCδ-siRNA-H2O2 groups (C).  
Figure 4. Proteolytically activated PKCδ-CF contributes to PKD1 
phosphorylation.    
N27 dopaminergic cells treated with H2O2 (100 μM) for 30, 60 or 90 minutes 
were monitored for PKCδ-CF (A).  N27 dopaminergic cells were treated with 
H2O2 ± DEVD-fmk (50 μM) and ± ZVAD-fmk (50 μM and 100 μM) for 60 min 
and monitored for PKD1 activation and PKCδ cleavage (B).  N27 
dopaminergic cells stably expressing the cleavage-resistant mutant of PKCδ 
(PKCδD327A) were treated with H2O2 and monitored for PKD1 activation (C).  
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PKD1 activation was monitored in N27 dopaminergic cells transfected with 
the catalytic fragment of PKCδ (PKCδ–CF) and the regulatory fragment of 
PKCδ (PKCδ–RF).  Additionally, the mock transfection group treated with or 
without H2O2 was also monitored for PKD1 activation (D).  
Figure 5. PKD1 has a cell survival function during oxidative stress in 
dopaminergic neuronal cells    
N27 dopaminergic cells were transfected with 1 μM PKD1 siRNA and non-
specific siRNA (A) and treated with 100 μM H2O2 for 120 minutes and 
monitored for cytotoxicity using Sytox green dye.  Fluorescence 
measurements for the incorporation of Sytox green read using a flourescence 
plate reader (B) and visualised by phase contrast and fluorescence 
microscopy (C&D).  DNA fragmentation assay (E) showed increased 
cytotoxicity and apoptosis in PKD1 knocked down samples exposed to H2O2. 
*, p<0.05 and ***, p<0.001 denote significant difference between Non-Specific 
siRNA- H2O2 and PKD1 siRNA-H2O2 treated groups.  
Figure 6. PKCδ-dependent phosphorylation of PKD1 at S916 site 
precedes PKD1 S744/S748 active loop phosphorylation  
N27 dopaminergic cells were treated with 100 μM H2O2 for 10-90 min and 
monitored for PKD1Y469, PKD1 S916 and PKD1 S744/S748  
phosphorylation (A).  N27 dopaminergic cells were treated with or without 50 
nM desmopressin for 1 h and monitored for PKD1 Y469 phosphorylation.  
The cells show PKD1 Y469 phosphorylation when exposed to desmopressin, 
while carbachol does not cause PKD1 Y469 phosphorylation (B).  N27 cells 
expressing PKD1S916A mutant blocked PKD1 activation during oxidative 
stress, as seen by Western blotting for PKD1 S744/S748 phosphorylation 
and HA expression (C).  N27 dopaminergic cells were transfected with 1 μM 
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PKCδ siRNA and non-specific siRNA and monitored for PKCδ protein 
expression and PKD1 S916 phosphorylation after treatment with or without 
H2O2  (D).  
Figure 7. PKD1 activation acts as an early protective compensatory 
mechanism.  
 A comparative time course graph based on quantifying PKD1 activation 
profile, PKCδ cleavage profile and cytotoxicity during H2O2 exposure (A).  
N27 dopaminergic cells transiently transfected with 5 μM full length PKD1 
plasmid (PKD1WT) and 5 μM vector plasmid  were treated with or without 100 
μM H2O2  for 150 minutes and monitored for cytotoxicity using sytox green; 
PKD1 protected against cytotoxicity (B).  N27 dopaminergic cells transiently 
transfected with 5 μM PKD1S916A plasmid and 5 μM vector  plasmid were 
treated with or without 100 μM H2O2 for 150 minutes and monitored for 
cytotoxicity using sytox green; increased cytotoxicity was observed in the 
cells (C).  N27 dopaminergic cells transiently transfected with 5 μM  PKD1 
S744E/S748E and 5 μM vector plasmid (D) were treated with or without 100 μM 
H2O2 and monitored for cytotoxicity at various time points using sytox green. 
***, p<0.001 denotes significant difference between treatment groups from 
n≥6. 
Figure 8. Activated PKD1 translocates to nucleus during H2O2 -induced 
oxidative stress.  
Immunofluorescence analysis of N27 dopaminergic cells stained for activated 
PKD1 using fluorescence microscopy during H2O2 exposure show 
translocation to nucleus. PKD1pS744/S748 – Green, Nucleus – Blue.  Nuclei 
were stained with Hoechst dye (A).  Immunofluorescence analysis of primary 
dopaminergic neurons staining for TH obtained from the mouse substantia 
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nigral region shows translocation of activated PKD1 to the nucleus during 
H2O2 exposure.TH-Green,  PKD1pS744/S748 – Red, Nucleus – Blue, Merge 
- Pink. Nuclei were stained with Hoechst dye (B).  Primary dopaminergic 
neurons staining for TH show presence of PKD1pS916 in both cytosol and 
nucleus during H2O2 exposure. TH – Green, PKD1pS916– Red, Nucleus – 
Blue, Pink – Merge in nucleus, yellow –Merge in cytosol.  Nuclei were stained 
with Hoechst dye (C).  
Figure 9. PKD1 is activated by 6-OHDA induced oxidative stress  
N27 dopaminergic neuronal cells were treated with or without 6-OHDA (100 
µM) for 1, 3, and 6 h and probed for PKD1 activation loop phosphorylation 
pS744/pS748 and PKCδ cleavage.  
Figure 10. Schematic of PKCδ-PKD1 signal transduction mechanism 
during oxidative stress in dopaminergic neuronal cells.  
1) Oxidative stress causes mitochondrial impairment; 2) activation of caspase 
cascade; 3) caspase-3 mediates proteolytic cleavage of PKCδ; 4) 
proteolytically cleaved PKCδ-catalytic fragment (CF) is active; 5) PKCδ-CF 
activates PKD1 by activation loop phosphorylation during the early stage of 
oxidative stress; 6) Fully active PKD1 regulates cell survival function in N27 
dopaminergic cells. 
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CHAPTER III: Protein Kinase D1 (PKD1) Activation 
Protects Against Dopaminergic Neuronal Degeneration 
Induced by Parkinsonian Specific Toxicant 6-OHDA  
Manuscript will be communicated to Biochimica et Biophysica Acta 
Arunkumar Asaithambi, Arthi Kanthasamy, Anamitra Gosh, Vellareddy 
Anantharam and Anumantha G. Kanthasamy§  
 
Abstract 
Oxidative stress has been shown to contribute to the specific dopaminergic 
degenerative process that occurs in Parkinon’s disease.  Protein kinases are 
involved in mediating both neuronal survival and death during this process.  
Several studies have implicated protein kinases that mediate apoptotic cell 
death, however, very little is available about protein kinases that regulate the 
cell survival to counteract the oxidative damage and neuronal degeneration.  
In the present study, we characterized the protective PKD1 signaling pathway 
in cell culture models of Parkinson’s disease.  We studied 6-hydroxy 
dopamine (6-OHDA) induced cell death in N27 dopaminergic cell model and 
in primary mesencephalic neurons.  Our results indicated that 6-OHDA-
induced induced PKD1 activation loop (PKD1S744/S748) phosphorylation 
during early stages of oxidative stress induced dopaminergic cell death.  Our 
results also indicated that 6-OHDA induced phosphorylation of C-terminally 
located S916 in PKD1.  PKD1 S916 phosphorylation precedes and is 
required for PKD1 activation loop (PKD1S744/748) phosphorylation.  
Importantly, negative modulation of PKD1 activation by RNAi knockdown or 
by pharmacological inhibitor kbNB-14270 augmented 6-OHDA induced 
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apoptosis, while positive modulation of PKD1 by the overexpression of full 
length PKD1 (PKD1WT) or constitutively active PKD1 (PKD1S744E/S748E), 
attenuated 6-OHDA induced apoptosis, suggesting an anti-apoptotic role for 
PKD1 during oxidative neuronal injury.  Collectively, our results suggest that 
positive modulation of the PKD1 mediated signal transduction can provide a 
novel neuroprotective strategy against PD. 
 
Keywords: 6-OHDA, Protein Kinase D1, Parkinson’s disease, Oxidative 
stress, Neuronal survival, Apoptosis 
 
 
1. Introduction 
Parkinson’s disease is a major neurodegenerative disorder affecting over a 
million Americans with an annual cost of several billion dollars.  The 
incidence of PD cases is projected to dramatically increase with the 
advancing median age of the U.S. population.  This creates a scientific 
imperative to improve the understanding of the causes and medical 
management of PD.  Several studies have shown that environmental 
toxicants and oxidative stress are the major factors for the etiology of age-
related neurodegeneration. Experimental findings from cell cultures, animal 
models, and humans indicate that oxidative stress and apoptosis may 
contribute to the pathophysiological processes in PD [1, 2].  Oxidative stress 
induced apoptosis is a continual cell death process involving multiple 
signaling molecules and therefore, identification of key molecules that 
contribute to the apoptotic cell death process in dopaminergic neurons might 
provide novel therapeutic targets [1-7].  To study the key signaling molecules 
involved in oxidative stress induced neuronal apoptosis in PD, we used the 
specific neurotoxicant 6-hydroxydopamine (2,4,5-trihydroxyphenylethylamine; 
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6-OHDA 6-OHDA has been shown to induce mitochondrial dysfunction and 
oxidative stress [8, 9].  Further 6-OHDA is oxidized in dopaminergic neurons 
to produce reactive oxygen species that damage various macro-molecules 
and organelles.  However, key intrinsic signaling molecules that contribute to 
increased vulnerability of dopaminergic neurons to oxidative damage are not 
well understood.  We have previously shown that oxidative stress and 
mitochondrial dysfunction induce caspase-3 mediate proteolytic cleavage of 
PKCδ, which then mediates apoptotic cell death in cell culture and animal 
models of PD [10-14].  We recently discovered that PKD1 is activated during 
the early stages as a compensatory mechanism against oxidative damage 
[15].  PKD1 is a calcium/calmodulin-dependent kinase and is activated in 
response to multiple stimuli in different disease models and activation has 
been shown to play a role in diverse cellular functions [16-23].  PKD1 can be 
activated by dual phosphorylation of seine residues at the activation loop (Ser 
744/ Ser 748) in the catalytic domain [24-26].  Here, we demonstrate 6-OHDA 
activated PKD1 signaling pathway serves as a key compensatory protective 
mechanism in dopaminergic neurons during the early stages of oxidative 
insult and dopaminergic degeneration in cell culture models of PD.   
 
2. Materials and Methods: 
2.1 Cell Culture  
The immortalized dopaminergic neuronal cell line obtained from the rat 
mesencephalon (N27 cells) was a kind gift from Dr. Kedar N. Prasad 
(University of Colorado Health Sciences Center, Denver, CO).  N27 cells 
were cultured in RPMI 1640 medium containing 10% fetal bovine serum, 2 
mm l-glutamine, 50 units of penicillin, and 50 μg/ml streptomycin. Cells kept 
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in a humidified atmosphere of 5% CO2 at 37 °C, as described previously [11].  
Various groups use N27 cells  as a cell culture model for PD [10,11] [27-29]. 
 
2.2 Primary mesencephalic neuronal culture  
Ventral mesencephalon of gestational 16- to 18-day-old mouse embryos 
were used to prepare primary mesencephalic neuronal cultures [30].  Tissues 
obtained from E16 to E18 mouse embryos were dissociated in Hanks' 
balanced salt solution containing trypsin-0.25% EDTA for 30 min at 37°C.  
The dissociated cells were then plated at equal density (0.5 × 106 cells) on 
0.1 mg/ml poly-D-lysine precoated 12 mm coverslips. Neurobasal medium 
fortified with B-27 supplements, 500 μM l-glutamine, 100 IU/ml penicillin, and 
100 μg/ml streptomycin (Invitrogen) were used to grow the cells.  The cells 
were maintained in a humidified CO2 incubator (5% CO2 and 37°C). 
Approximately 5- to 6-day-old cultures were used for experiments.  Primary 
mesencephalic dopaminergic neuronal cells were exposed to 10 μM 6-OHDA 
for 1 h.  
 
2.3 Treatment Paradigm 
N27 cells were exposed to 6-OHDA (100 μm) for 0–9 h at 37°C. Primary 
neurons were exposed to 6-OHDA (10 μm) for 1-3 h.  Cell lysates were used 
for Western blotting and immunoprecipitation studies.  Untreated cells were 
grown in the complete medium and used as the experimental control. 
 
2.4 Cytotoxicity Assays  
 Cytotoxicity of N27 cells against 6-OHDA (100 μm) was determined using 
the Sytox green cytotoxicity assay, as described previously.  This cytotoxicity 
assay was optimized for a multiwll high-throughput format, which is more 
efficient and sensitive than other cytotoxicity measurements [31,32].  Briefly, 
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N27 cells were grown in 24-well cell culture plates at 100,000 cells per well 
and treated with 6-OHDA (100 μm) along with 1 μm Sytox green fluorescent 
dye.  The Sytox green assay allows dead cells to be viewed directly under a 
fluorescence microscope.  Further, the flourescence can be quantitatively 
measured using a fluorescence microplate reader (excitation 485 nm; 
emission 538 nm) (Biotek).  Phase contrast and fluorescent images were 
taken after 6-OHDA exposure using a NIKON TE2000 microscope, and 
captured with a SPOT digital camera.  
 
2.5 Immunocytochemistry 
 The primary mesencephalic neurons or N27 cells after H2O2 treatment were 
fixed using 4% paraformaldehyde.  Non-specific sites were blocked with 2% 
bovine serum albumin, 0.5% Triton and 0.05% Tween-20 in phosphate-
buffered saline (PBS).  The cells then were incubated with anti- TH, anti-
native PKD1 and anti-PKD1-pS744/S748 primary antibodies in PBS 
containing 1% BSA at 4°C overnight.  This was followed by incubation with 
Alexa 488 and Alexa 568 conjugated secondary antibodies in PBS containing 
1% BSA. Further incubation with done with nuclear Hoechst 33342 dye to 
stain the nucleus.  After further washing, the coverslips were mounted on 
slides, and viewed under a Nikon inverted fluorescence microscope (model 
TE-2000U; Nikon, Tokyo, Japan).  The images were captured with a SPOT 
digital camera (Diagnostic Instruments, Inc., Sterling Heights, MI). 
 
2.6 Western Blot Analysis  
Cells were lysed in either modified RIPA buffer or M-PER buffer (Thermo 
Scientific) for Western blot, immunoprecipitation and kinase assays.  PKD1 
polyclonal (1:1000), PKD1-pS744/S748 (1:1000), PKD1-pS916 (1:1000), and 
β-actin (1:10000) antibodies were used to blot the membranes. IR dye-800 
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conjugated anti-rabbit (1:5000) and Alexa Fluor 680 conjugated anti-mouse 
(1:10000) were used for antibody detection with the Odyssey IR Imaging 
system (LICOR), as previously described. 
 
2.7 Transient Transfections  
Full-length human PKD1 plasmids (PKD1-FL) were obtained from Addgene, 
Inc. [33].  Electroporation was carried out with an Amaxa Nucleofector 
transfector instrument, as per the manufacturer's protocol.  The transfected 
cells were then transferred to T-75 flasks or 6-well plates as desired and 
allowed to grow for a 24 h period before the treatment.  
 
 
2.8 RNAi 
Predesigned PKD1-siRNA was purchased from IDT, Inc.  PKD1-siRNA 
effectively suppressed  > 80% of PKD1 protein expression levels after 36 h 
post-transfection.  N27 cells (50–70% confluence) were transfected with 
siRNA duplexes using an Amaxa Nucleofector kit (Amaxa), as described in 
our  previous study [27]. 
 
2.9 Statistical Analysis 
Data analysis was done using Prism 3.0 software (GraphPad Software, San 
Diego, CA). Bonferroni's multiple comparison testing was applied to find if the 
differences are significant between treatment and control groups.  Differences 
with p < 0.05, p < 0.01, and p < 0.001 were considered significantly different 
from two or more independent experiments (n≥6), and are indicated in the 
figures.  
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3. Results 
3.1 6-OHDA induces cytotoxic cell death of N27 dopaminergic cells 
We first determined the vulnerability of N27 dopaminergic neuronal cells to 6-
OHDA induced cytotoxicity using Sytox cell death assay.  The N27 cells were 
treated with 100 M 6-OHDA for upto 7 hrs.  As shown in Fig 1A, 6-OHDA 
induced cytotoxic cell death in a time-dependent manner begining at 3 hr.  6-
OHDA induced more than 3-fold increase in cell death at 9h.  Visualization of 
Sytox stained N27 cells treated with fluorescence microscopy further 
confirmed the sensitivity of cells to 6-OHDA induced cytotoxicity (Fig 1B).  
These results suggested that 6-OHDA induced cytotoxic cell death in a time-
dependent manner. 
 
3.2 6-OHDA induces activation loop phosphorylation of PKD1.  
Phosphorylation of ser744/S748 located in the activation loop of PKD1 results 
in its activation.  Therefore, we determined if 6-OHDA induces activation loop 
phosphorylation of PKD1 in N27 dopaminergic cells.  We used the antibody 
directed against phosphorylated Ser744/Ser748 in PKD1.  As shown in Fig 
2A, PKD1 activation occurs in a time dependent manner from 0 - 7 hr as 
determined by western blot analysis of phosphorylated Ser744/Ser748.  The 
phosphorylated Ser744/Ser748 PKD1, 110 kDa band peaks 1 hr and goes 
back to basal levels over 7 hrs.  Densitometry analysis revealed that 6-OHDA 
induced an increase in phosphorylated Ser744/Ser748 PKD1 band by many 
folds in 1 hr and decreased to control levels in 3 hr (Fig 2B).  Thus, 6-OHDA 
induced phosphorylation of PKD1 Ser744/Ser748 occurred at early stages of 
oxidative insult and preceded cytotoxic cell death (Fig 2B). 
Immunohistochemical staining with phospho-specific antibody revealed that 
-OHDA-induced nuclear translocation of activation loop 
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phosphorylated PKD1 (pS744/pS748, green) staining as evidenced by co-
localized with the nuclear Hoechst stain (blue) as visualized by fluorescence 
microscopy (Fig 2C).  
 
3.3 6-OHDA induces activation loop phosphorylation of PKD1 in primary 
mesencephalic neurons 
Next, we examined if PKD1 activation occurs in primary mesencephalic 
neurons exposed to 6-OHDA.  Immunocytochemical staining was performed 
to examine the subcellular localization of PKD1 in primary mesencephalic 
neurons.  We were excited to see high level expression of PKD1 in the 
cytosolic region of tyrosine hydroxylase (TH) (green) positive primary 
dopaminergic neurons obtained from mouse substantia nigra (Fig 3A).  
Further, we performed immunocytochemical staining to examine the 
localization pattern of activated PKD1 in a parkinsonian specific cell culture 
model. Our immunocytochemical staining for activated PKD1 showed that the 
activated PKD1 (pS744/pS748) (red) co-localized with the nuclear Hoechst 
stain (blue) during 10µM 6-OHDA-induced oxidative stress in primary 
mesencephalic neurons , as visualized by fluorescence microscopy (Fig 3B).  
Unlike phosphorylated PKD1, 6-OHDA does not induce nuclear translocation 
native PKD1 (data not shown).  These results indicate that only activated 
PKD1 translocates to the nucleus of primary dopaminergic neurons when 
treated with a parkinsonian specific toxicant like 6-OHDA. 
 
3.4 Ser 916 phosphorylation precedes activation loop phosphorylation 
PKD1  
In addition at activation loop phosphorylation of PKD1 (pS744/pS748), 
oxidative stress has been shown to also induce PKD1 Ser 916 
phosphorylation.  Further, we and others have observed that ser916 
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phosphorylation occurs prior to and is prerequisite for activation loop PKD1 
(pS744/pS748) phosphorylation (unpublished observations) [34]  Here, we 
investigated the role of PKD1 C-terminal Ser 916 phosphorylation during 6-
OHDA treatment.  As shown in Fig 4A,  exposure to 100 -OHDA 
induced PKD1  Ser 916 phosphorylation occurs as early as 30 min and 
precedes activation loop PKD1 (pS744/pS748), phosphorylation (Fig 4A).  To 
further, confirm the role of PKD1 Ser 916 phosphorylation in 6-OHDA induced 
PKD1 activation, we overexpressed the phosphorylation defective mutant 
PKD1S916A mutant and native wild type PKD1WT in N27 dopaminergic cells by 
-OHDA for 1 hr.  
Overexpression of PKD1S916A mutant blocked 6-OHDA induced PKD1 
activation loop phosphorylation, suggesting that Ser 916 phosphorylation 
precedes and is required for PKD1 activation loop phosphorylation (Fig 4B).  
Furthermore, immunocytochemical staining for Ser 916 phosphorylation 
showed that PKD1pS916 (red) was localized (pink/yellow) in both cytosol and 
nucleus of TH +ve (green) primary mesencephalic neurons during 10µM 6-
OHDA treatment (Fig 4C).  Together, these results suggest that C-terminal 
PKD1 Ser916 phosphorylation regulates PKD1 activation during 6-OHDA 
treatment in N27 dopaminergic cells and in primary mesencephalic cultures.   
 
3.5 Pharmacological inhibition and RNAi suppression of PKD1 
expression and activation exacerbates 6-OHDA induced dopaminergic 
cell death  
Previous reports have shown that PKD1 act as a cell survival kinase in non-
neuronal models [22] [35-38].  To determine if PKD1’s plays a survival role in 
6-OHDA induced dopaminergic cell death, we used an allosteric PKD 
inhibitor kbNB 142-70.  Briefly, N27 dopaminergic cells were exposed to 100 
- tor kbNB 142-
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70 and determined cytotoxic cell death suing Sytox green assay.  As shown 
in Fig 5A, co- -70 exacerbated 6-OHDA-
induced cytotoxic cell death by more than 50% compared to 6-OHDA alone 
treated cells.  To further confirm cell survival role of PKD1, we used siRNA 
directed against the coding region of PKD1 to suppress its expression and 
monitored cell death using Sytox cell death assay.  Briefly, N27 dopaminergic 
cells were transfected with PKD1 siRNA and non-specific siRNA, 24 hrs post-
transfection cells were exposed to 100 -OHDA.  PKD1 expression was 
almost completely suppressed in PKD1 siRNA transfected compared to non-
specific siRNA-transfected N27 dopaminergic cells (Fig 5B).  As shown in Fig 
5C, in Sytox assays, 6-OHDA induced cytotoxic cell death increased by 10-
fold in PKD1 siRNA transfected cells compared to 5-fold in non-specific 
siRNA transfected dopaminergic cells at 9 hr.  Together these results suggest 
that negative modulation of PKD1 using pharmacological and siRNA 
approaches results in exacerbated cell death in the presence of 6-OHDA and 
the cell survival role for PKD1.   
 
3.6 Overexpression of wild-type and constitutively active PKD1 protects 
against 6-OHDA induced cytotoxic cell death 
To unequivocally confirm the cell survival role of PKD1 we overexpressed the 
full length wild-type human PKD1 plasmid (PKD1WT) and constitutively active 
PKD1S744E/S748E in N27 cells and then exposed to 6-OHDA.  Mutation of serine 
residues at position 744 and 748 results in constitutively active PKD1 [39].  
As shown in Fig. 6A, overexpression of PKD1WT significantly attenuated 6-
OHDA induced cytotoxic cell death compared to vector transfected 
dopaminergic cells in a time-dependent manner.  Similarly, overexpression of 
constitutively active PKD1S744E/S748E also significantly attenuated 6-OHDA 
induced cytotoxic cell death compared to vector transfected dopaminergic 
83 
 
cells in a time-dependent manner (Fig. 6B).  These results unequivocally 
demonstrate cell survival role as well as protective compensatory role of 
PKD1 during 6-OHDA induced dopaminergic cell death.  
 
 
4. Discussion 
This study reveals the existence of a novel defensive signaling mechanism in 
cell culture models of PD.  Here, we report for the first time three key findings 
in a dopaminergic degeneration model using 6-OHDA: (i) PKD1 activation 
counteracts early stage oxidative damage in cell culture models of PD (ii) 
Phosphorylation of Ser 916 residue regulates activation loop phosphorylation 
(PKD1- pS744/S748); (ii) Modulation of PKD1 signaling has protective effects 
against 6-OHDA induced dopaminergic cell death.  
 
Oxidative stress triggers apoptosis and causes neurodegeneration through 
activation of multiple signaling molecules including kinases and proteases 
[10][40-43].  Even though previous studies have shown  the presence of 
cellular compensatory mechanisms that counteract the early oxidative insult, 
the protein kinases that are involved in this mechanism are still being 
investigated [44-46].  PKD1 is an important survival signaling transduction 
kinase associated with oxidative stress in non-neuronal cell lines [22] [35-38] 
[47].  Studies have shown that oxidative stress induces PKD1 activation via 
activation loop phosphorylation pS744/pS748.  Several PKCs including 
non-neuronal systems [47-51].  The role of PKD1 in the brain, especially in 
dopaminergic degeneration remains unknown.  The relationship between 
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PKD1 signaling and neurodegeneration has not yet been examined before in 
detail.  
In the current study, we explored the relationship between PKD1 signaling 
and dopaminergic degeneration in cell culture models of PD.  Several studies 
have demonstrated DNA fragmentation during late stages of 6-OHDA 
induced apoptotic cell death.  DNA fragmentation is preceded by ROS 
generation, mitochondrial dysfunction,  and caspase-3 activation [52-54].  We 
have recently shown ROS generation, mitochondrial dysfunction and 
caspase-3-mediated proteolytic activation play a critical role 6-OHDA induced 
dopaminergic degeneration in cell culture and animal models of PD 
(Kanthasamy 2006 and unpublished obesrvations).  In the present study, we 
report the activation of PKD1 during the early stages of 6-OHDA induced 
oxidative stress in cell culture models of PD.  Multiple phosphorylation sites 
have been implicated in PKD1 activation loop phosphorylation, depending on 
the cell types and stimuli [26] [55].  Previous groups have shown the 
involvement of Ser 916 phosphorylation in PKD1 activation in non-neuronal 
models [34, 50, 56].  We demonstrate that S916 phosphorylation is a 
preceding event required for PKD1ser744/Ser748 activation loop 
phosphorylation [15].  Our data suggest phosphorylation of C-terminally 
located Ser 916 phosphorylation results in unmasking of the ser744/Ser748 
residues located in the activation loop for subsequent phosphorylation and 
PKD1 activation during 6-OHDA induced cytotoxicity.  Further both the 
pharmacological and genetic inhibition exacerbated 6-OHDA induced 
dopaminergic cell death suggesting that PKD1 is a cell survival kinase.  
Comparison of PKD1 activation and 6-OHDA induced cytotoxicity shows that 
PKD1 activation is maximal during the early oxidative stress stage when no 
measurable cytotoxicity is occurs.  Interestingly, when PKD1 activation 
begins to decline at the end of the early stage oxidative stress, cell death 
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begins to occur.  When the constitutively active PKD1 mutant 
(PKD1S744E/S748E) or wild-type PKD1 plasmid (PKD1WT) is overexpressed, 
dopaminergic  cells are resistant to 6-OHDA -induced cytotoxicity, even 
during the late stages of oxidative stress, which is consistent with our 
hypothesis that PKD1 activation protects against oxidative damage in 
dopaminergic cells.  Furthermore, we also observed 6-OHDA treatment 
induces nuclear translocation of phosphorylated PKD1 to possibly regulate 
transcription of cell survival transcription factors and genes in dopaminergic 
cell death.  Our results are consistent with recent studies demonstrating 
nuclear translocation of PKD1 in B cells, cardiomyocytes & oestoblasts [22] 
[25] [57, 58].   
In conclusion, our results demonstrate the existence of a novel protective 
signaling mechanism mediated by PKD1 in dopaminergic neurons.  During 
the early stage of 6-OHDA induced oxidative stress, PKD1 is activated and 
has protective function against oxidative damage.  However, prolonged 
oxidative insult causes deactivation of PKD1 which might contribute to 
neuronal death.  Further negative modulation of PKD1 increases cell death, 
while positive modulation decreases cell death.  Our results suggest that 
PKD1 may function as a cell survival switch in dopaminergic neurons and its 
modulation can be a novel neuroprotective strategy against oxidative damage 
in PD.  
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Figure legends 
Figure 1. 6-OHDA -induced oxidative stress causes cell death in N27 
dopaminergic neuronal cell models. 
N27 dopaminergic cells were treated with 6-OHDA (100 µM) for 0-9 hr and 
assayed for cytotoxicity using Sytox green dye. Fluorescence measurements 
for the incorporation of Sytox green read using a flourescence plate reader.  
Non-linear regression graph was performed from two or more independent 
experiments (n=6-8) (A) and visualised by fluorescence microscopy (B).  
Figure 2. PKD1 is activated in N27 cells during 6-OHDA -induced 
oxidative stress  
N27 dopaminergic neuronal cells were treated with or without 6-OHDA (100 
µM) for 1- 7 hr and probed for PKD1 activation loop phosphorylation 
pS744/pS748 and native PKD1 expression (A).  A comparative time course 
graph based on quantifying PKD1 activation profile, and cytotoxicity during 6-
OHDA exposure (B).  Immunofluorescence analysis of N27 dopaminergic 
cells stained for activated PKD1 using fluorescence microscopy during 6-
OHDA exposure show translocation to nucleus. PKD1pS744/S748 – Green, 
Nucleus – Blue. Nuclei were stained with Hoechst dye (C). 
 
Figure 3. PKD1 is highly expressed in dopaminergic neurons and 
activated during 6-OHDA -induced oxidative stress  
Primary dopaminergic neurons staining for tyrosine hydroxylase (TH) 
obtained from the mouse substantia nigral region show co-localization of 
native PKD1 with TH in the cytosol. TH – Green, PKD1 native – Red, Nucleus 
– Blue, Yellow -Merge. Nuclei were stained with Hoechst dye (A).  
Immunofluorescence analysis of primary dopaminergic neurons staining for 
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TH obtained from the mouse substantia nigral region shows translocation of 
activated PKD1 to the nucleus during 6-OHDA exposure. TH-Green, 
PKD1pS744/S748 – Red, Nucleus – Blue, Merge - Pink. Nuclei were stained 
with Hoechst dye (B). 
Figure 4. PKCδ-dependent phosphorylation of PKD1 at S916 site 
precedes PKD1 S744/S748 active loop phosphorylation  
N27 dopaminergic cells were treated with 100 μM 6-OHDA for 1-7h and 
monitored for PKD1 S916 and PKD1 S744/S748 phosphorylation (A).  N27 
cells transiently expressing PKD1S916A mutant prevent PKD1 activation during 
oxidative stress, as seen by Western blotting for PKD1 S744/S748 
phosphorylation and HA expression (B).  Primary dopaminergic neurons 
staining for TH show presence of PKD1pS916 in both cytosol and nucleus 
during 6-OHDA exposure. TH – Green, PKD1pS916– Red, red/yellow – 
Merge (C).  
Figure 5. PKD1 activation is essential for cell survival function during 6-
OHDA induced oxidative stress in dopaminergic neurons   
N27 dopaminergic cells were transfected with 1 μM PKD1 siRNA and non-
specific siRNA (A) and treated with 100 μM 6-OHDA for 9h and monitored for 
cytotoxicity using Sytox green dye.  Fluorescence measurements for the 
incorporation of Sytox green read using a flourescence plate reader. **, 
p<0.01 denote significant difference between Non-Specific siRNA-6-OHDA 
and PKD1 siRNA-6-OHDA treated groups (B).  N27 cells were co-treated with 
or without PKD1 inhibitor kb-NB 14270 and monitored for cell death during 6-
OHDA treatment for 4h (C). 
Figure 6. Modulation of PKD1 offers neuroprotection in dopaminergic 
neuronal cells  
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N27 dopaminergic cells transiently transfected with 5 μM full length PKD1 
plasmid (PKD1WT) and 5 μM vector plasmid  were treated with or without 100 
μM 6-OHDA  and monitored for cytotoxicity at various time points using sytox 
green. ***, p<0.001 denotes significant difference between treatment groups 
from n≥6 (A).  N27 dopaminergic cells transiently transfected with 5 μM PKD1 
constitutively active PKD1S744E/S748E mutant and 5 μM vector plasmid were 
treated with or without 100 μM 6-OHDA and monitored for cytotoxicity at 
various time points using sytox green. ***, p<0.001 denotes significant 
difference between treatment groups from n≥6 (B).  
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Abstract 
Background 
Protein Kinase Cδ (PKCδ) is a major pro-apoptotic kinase that contributes to 
neurodegeneration in Parkinons’s disease (PD). While studying the key pro-
apoptotic signaling events down stream of PKCδ, we unravelled the novel 
Protein Kinase D1 (PKD1) signaling mechanism which acted as a key 
compensatory protective response against early oxidative damage in 
dopaminergic system. Therefore, the purpose of the present study was to 
extensivley characterize the key protein kinases involved in this survival 
signaling pathway in experimental models of Parkinson’s disease.   
Results 
Exposure of dopaminergic neurons to MPP+ / MPTP in both cell culture and 
animal models induced PKD1 activation loop (PKD1S744/748) 
phosphorylation, activation and nuclear translocation in the nigral 
dopaminergic neurons. Inhibition of PKCδ prevented PKD1 activation during 
MPP+ treatment. PKD1 was also not activated in the nigral dopaminergic 
neurons of PKCδ knock-out (PKCδ -/-) mice exposed to acute MPTP 
treatment.  Earlier we reported that Fyn kinase regulates PKCδ in 
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dopaminergic cells and the Fyn knock-out (Fyn -/-) mice exposed to acute 
MPTP treatment showed no PKD1activation. Also, the C-terminus S916 
phosphorylation occurs only in MPTP treated naïve mice but not in (PKCδ -/-) 
mice, confirming PKCδ’s tight control over PKD1 activation.  Further 
Dopaminergic neurons co-treated with PKD1 inhibitor kbNB 142-70 and 
exposed to MPP+ exacerbated neuronal death confirming the survival role of 
PKD1. Consistent with other results PKD1 was found activated in the 
surviving nigral dopaminergic neurons of human post-mortem PD brains 
Conclusion 
Collectively, our results demonstrate that PKD1 is regulated in a Fyn- PKCδ 
dependent manner and represents a novel intrinsic protective response in 
counteracting early stage oxidative damage in PD.  
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Introduction 
The incidence of Parkinson’s disease (PD) cases is dramatically increasing 
with in the U.S. population, with more than 80% of the cases being idiopathic.  
Current PD treatment options available are only symptomatic, creating a 
scientific imperative to understand the causes and medical management of 
PD (1, 2).  Oxidative stress is a major factor that contributes to 
neurodegeneration in PD ((3) (4) (5) (6) (7).  Better understanding of the key 
signaling molecules involved during the degenerative process caused by 
oxidative damage will open up novel neuroprotective avenues in Parkinson’s 
disease (8), (1), (9) (10) (2) (11) (12).  Our laboratory elucidated a novel pro-
apototic signaling mechanism in dopaminergic system; we showed that PKCδ 
is an oxidative stress sensor that is persistently activated by caspase-3 
dependent proteolytic cleavage (7) (13) (14) (15) (16). 
 PKD1 is a CAMK family member and activated in response to various stimuli 
in different disease models and activation has been shown to play a role in 
diverse cellular functions including proliferation, cytoskeletal reorganization, 
golgi function and immune response (17-20) (19, 21-24).  PKD1 can be 
activated by dual phosphorylation of seine residues at the activation loop (Ser 
744/ Ser 748) in the catalytic domain in response to multiple stimuli including 
growth factors, phorbol esters, G-protein coupled receptors, genotoxic stress 
and oxidative stress (25-27).  The role of PKD1 signaling in 
neurodegenerative diseases remains unexplored. 
While studying the downstream targets of PKCδ, our initial in-silico and in-
vitro analyses indicated that PKCδ can phosphorylate the activation loop 
serine residue of PKD1.  Surprisingly, PKD1 was found to be a PKCδ- 
dependent cell survival kinase rather than a cell death kinase in dopaminergic 
models. This led us to further investigate the signaling mechanisms 
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underlying the neuroprotective function mediated by PKD1 in experimental 
models of PD.  In this study, we used the classic MPP+/MPTP toxicant based 
model to understand PKD1 signaling in Parkinson’s disease. MPTP becomes 
toxic after it is metabolized into 1-methyl-4-phenylpyridinium (MPP+) in glial 
cells and interferes with the functioning of complex I of the electron transport 
chain in neurons leading to generation of free radicals and causes cell death 
(28, 29).  Herein, we report a novel functional interplay between protein 
kinases in which the PKD1 survival signaling pathway is regulated in a Fyn-
PKCδ dependent fashion in MPP+/MPTP induced neurodegeneration in both 
cell culture and animal models of PD.   
 
Materials and Methods: 
Cell Culture  
The immortalized rat mesencephalic dopaminergic neuronal cell line (N27) 
was a kind gift from Dr. Kedar N. Prasad (University of Colorado Health 
Sciences Center, Denver, CO). N27 cells were grown in RPMI 1640 medium 
containing 10% fetal bovine serum, 2 mm l-glutamine, 50 units of penicillin, 
and 50 μg/ml streptomycin. Cells were maintained in a humidified 
atmosphere of 5% CO2 at 37 °C, as described previously (13). N27 cells are 
used widely as a cell culture model for PD (45) (7) (33) (13, 34). 
 
Primary mesencephalic neuronal culture  
Primary mesencephalic neuronal cultures were prepared from the ventral 
mesencephalon of gestational 16- to 18-day-old mouse embryos, as 
described earlier (46). Tissues were dissected from E16 to E18 mouse 
embryos maintained in ice cold Ca2+-free Hanks' balanced salt solution and 
then dissociated in Hanks' balanced salt solution containing trypsin-0.25% 
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EDTA for 30 min at 37°C. The dissociated cells were then plated at equal 
density (0.5 × 106 cells) on 12 mm coverslips precoated with 0.1 mg/ml poly-
D-lysine.  Cultures were maintained in neurobasal medium fortified with B-27 
supplements, 500 μM l-glutamine, 100 IU/ml penicillin, and 100 μg/ml 
streptomycin (Invitrogen). The cells were maintained in a humidified CO2 
incubator (5% CO2 and 37°C). Half of the culture medium was replaced 
every 2 days. Approximately 6- to 7-day-old cultures were used for 
experiments. Primary mesencephalic dopaminergic neuronal cells were 
exposed to 10 μM for 1 h.  
 
Treatment Paradigm 
  N27 cells were exposed to MPP+ (300 μm) for 0– 24h at 37°C. Cell lysates 
were used for Western blotting and immunoprecipitation studies. Primary 
neurons were exposed to MPP+ (5 μm /10 μm) for 24/48 h for 
immunochemical staining and dopamine uptake assays. Untreated cells were 
grown in the complete medium and used as the experimental control. 
 
Cytotoxicity Assays  
 Cell death was determined using the Sytox green cytotoxicity assay, after 
exposing the N27 cells to MPP+ (300 μm), as described previously. This 
cytotoxicity assay was optimized for a multiwell format, which is more efficient 
and sensitive than other cytotoxicity measurements (47) (48). Briefly, N27 
cells were grown in 24-well cell culture plates at 100,000 cells per well and 
treated with MPP+ (300 μm) and 1 μm Sytox green fluorescent dye. The 
Sytox green assay allows dead cells to be viewed directly under a  
fluorescence microscope, as well as quantitatively measured with a 
fluorescence microplate reader (excitation 485 nm; emission 538 nm) 
(Biotek). Phase contrast and fluorescent images were taken after MPP+  
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exposure with a NIKON TE2000 microscope, and pictures were captured with 
a SPOT digital camera.  
 
Human Post-mortem PD brain slices 
Human tissues are obtained from the VA Medical Center at the University of 
Iowa.  40 M free floating sections were used for immunostaining with anti-
phospho antibodies specific for TH, and PKD1.  Very recently, we have 
optimized the condition for immunohistochemical analysis of human brain 
tissues in our laboratory.  Biochemical and histological data will be compared 
between control and PD post-mortem brains.   
 
Immunocytochemistry    
 The primary mesencephalic neurons or N27 cells after MPP+ treatment were 
fixed with 4% paraformaldehyde and processed for immunocytochemical 
staining. First, nonspecific sites were blocked with 2% bovine serum albumin, 
0.5% Triton and 0.05% Tween-20 in phosphate-buffered saline (PBS) for 20 
min. The cells then were incubated with antibodies directed against TH, 
native PKD1 and PKD1-pS744/S748 in PBS containing 1% BSA at 4°C 
overnight, followed by incubation with Alexa 488 and Alexa 568 conjugated 
secondary antibodies in PBS containing 1% BSA. Secondary antibody 
treatments were followed by incubation with Hoechst 33342 dye for 5 min at 
room temperature to stain the nucleus.  The coverslips containing stained 
cells were washed with PBS, mounted on slides, and viewed under a Nikon 
inverted fluorescence microscope (model TE-2000U; Nikon, Tokyo, Japan). 
Both fluorescence and confocal images were captured with a SPOT digital 
camera (Diagnostic Instruments, Inc., Sterling Heights, MI). 
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Immunohistochemical staining of brain slices. 
Mice were perfused with 4% paraformaldehyde and then the brain slices 
were cut on a microtome into 20 μm sections.  Brain sections were blocked 
with PBS containing 1% BSA and 0.1% Triton X-100 in for 20 min and then 
incubated with antibodies directed against PKD1, PKD1-pS744/S748 and TH 
overnight at 4°C followed by incubation with either Alexa 488-conjugated 
(green, 1:1000) or Alexa 568-conjugated (red, 1:1000) secondary antibody for 
1 h at RT.  Secondary antibody treatments were followed by incubation with 
Hoechst 33342 (10 μg/ml) for 3 min at RT to stain the nucleus.  Then the 
slices were mounted on a slide and viewed under a Nikon inverted 
fluorescence microscope (model TE-2000U); images were captured with a 
SPOT digital camera (Diagnostic Instruments, Sterling Heights, MI). 
 
Western Blot Analysis  
Cells were lysed in either modified RIPA buffer or M-PER buffer (Thermo 
Scientific) for Western blot, immunoprecipitation and kinase assays. Lysates 
containing equal amounts of protein were loaded in each lane and separated 
on 10-12% SDS-PAGE, as described previously (Kaul et al., 2003).  PKD1 
polyclonal (1:1000), PKCδ polyclonal (1: 1000), PKD1-pS744/S748 (1:1000), 
PKD1-pS916 (1:1000), Fyn (1:1000), - and β-actin (1:10000) antibodies were 
used to blot the membranes. IR dye-800 conjugated anti-rabbit (1:5000) and 
Alexa Fluor 680 conjugated anti-mouse (1:10000) were used for antibody 
detection with the Odyssey IR Imaging system (LICOR), as previously 
described. 
 
PKCδ Kinase Assay 
Immunoprecipitation and PKCδ kinase assay were performed as described 
earlier (7). After cell lysis, cell were immunoprecipitated using a polyclonal 
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PKCδ rabbit antibody and protein A Sepharose, and washed three times with 
PKCδ kinase buffer (40 mM Tris (pH 7.4), 20 mM MgCl2, 20 μM ATP, 2.5 mM 
CaCl2). The reaction was started by adding 20 μl of buffer containing 0.4 mg 
histone and 5 μCi of [γ-32P]ATP (4,500 Ci/mM). After incubation for 10 min at 
30°C, SDS loading buffer (2X) was added to the samples to terminate the 
reaction. The reaction products were separated on SDS-PAGE (12%), and 
the H1-phosphorylated bands were detected using a phosphoimager (Fujifilm 
FLA-5100) and quantified with MultiGauge V3.0 software. 
 
Protein Kinase D1 Kinase Assay  
 The cells were exposed to MPP+ (300 μM) for 1 h and cell lysates were 
immunoprecipitated, as previously reported, with native PKD1 antibody 
(Santa Cruz). The kinase reaction was carried out at room temperature for 20 
min after adding 10 μl of kinase substrate mix (0.1 mM ATP + 10 µci  [γ-32P] 
ATP + 2 ug Syntide 2 peptide substrate in kinase buffer). Kinase buffer 
contains 20 mM Tris  pH 7.5, 10 mM MgCl2, and 1 mM DTT.  The samples 
were centrifuged to terminate the kinase reaction, and the supernatants 
containing the phosphorylated peptide were applied as spots to P81 
phosphocellulose squares (Whatmann). The papers were washed four times 
with 0.75% phosphoric acid and once with acetone and dried, and activity 
was determined by liquid scintillation counting. The samples were also loaded 
on a SDS-PAGE and probed for native PKD1 to determine equal loading. 
 
Uptake of [3H] Dopamine 
The effects of PKD1 inhibitor Kb-NB142-70 on the uptake of dopamine were 
assessed in fetal mouse mesencephalic cultures using [3H]dopamine (DA), 
as described previously (Afeseh et al., 2009).  In brief, after incubation for 48 
h with 5 μM MPP+, with or without Kb-NB142-70, medium with the treatment 
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was removed and cells were then washed once by assay incubation (Krebs-
Ringer) buffer (5.6 mM glucose, 1.3 mM EDTA, 1.2 mM magnesium sulfate, 
1.8 mM calcium chloride, 4.7 mM potassium chloride, 120 mM sodium 
chloride, and 16 mM sodium phosphate). Cells were incubated with 10 μM 
[3H] DA (30 Ci/mol) for 20 min at 37°C. The uptake was stopped by removing 
the reaction mixture and followed by three washes with fresh Krebs-Ringer 
buffer.  Cells were then collected with the use of 1 N NaOH, and the 
radioactivity was measured by liquid scintillation counting.   
 
RNAi  
PKCδ-siRNA was prepared by an in vitro transcription method, as described 
previously (45). PKCδ-siRNA effectively suppressed  > 80% of PKCδ protein 
expression levels within 24 h post-transfection.  
 
Statistical Analysis 
Data analysis was performed using Prism 3.0 software (GraphPad Software, 
San Diego, CA). Bonferroni's multiple comparison testing was used to find 
the significant differences between treatment and control groups. Differences 
with p < 0.05, p < 0.01, and p < 0.001 were considered significantly different 
from n≥6 from two or more independent experiments, and are indicated in the 
figures.  
 
RESULTS 
Parkinsonian specific toxicant MPP+ induces PKD1 activation in cell 
culture models of PD 
We examined the activation loop phosphorylation (Ser744/Ser748) of PKD1.  
MPP+ (300 µM) induced PKD1 activation loop phosphorylation and activation 
in N27 dopaminergic cells.  As shown in Fig 1A, PKD1 activation loop 
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phosphorylation occurs in a time dependent manner from 0 - 24 hr as 
determined by western blot analysis.  PKD1 phosphorylation at 
Ser744/Ser748, peaks at 12 hr over a 24 hr period.  Furthermore, the 
Phosphorylation of PKD1 Ser744/Ser748 residues increased PKD1 kinase 
activity, as measured by a [32P] kinase assay using Syntide 2 substrate at 12 
h (Fig 1B).   
 
Next, we examined PKD1 signaling in primary mesencephalic neurons 
exposed to 10 µM MPP+ for 24 h.  Immunocytochemical staining was 
performed to examine the subcellular localization of native PKD1 in primary 
mesencephalic neurons.  We saw high level expression of PKD1 in the 
cytosolic region of MPP+ treated or untreated tyrosine hydroxylase (TH) 
(green) positive primary dopaminergic neurons obtained from mouse 
substantia nigra (Fig 1C).  Further, we performed immunocytochemical 
staining to examine the localization pattern of activated PKD1 in MPP+ 
treated neurons.  Our immunocytochemical staining for activated PKD1 
showed that the activated PKD1 (pS744/pS748) (red) co-localized with the 
nuclear Hoechst stain (blue) during 10µM MPP+-induced oxidative stress in 
primary mesencephalic neurons , as visualized by fluorescence microscopy 
(Fig 1D).  These results indicate that only activated PKD1 translocates to the 
nucleus of primary dopaminergic neurons when treated with a parkinsonian 
specific toxicant like MPP+. 
 
MPTP induces PKD1 activation in mouse substantia nigra 
Extension of the PKD1 oxidative signaling pathway from cell culture models 
to animal models is the next logical step in understanding the role of PKD1 
signaling in PD.  Therefore, we verified PKD1 expression pattern in mouse 
nigral tissues using immunostaining. As shown in Fig 2A cytosolic region of 
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tyrosine hydroxylase (TH) (green) positive dopaminergic neurons showed 
high expression of native PKD1.   
Since PKD1 is highly expressed in the nigral tissue, we examined the 
activation patttern of PKD1 (pSer744/pSer748).  As shown in Fig 2B time 
course studies of PKD1 activation in mice subjected to acute MPTP treatment 
paradigm shows that PKD1 is activated at 24 hours in the substantia nigral 
region as monitored by PKD1 activation loop phosphorylation (pS744/pS748). 
Further immunochemical staining of activated PKD1 (PKD1-pS744/pS748) at 
24 hrs after acute MPTP treatment shows co-localization of activated PKD1 
(red) in the nucleus of TH positive dopaminergic neurons (green) in mouse 
substantia nigra supporting the results obtained using MPP+ in cell culture 
models of PD (Fig 2C).  These results suggest that PKD1 is activated in the 
dopaminergic neurons present in the substantia nigra.   
 
PKCδ mediates PKD1 activation in cell culture models 
The activation loop serine residue was predicted to be phosphorylated by 
PKCδ at a high stringency in-silico analysis (Asaithambi et al. 2011). So we 
tested the involvment of PKC in PKD1 activation in specific dopaminergic 
degeneration induced by MPP+ / MPTP.  Knockdown of PKC  by specific 
siRNA (Fig 3A) greatly reduced PKC kinase activity as measured by ability 
of immunoprecipitated PKC to phosphorylate the substrate histone at 15 hr 
MPP+ treatment using [32P] ATP (Fig S1).  Further,  PKC knockdown greatly 
reduced PKC kinase activity as measured by a [32P] kinase assay using 
Syntide 2 substrate during  15h MPP+ treatment suggesting the involvment of 
PKC in PKD1 regulation (Fig 3B).  We also have shown that the caspase-3 
inhibitor DEVD-fmk and src family kinases inhibitor TSKI can inhibit PKC 
kinase activity during oxidative stress (Kaul et al. 2003).  Therefore, in this 
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study we used these inhibitors to confirm if PKC inhibition can block PKD1 
activation.  DEVD-fmk and TSKI treatment significantly attenuated PKC 
kinase activity (Fig S 2) and PKD1 kinase activity as measured by [32P] 
kinase assay using Syntide 2 substrate (Fig 3C).  Collectively, these results 
confirm the role of PKCδ in regulating PKD1 activation in N27 cells using 
MPP+. 
 
Attenuation of PKD1 activation in PKC knock out (-/-) mice 
After establishing the involvment of PKC in PKD1 signal transduction in cell 
culture models, these findings were extended to animal models using PKC 
knock out (PKC (-/-)) mice.  We used the primary mesencephalic 
dopaminergic neurons obtained from embryos of naïve and PKC knockout 
mice.  We treated the primary dopaminergic neurons with 10µM MPP+ for 24 
hours and compared the activation of PKD1 using PKD1-pS744/pS748 
antibody between PKC (+/+) and PKC (-/-) mice.  As shown in Fig 4A, 
Activated PKD1 (PKD1pS744/pS748) (red) co-localized with the nuclear 
Hoechst stain (blue) during 10µM MPP+ -induced oxidative stress in primary 
mesencephalic neurons obtained from PKC (+/+)  but not in PKC (-/-), as 
visualized by fluorescence microscopy.  Additional validation of this study 
was done using substantia nigra brain tissues obtained from adult PKC (-/-) 
and PKC (+/+) mice exposed to acute MPTP treatment paradigm.  Mice 
were treated with 4 doses of MPTP (18 mg/kg) in two hour intervals and 
sacrificed 24 hours after the last injection.  As shown in Fig 4B, PKD1 
pS744/pS748 levels were completeley attenuated in the brain lysates of 
PKC (-/-) mice compared with PKC (+/+) mice.  These results confirm that 
PKC is the upstream regulator of PKD1 in both cell culture and animal 
models of PD. 
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Fyn Kinase is the upstream regulator of PKC -PKD1 signaling in 
dopaminergic neurons 
Recently, we showed that Fyn kinase regulates PKCδ during oxidative stress 
(30).  In this study, we examined if Fyn kinase acts as an upstream regulator 
of PKCδ-PKD1 signaling in dopaminergic neurons.  We used the primary 
mesencephalic dopaminergic neurons obtained from embryos of naïve and 
Fyn knock out (Fyn (-/-)) mice.  We treated the cultured primary neurons with 
10µM MPP+ for 24 hours and compared the activation of PKD1 using PKD1-
pS744/pS748 antibody between the two groups.  As shown in Fig 5A, 
Activated PKD1 (PKD1pS744/pS748) (red) co-localized with the nuclear 
Hoechst stain (blue) during MPP+ -induced oxidative stress in primary 
mesencephalic neurons obtained from Fyn (+/+)  but not in Fyn (-/-), as 
visualized by fluorescence microscopy.  Further these results obtained in cell 
culture studies were extended to animal models of PD.  Fyn (-/-) and Fyn 
(+/+) mice were treated with 4 doses of MPTP (18 mg/kg) in two hour 
intervals and sacrificed 24 hours after the last injection.  As shown in Fig 5B, 
PKD1 pS744/pS748 levels were completeley attenuated in the brain lysates 
of Fyn (-/-) mice compared with Fyn (+/+) mice.  These results confirm that 
Fyn kinase is the upstream regulator of PKCδ-PKD1 signal transduction in 
both cell culture and animal models of PD. 
 
PKC dependent PKD1 S916 phosphorylation in dopaminergic neurons 
In addition to the activation loop phosphorylation of PKD1 (pS744/pS748), 
oxidative stress has been shown to cause PKD1 Ser 916 phosphorylation 
(31, 32).  In this study, we investigated PKD1 C-terminal Ser 916 
phosphorylation in specific dopaminergic degeneration. We used the primary 
mesencephalic neurons obtained from E16-E18 mouse embryos and treated 
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with 10µM MPP+.  As shown in Fig 6A, PKD1pS916 (red) was localized 
(pink/yellow) in both cytosol and nucleus of TH +ve primary mesencephalic 
neurons staining for green during MPP+ treatment.  Next, we examined the 
primary dopaminergic neurons obtained from embryos of PKC (-/-) and 
PKC  (+/+) for PKD1-pS744/pS748 levels.  We treated the primary neurons 
with 10µM MPP+ for 24 hours and compared the activation of PKD1 using 
PKD1-pS744/pS748 antibody between the two groups.  As shown in Fig 6B, 
Activated PKD1 (PKD1pS744/pS748) (red) co-localized with both cytosol and 
nucleus in dopaminergic neurons obtained from PKC (+/+) animals but not 
in PKC (-/-) animals, as visualized by fluorescence microscopy.  Together, 
these results suggest that a PKC dependent C-terminal PKD1 Ser916 
phosphorylation occurs in dopaminergic neurons. 
 
PKD1 activation acts as a novel compensatory mechanism in PD 
models 
The role of PKD1 was tested in this model using a specific PKD1 allosteric 
inhibitor (kbNB 142-70).  kbNB 142-70 inhibited PKD1 by completley 
attenuating PKD1-S744/S748 and PKD1-S916 phosphorylation levels (Fig 
7A).  Surprisingly, the co-treatment of N27 cells with 50 µM kbNB 142-70 
exacerbated cell death nearly two folds when exposed to MPP+ and 
monitored cell death using Sytox cell death assay indicating a cell survival 
role for PKD1(Fig 7B).  Next, we checked the effects of PKD1 inhibition on 
the functional efficiency of dopaminergic neurons using H3 dopamine uptake 
assay.  We co-treated primary mesencephalic neurons obtained from E16-
E18 mouse embryos with 50 µM PKD1 inhibitor kbNB 142-70 and performed 
[H3] dopamine uptake assay during 5 µM MPP+ treatments for 48 hr.  As 
shown in Fig 8C, PKD1 inhibition reduced the dopamine uptake of the 
primary neurons nearly two folds compared to MPP+ only treatment.  
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Together, these results confirm that PKD1 is anti-apoptotic in dopaminergic 
neurons exposed to MPP+ toxicity. 
 
PKD1 activation in human PD patients 
The biomedical relevance of these findings in cell culture and animal models 
were tested in humans using the tissues obtained from post-mortem PD 
cases.  We performed immunohistochemical staining to examine PKD1 
activation in human PD brain.  Activated PKD1 (PKD1pS744/pS748) (green) 
co-localized with the nuclear Hoechst stain (blue) in TH +ve (green) 
dopaminergic neurons of PD patients, as visualized by fluorescence 
microscopy.  These results indicate that activated PKD1 translocates to the 
nucleus of intact surviving dopaminergic neurons possibly to carry out 
neuronal survival functions.  These results indicate that PKD1 plays a very 
important role in survival functions in PD patients.  
 
Discussion 
This study systematically elucidates the presence of a novel neuronal survival 
signaling mechanism in PD models.  Using the classical MPTP model to 
induce dopaminergic degeneration, we demonstrate the following: (i) The 
anti-apoptotic protein kinase D1 (PKD1) is activated during early stage 
oxidative damage caused by MPP+/MPTP in cell culture and animal models 
of PD (ii) PKCδ regulates PKD1 activation (iii) Fyn Kinase acts as an 
upstream regulator of PKCδ – PKD1 signaling.  The elucidation of this novel 
survival signaling pathway in dopaminergic degenerative processes may lead 
to the development of novel treatment modalities. 
Oxidative damage induced apoptosis through activation of many pro-
apoptotic signaling kinases and proteases in neurodegeneration (3) (4) (5) (6) 
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(7).  We earlier reported a novel pro-apoptotic signaling mechanism mediated 
by  PKCδ in dopaminergic system (7) (33) (13, 34). Caspase-3-mediated 
proteolytic activation of PKCδ plays a critical role  in causing 
neurodegeneration in various cell culture and animal models including  6-
OHDA and MPTP/MPP+ induced dopaminergic degeneration (7) (33) (13, 
34).  While studying the downstream pro-apoptotic signal tranducers of 
PKCδ, preliminary in-silico analyses predicted that PKCδ can phosphorylate 
the activation loop serine residue of PKD1(31). Studies have previously 
shown that protein kinase D1 (PKD1) was a key signal transduction kinase 
associated with oxidative stress, so we hypothesized that PKCδ might cause 
cell death through activating PKD1 (23) (35, 36).  Unexpectedly, we found out 
that PKD1 is a cell survival kinase that protects against early oxidative 
damage in parkinsonian specific MPP+/MPTP models. Our results show that 
MPP+ induced PKD1 activation in a PKCδ dependent mechanism.  Our 
findings were strengthened by using PKCδ (-/-) (PKCδ knock out) mice 
subjected to acute MPTP treatment.  These results confirm the presence of 
the novel protective PKCδ-PKD1 pathway in dopaminergic neurons in 
Parkinsonian condition.  This is the first study to extensively delineate the role 
of PKD1 in a parkinsonian specific neurodegenerative model and supports 
our earlier results using a general oxidant like H2O2 (31).   
Following this observation, we probed for the key upstream regulator of 
PKCδ-PKD1 signaling.  Fyn kinase, a non-receptor tyrosine kinase from Src 
family has been shown to regulate PKCδ proteolytic activation in 
experimental models of PD (31). Dopaminergic neurons from Fyn (-/-) (Fyn 
kinase knock out) mice treated with MPTP donot show PKD1 activation which 
is in agreement with the results obtained in cell culture models treated with 
MPP+.  Our results indicate that Fyn kinase regulates PKCδ-PKD1 signaling 
pathway in PD experimental models. Multiple phosphorylation sites have 
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been implicated in PKD1 activation loop phosphorylation, depending on the 
cell types and stimuli (27) (37).  Previous groups have shown the involvement 
of Ser 916 phosphorylation in PKD1 activation in non-neuronal models (32, 
38, 39).  Ser 916 phosphorylation is a preceding event required for 
PKD1ser744/Ser748 activation loop phosphorylation (31).  Our current data 
suggest that phosphorylation of C-terminally located Ser 916 phosphorylation 
occurs in primary neurons treated with MPP+.  Further, Dopaminergic 
neurons from PKCδ (-/-) mice exposed to MPTP/MPP+ treatment donot show 
PKD1 Ser 916 phosphorylation, confirming a PKCδ dependent Ser 916 
phosphorylation in PD models. 
Eventhough our current study has confirmed the activation of anti-apoptotic 
PKD1 in pre-clinical models of PD.  The findings will be more relevant if 
demonstrated in human Parkinsonian patients.  Our examination of samples 
obtained from post-mortem human PD patients showed high levels of PKD1 
activation compared to age matched controls.  Put together we suggest that 
the anti-apoptotic PKD1 signaling controlled by Fyn-PKCδ is activated as an 
early protective compensatory mechanism in Parkinosn’s disease.  
Some of the key pro-apoptotic signaling kinases known to cause 
dopaminergic degeneration include JNK, MLK, MAPK, LRRK2, etc. (40-43).  
Therapeutic intervention by inhibiting the pro-apoptotic MLK family of kinases 
failed to stop PD progression in clinical trials (44).  An alternative approach 
for neuroprotection against PD could be through positively modulating the 
anti-apoptotic signaling mechanisms in neurons. But so far not much is 
known about kinases having survival function in dopaminergic system. Our 
elucidation of a novel early protective signal transduction mechanism in 
dopaminergic system could open up a new chapter in neuroprotection. 
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Studies are currently underway to functionaly modulate PKD1 signaling and 
see if it can be a possible neuroprotective strategy in PD. 
In conclusion, our results demonstrate the activation of the novel protective 
signaling mechanism mediated by PKD1 in MPTP induced dopaminergic 
degeneration.  PKD1 activation is tightly regulated by Fyn – PKCδ signaling 
pathway. Our results suggest that positive modulation of the anti-apoptotic 
PKD1 pathway can be a novel neuroprotective strategy against oxidative 
damage in PD.  
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Figure legends 
Figure 1. PKD1 is activated during MPP+ -treatment in cell culture 
models of PD   
N27 dopaminergic neuronal cells were treated with or without MPP+ (300 µM) 
for 8, 12 or 24 h and probed for PKD1 activation loop phosphorylation 
pS744/pS748 (A).  N27 cells were treated with or without MPP+ (300 µM) and 
PKD1 kinase activity was measured by [32P] kinase assay using syntide 2 
substrate at 12 h.  *, p<0.05 denotes significant difference between untreated 
and MPP+ -treated groups (B).  Primary dopaminergic neurons staining for 
tyrosine hydroxylase (TH) obtained from the mouse substantia nigral region 
show co-localization of native PKD1 with TH. TH – Green, PKD1 native – 
Red, Nucleus – Blue, Yellow -Merge. Nuclei were stained with Hoechst dye 
(C).  Primary dopaminergic neurons staining for tyrosine hydroxylase (TH) 
obtained from the mouse substantia nigral region show co-localization of 
activated PKD1 (pS744/pS748) with nucleus.  TH – Green, PKD1 
(pS744/pS748)– Red, Nucleus – Blue, Pink -Merge.  Nuclei were stained with 
Hoechst dye (D).  
Figure 2. PKD1 is activated during MPTP treatment in animal models of 
PD  
Immunohistochemical analysis of Mouse brain slices cut at the level of the 
substantia nigra staining for tyrosine hydroxylase (TH) show co-localization of 
native PKD1 with TH. TH – Green, PKD1 native – Red, Nucleus – Blue, 
Yellow -Merge. Nuclei were stained with Hoechst dye (A).  C57Bl/6 mice 
were exposed to acute MPTP treatment and sacrificed at 3, 12, 24, 72h and 
probed for PKD1 activation loop phosphorylation (pS744/pS748) (B).  
Immunohistochemical analysis of dopaminergic neurons staining for tyrosine 
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hydroxylase (TH) from Mouse brain slices cut at the level of the substantia 
nigra after acute MPTP treatment show co-localization of active PKD1 
(pS744/pS748) with nucleus.  TH – Green, PKD1 (pS744/pS748) – Red, 
Nucleus – Blue, Pink -Merge. Nuclei were stained with Hoechst dye (C). 
Figure 3. PKD1 activation is regulated by PKCδ in cell culture models of 
PD 
N27 dopaminergic cells were transfected with 1 μM PKCδ siRNA and non-
specific siRNA and monitored for PKCδ protein expression (A), and PKCδ 
kinase activity assay (B) and PKD1 kinase activity assay was performed (C).  
***, p<0.01 denotes significant difference between NS-siRNA-MPP+ and 
PKCδ-siRNA-MPP+ groups.  N27 dopaminergic cells were treated with MPP
+
 
(300 μM) with or without 50 μM DEVD and 5 μM TSKI, and further PKCδ 
kinase activity assay (D) and PKD1 kinase activity assay was performed (E).  
***, p<0.01 denotes significant difference between MPP+ and DEVD/TSKI co-
treated groups.   
Figure 4. PKD1 activation is regulated by PKCδ in animal models of PD.    
Primary mesencephalic cultures obtained from PKCδ WT (+/+) and PKCδ KO 
(-/-) mice were treated with 10 µM MPP+ and immunochemical staining was 
performed.  Activated PKD1 (pS744/pS748) co-localized with the nucleus of 
dopaminergic neurons obtained only from PKCδ WT (+/+) staining for 
tyrosine hydroxylase (TH).  TH – Green, PKD1 (pS744/pS748) – Red, 
Nucleus – Blue, Pink -Merge.  Nuclei were stained with Hoechst dye (D).  
PKCδ WT (+/+) and PKCδ KO (-/-) adult mice were exposed to acute MPTP 
treatment and sacrificed at 24h after the last injection and the brain 
homegenates from the substantia nigral region were blotted for active PKD1 
(pS744/pS748) (B). 
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Figure 5. Fynkinase acts as an upstream regulator of PKCδ-PKD1 
signaling  
Primary mesencephalic cultures obtained from Fyn WT (+/+) and Fyn KO (-/-) 
mice were treated with 10 µM MPP+ and immunochemical staining was 
performed.  Activated PKD1 (pS744/pS748) co-localized with the nucleus of 
dopaminergic neurons obtained only from Fyn WT (+/+) staining for tyrosine 
hydroxylase (TH).  (A).  Fyn WT (+/+) and Fyn KO (-/-) adult mice were 
exposed to acute MPTP treatment and sacrificed at 24h after the last 
injection and the brain homegenates from the substantia nigral region were 
blotted for active PKD1 (pS744/pS748) (B).  TH – Green, PKD1 
(pS744/pS748) – Red, Nucleus – Blue, Pink -Merge.  Nuclei were stained 
with Hoechst dye 
Figure 6. PKD1 S916 phosphorylation is dependent on PKCδ 
Primary dopaminergic neurons staining for TH show presence of PKD1pS916 
in both cytosol and nucleus during 10 µM MPP+ exposure. (A).  Primary 
mesencephalic cultures obtained from PKCδ WT (+/+) and PKCδ KO (-/-) 
mice were treated with 10 µM MPP+ and immunochemical staining was 
performed.  PKD1 pS916 co-localized with the nucleus and cytosol of 
dopaminergic neurons obtained only from PKCδ WT (+/+) staining for 
tyrosine hydroxylase (TH).  TH – Green, PKD1 (pS744/pS748) – Red, 
Nucleus – Blue, Pink -Merge.  Nuclei were stained with Hoechst dye (D).   
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Figure 7. PKD1 protects against MPP+ induced oxidative stress in 
dopaminergic neurons  
 N27 cells were co-treated with or without 50 µM PKD1 inhibitor kb-NB 14270 
(A) and monitored for cell death during MPP+ treatment (B).Mouse primary 
mesencephalic neurons were co-treated with or without 50 µM PKD1 inhibitor 
kb-NB 14270 and monitored for viability during MPP+ treatment using 3H 
dopamine uptake assay (C).  ***, p<0.001  and **, p<0.01  denotes significant 
difference between treatment groups from n≥6. 
Figure 8. PKD1 activation occurs in human PD patients 
Human post-mortem PD brain sections were blotted for active PKD1 
(pS744/pS748) (A).  TH – Green, PKD1 (pS744/pS748) – Red, Nucleus – 
Blue, Pink -Merge.  Nuclei were stained with Hoechst dye 
Figure 9. Schematic of Fyn-PKCδ-PKD1 signal transduction mechanism 
in pre-clinical models 
1) Oxidative stress causes mitochondrial impairment; 2) Activation of 
Fynkinase; 3) Fyn kinase regulates the proteolytic activation of PKCδ; 4) 
Proteolytically activated PKCδ activates PKD1; 5) PKD1 activation protects 
stress during the early stages of oxidative stress in dopaminergic neurons 
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Chapter V: Rationally designed PKD1 activator protects 
against neurodegeneration in pre-clinical models of 
Parkinson’s disease 
Planned communication to Science Translational Medicine 
Arunkumar Asaithambi, Anamitra Ghosh*, Muhammet Ay*, Arthi 
Kanthasamy, Katherine Mullin, Vellareddy Anantharam and 
Anumantha G. Kanthasamy§  
Abstract 
Oxidative stress leads to degeneration in Parkinson’s disease (PD). The key 
signal transduction and regulatory networks that are involved during this 
degenerative process in PD are currently being investigated for novel neuro-
protective strategies. We recently discovered that the activation of Protein 
Kinase D1 (PKD1) acts as a novel compensatory mechanism in Parkinson’s 
disease models and positive modulation of PKD1 can be a therapeutic 
strategy.  Therefore, the purpose of the present study was to take a 
translational approach by developing a PKD1 activator and characterizing the 
protective function in pre-clinical models of Parkinson’s disease.   
Results  
Positive genetic modulation of PKD1 by overexpression of constitutively 
active PKD1 protected against MPP+ induced toxicity.  Pharmacological 
activation by Rosiglitazone protected, whereas inhibition by kbNB 142-70 
exacerbated against MPP+ and 6-OHDA toxicity in cell culture PD models. 
Peptides were rationally designed and screened for their ability to activate 
PKD1 using various screening methods. Peptide AK-P4 was identified to 
activate PKD1 specifically and protect against MPP+ and 6-OHDA in both 
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N27 cells and primary mesencephalic neurons. Further AK-P4 tagged with 
TAT sequence (AK-P4T) delivered using intra-venous injections activated 
PKD1 in mice. The neuro-protective effects of AK-P4T were tested using the 
sub-chronic MPTP mice model. Co-treatment with AK-P4T restored the 
neurotransmitter levels and the behavioral and locomotory activities of the 
MPTP treated mice significantly.   
 
Collectively, our results demonstrate that rationally designed PKD1 activator 
peptide AK-P4T positively modulated PKD1 and protected against 
neurodegeneration in the pre-clinical models of PD. Our results suggest that 
positive modulation of the PKD1 using AK-P4T shows promise as a potential 
therapeutic agent against PD. 
 
Introduction 
Parkinson’s disease (PD) is the second common neurodegenerative disorder 
affecting over a million Americans. Current treatment approaches available 
for Parkinson’s disease are symptomatic and fail to prevent the progression 
of the neurodegenerative process.  The currently available drugs are limited 
in their effectiveness to either slow or stop the progressive neurodegenerative 
processes in PD, largely due to the lack of mechanistic insights into the 
selective dopaminergic degenerative process (1, 2). 
Experimental findings from cell cultures, animal models, and humans indicate 
that oxidative stress and apoptosis may contribute to the pathophysiological 
processes in PD.  Neuronal cells maintain an oxidant / antioxidant 
homeostatic balance.  Any breach in this homeostasis causes excessive 
ROS production and oxidative damage, which might lead to 
neurodegenerative disorders (3), (1), (4) (5) (2) (6) (7).   
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Most investigations of signaling in neurodegenerative disorders including ours 
have primarily focused on signaling pathways that is involved in execution of 
cell death during this oxidant / antioxidant homeostatic breach (8) (9) (10) 
(11) (12).  None of the therapeutic interventions developed against the major 
cell death kinases have progressed to the treatment stage, probably due to 
the lack of understanding of the complex signal transduction process (13).    
This resulted in an imperative to find an alternative approach to prevent PD 
progression.   
The protective compensatory mechanisms to counteract the oxidative 
damage in Parkinson’s disease are still largely unexplored.  Recently, we 
reported that protein kinase D1 (PKD1) an oxidative stress sensor is 
activated during the early stages of oxidative stress to maintain the 
homeostatic balance and promote cell survival in PD cell culture and animal 
models (14). PKD1 get fully activated through phosphorylation at activation 
loop serine sites (S744/S748).  Further phosphorylation at PKD1 S916 
preceeds and regulates the activation loop phosphorylation (14) 
We hypothesized that positive modulation of PKD1 .can ba a novel 
therapeutic approach against PD.  So, we rationally designed peptide 
modulators to activate PKD1.  The PKD1 activator peptide AK-P4T protected 
against neurodegeneration in both cell culture and animal models of PD.  
Herein, we describe the design, development and characterization of the 
peptide based drug AK-P4T as a novel therapeutic agent in pre-clinical 
models of Parkinson’s disease.   
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Materials and Methods: 
Cell Culture  
The immortalized rat mesencephalic dopaminergic neuronal cell line (N27) 
was a kind gift from Dr. Kedar N. Prasad (University of Colorado Health 
Sciences Center, Denver, CO). N27 cells were grown in RPMI 1640 medium 
containing 10% fetal bovine serum, 2 mm l-glutamine, 50 units of penicillin, 
and 50 μg/ml streptomycin. Cells were maintained in a humidified 
atmosphere of 5% CO2 at 37 °C, as described previously (28). N27 cells are 
used widely as a cell culture model for PD (29) (12) (30) (28, 31). 
 
Primary mesencephalic neuronal culture  
Primary mesencephalic neuronal cultures were prepared from the ventral 
mesencephalon of gestational 16- to 18-day-old mouse embryos, as 
described earlier (32). Tissues were dissected from E16 to E18 mouse 
embryos maintained in ice cold Ca2+-free Hanks' balanced salt solution and 
then dissociated in Hanks' balanced salt solution containing trypsin-0.25% 
EDTA for 30 min at 37°C. The dissociated cells were then plated at equal 
density (0.5 × 106 cells) on 12 mm coverslips precoated with 0.1 mg/ml poly-
D-lysine.  Cultures were maintained in neurobasal medium fortified with B-27 
supplements, 500 μM l-glutamine, 100 IU/ml penicillin, and 100 μg/ml 
streptomycin (Invitrogen). The cells were maintained in a humidified CO2 
incubator (5% CO2 and 37°C). Half of the culture medium was replaced 
every 2 days. Approximately 6- to 7-day-old cultures were used for 
experiments. Primary mesencephalic dopaminergic neuronal cells were 
exposed to 10 μM for 1 h.  
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Cytotoxicity Assays  
 Cell death was determined using the Sytox green cytotoxicity assay, after 
exposing the N27 cells to H2O2 (100 μm), as described previously. This 
cytotoxicity assay was optimized for a multiwell format, which is more efficient 
and sensitive than other cytotoxicity measurements (33) (34). Briefly, N27 
cells were grown in 24-well cell culture plates at 100,000 cells per well and 
treated with H2O2 (100 μm) and 1 μm Sytox green fluorescent dye. The Sytox 
green assay allows dead cells to be viewed directly under a  fluorescence 
microscope, as well as quantitatively measured with a fluorescence 
microplate reader (excitation 485 nm; emission 538 nm) (Biotek). Phase 
contrast and fluorescent images were taken after H2O2 exposure with a 
NIKON TE2000 microscope, and pictures were captured with a SPOT digital 
camera.  
 
Immunocytochemistry    
 The primary mesencephalic neurons or N27 cells after H2O2 treatment were 
fixed with 4% paraformaldehyde and processed for immunocytochemical 
staining. First, nonspecific sites were blocked with 2% bovine serum albumin, 
0.5% Triton and 0.05% Tween-20 in phosphate-buffered saline (PBS) for 20 
min. The cells then were incubated with antibodies directed against TH, 
native PKD1 and PKD1-pS744/S748 in PBS containing 1% BSA at 4°C 
overnight, followed by incubation with Alexa 488 and Alexa 568 conjugated 
secondary antibodies in PBS containing 1% BSA. Secondary antibody 
treatments were followed by incubation with Hoechst 33342 dye for 5 min at 
room temperature to stain the nucleus.  The coverslips containing stained 
cells were washed with PBS, mounted on slides, and viewed under a Nikon 
inverted fluorescence microscope (model TE-2000U; Nikon, Tokyo, Japan). 
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Both fluorescence and confocal images were captured with a SPOT digital 
camera (Diagnostic Instruments, Inc., Sterling Heights, MI). 
 
Immunohistochemical staining of brain slices. 
Mice were perfused with 4% paraformaldehyde and then the brain slices 
were cut on a microtome into 20 μm sections.  Brain sections were blocked 
with PBS containing 1% BSA and 0.1% Triton X-100 in for 20 min and then 
incubated with antibodies directed against PKD1, PKD1-pS744/S748 and TH 
overnight at 4°C followed by incubation with either Alexa 488-conjugated 
(green, 1:1000) or Alexa 568-conjugated (red, 1:1000) secondary antibody for 
1 h at RT.  Secondary antibody treatments were followed by incubation with 
Hoechst 33342 (10 μg/ml) for 3 min at RT to stain the nucleus.  Then the 
slices were mounted on a slide and viewed under a Nikon inverted 
fluorescence microscope (model TE-2000U); images were captured with a 
SPOT digital camera (Diagnostic Instruments, Sterling Heights, MI). 
 
Diaminobenzidine immunostaining and stereological counting of TH-
positive neurons 
Tyrosine hydroxylase–diaminobenzidine (DAB) immunostaining was 
performed in striatal and substantia nigral sections as described previously. 
Mice brains after sacrifice were perfused with 4% paraformaldehyde (PFA) 
and postfixed with PFA and 30% sucrose. The fixed brains were 
subsequently cut using previous termanext term cryostat into 30-μm coronal 
sections and kept in 30% sucrose–ethylene glycol solution at − 20 °C. On the 
day of staining, sections were rinsed with PBS and incubated with the anti-TH 
antibody (Calbiochem rabbit anti-mouse, 1:1600) overnight at 4 °C. 
Biotinylated anti-rabbit secondary antibody was used for 1 h at room 
temperature. The sections were then incubated with avidin peroxidase 
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(Vectastatin ABC Elite kit) for 30 min at room temperature. Immunolabeling 
was observed using DAB, which yielded previous termanext term brown 
stain. Total numbers of TH-stained neurons in SNpc were counted 
stereologically with Stereo Investigator software (MicroBrightField, Williston, 
VT, USA), using an optical fractionators. 
 
Western Blot Analysis  
Cells were lysed in either modified RIPA buffer or M-PER buffer (Thermo 
Scientific) for Western blot, immunoprecipitation and kinase assays. Lysates 
containing equal amounts of protein were loaded in each lane and separated 
on 10-12% SDS-PAGE, as described previously (Kaul et al., 2003).  PKD1 
polyclonal (1:1000), PKCδ polyclonal (1: 1000), PKD1-pS744/S748 (1:1000), 
PKD1-pS916 (1:1000), PKD1-pY469 (1:1000), - and β-actin (1:10000) 
antibodies were used to blot the membranes. IR dye-800 conjugated anti-
rabbit (1:5000) and Alexa Fluor 680 conjugated anti-mouse (1:10000) were 
used for antibody detection with the Odyssey IR Imaging system (LICOR), as 
previously described. 
 
PKCδ Kinase Assay 
Immunoprecipitation and PKCδ kinase assay were performed as described 
earlier (12). After cell lysis, cell were immunoprecipitated using a polyclonal 
PKCδ rabbit antibody and protein A Sepharose, and washed three times with 
PKCδ kinase buffer (40 mM Tris (pH 7.4), 20 mM MgCl2, 20 μM ATP, 2.5 mM 
CaCl2). The reaction was started by adding 20 μl of buffer containing 0.4 mg 
histone and 5 μCi of [γ-32P]ATP (4,500 Ci/mM). After incubation for 10 min at 
30°C, SDS loading buffer (2X) was added to the samples to terminate the 
reaction. The reaction products were separated on SDS-PAGE (12%), and 
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the H1-phosphorylated bands were detected using a phosphoimager (Fujifilm 
FLA-5100) and quantified with MultiGauge V3.0 software. 
 
Protein Kinase D1 Kinase Assay  
 The cells were exposed to H2O2 (100 μM) for 1 h and cell lysates were 
immunoprecipitated, as previously reported, with native PKD1 antibody 
(Santa Cruz). The kinase reaction was carried out at room temperature for 20 
min after adding 10 μl of kinase substrate mix (0.1 mM ATP + 10 µci  [γ-32P] 
ATP + 2 μg Syntide 2 peptide substrate in kinase buffer). Kinase buffer 
contains 20 mM Tris  pH 7.5, 10 mM MgCl2, and 1 mM DTT.  Kinase assay 
performed using recombinant PKD1 protein in cell free system contained 90 
μg/ml Phospatidyl serine and 175 nM PMA in addition in the assay buffer. 
The samples were centrifuged to terminate the kinase reaction, and the 
supernatants containing the phosphorylated peptide were applied as spots to 
P81 phosphocellulose squares (Whatmann). The papers were washed four 
times with 0.75% phosphoric acid and once with acetone and dried, and 
activity was determined by liquid scintillation counting. The samples were 
also loaded on a SDS-PAGE and probed for native PKD1 to determine equal 
loading. 
 
 Transient and Stable Transfections  
PKD1 activation loop, active PKD1S744E/S748E (PKD1-CA) were obtained 
from Addgene, Inc. (15). Electroporation was carried out with an Amaxa 
Nucleofector instrument, as per the manufacturer's protocol. The transfected 
cells were then transferred to T-75 flasks or 6-well plates as desired and 
allowed to grow for a 24 h period before the treatment.  
Uptake of [3H] Dopamine 
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The effects of PKD1 inhibitor AK-P4T on the uptake of dopamine were 
assessed in fetal mouse mesencephalic cultures using [3H]dopamine (DA), 
as described previously (Afeseh et al., 2009).  In brief, after incubation for 48 
h with 5 μM MPP+, with or without Kb-NB142-70, medium with the treatment 
was removed and cells were then washed once by assay incubation (Krebs-
Ringer) buffer (5.6 mM glucose, 1.3 mM EDTA, 1.2 mM magnesium sulfate, 
1.8 mM calcium chloride, 4.7 mM potassium chloride, 120 mM sodium 
chloride, and 16 mM sodium phosphate). Cells were incubated with 10 μM 
[3H] DA (30 Ci/mol) for 20 min at 37°C. Positive controls were obtained by 
incubating the cells with 10 μM [3H] DA together with 1 nM mazindol (potent 
dopamine reuptake inhibitor). The uptake was stopped by removing the 
reaction mixture and followed by three washes with fresh Krebs-Ringer 
buffer.  Cells were then collected with the use of 1 N NaOH, and the 
radioactivity was measured by liquid scintillation counting.   
 
HPLC analysis of striatal dopamine and its metabolite levels 
High-performance liquid chromatography (HPLC) with electrochemical 
detection were used to quantify striatal dopamine (DA), 3,4-
dihydroxyphenylacetic acid (DOPAC), and homovanillic acid (HVA) levels. 
Samples briefly, after 7 days of MPTP injection, mice were sacrificed and 
striata were collected and stored at − 80 °C. On the day of analysis, 
neurotransmitters from striatal tissues were extracted in 0.1 M perchloric acid 
solutions containing 0.05% Na2EDTA and 0.1% Na2S2O5 and isoproterenol 
(as an internal standard). The extracts were filtered in 0.22-μm spin tubes, 
and 20 μl of the sample was loaded for analysis. DA, DOPAC, and HVA were 
separated isocratically in a reversed-phase column using  a  flow rate of 0.7 
ml/min. An HPLC system (ESA, Bedford, MA, USA) with an automatic 
sampler equipped with a refrigerated temperature control  
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(Model 542; ESA) was used in these experiments. The electrochemical 
detection system consisted of a Coulochem Model  5100A with  a  
microanalysis cell  
(Model  5014A) and  a  guard cell ( Model  5020; ESA). Standard stock 
solutions of catecholamines (1 mg/ml) were prepared in perchloric acid 
solution and further diluted to a final working concentration of 50 pg/μl before 
injection. The data acquisition and analysis were performed using the EZStart 
HPLC software (ESA). 
 
Animals and treatment 
Six- to 8-week-old male C57BL/6 mice weighing 24 to 28 g were housed 
under standard conditions: constant temperature (22 ± 1 °C) and humidity 
(relative, 30%) and a 12-h light/dark cycle. Mice were allowed free access to 
food and water. Use of the animals and protocol procedures were approved 
and supervised by the Committee on Animal Care at Iowa State University 
(Ames, IA, USA). Mice received AK-P4T (5 mg/kg dose) and the control 
peptide intravenous injections for 1 day (pretreatment before MPTP 
administration), 5 days (co-treatment with MPTP), and 7 days (post-treatment 
with MPTP). In the subchronic MPTP regimens, MPTP (25 mg/kg) was 
injected intraperitoneally via a single dose daily starting on day 2 for 5 days. 
The control mice received saline at the same dose.  
 
Behavioral measurements 
An open-field experiment for testing locomotor activities after MPTP and AK-
P4T treatments An automated device (AccuScan, Model RXYZCM-16; 
Columbus, OH, USA) was used to measure the spontaneous activity of the 
mice. The activity chamber was 40 × 40 × 30.5 cm, made of clear Plexiglas, 
and covered with a Plexiglas lid with holes for ventilation. The infrared 
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monitoring sensors were located every 2.54 cm along the perimeter (16 
infrared beams along each side) and 2.5 cm above the floor. Two additional 
sets of 16 sensors were located 8.0 cm above the floor on opposite sides. 
Data were collected and analyzed by a VersaMax analyzer (AccuScan, 
Model CDA-8). Before any treatment, mice were placed inside the infrared 
monitor for 10 min daily for 3 consecutive days to train them. Five days after 
the last MPTP injection, both open-field and rotarod experiments were 
conducted.  
 
Statistical Analysis 
Data analysis was performed using Prism 3.0 software (GraphPad Software, 
San Diego, CA). Bonferroni's multiple comparison testing was used to find 
the significant differences between treatment and control groups. Differences 
with p < 0.05, p < 0.01, and p < 0.001 were considered significantly different 
from n≥6 from two or more independent experiments, and are indicated in the 
figures.  
 
Results 
Genetic and Pharmacological modulation of PKD1 activation protects 
against cell death in PD cell culture model 
We used the two major parkinsonian toxicants 6-OHDA and MPP+ in the 
current study.  We have previously shown that PKD1 is activated in 6-OHDA 
and MPP+ induced oxidative stress (14). As shown in Fig 1A 100 µM 6-OHDA 
and 300µM MPP+ induces PKD1 activation loop phosphorylation 
(pS744/pS748) in a time dependent manner in N27 dopaminergic cells.  
Further, positive and negative genetic manipulation of PKD1 confirms the cell 
survival role of PKD1.  We overexpressed the constitutivley active human 
144 
 
PKD1 plasmid (PKD1-S744E/S748E) and phospho-defective PKD1S916A in N27 
cells and then exposed to 6-OHDA and MPP+.  Mutation of serine residues at 
position 744 and 748 results in constitutively active PKD1 (15).  As shown in 
Fig. 1C, overexpression of PKD1S744E/S748E significantly attenuated 6-OHDA 
and MPP+ induced cytotoxic cell death compared to vector transfected 
dopaminergic cells, whereas overexpression of phospho-defective PKD1S916A  
significantly attenuated 6-OHDA and MPP+ induced cytotoxic cell death 
compared to vector transfected dopaminergic cells.   
Since genetic modulation of PKD1 can protect neuronal cells, we 
hypothesized that pharmacological modulation of PKD1 should influence cell 
survival and death.  N27 dopaminergic cells were exposed to + 
-70 and 
cytotoxic cell death was determined using Sytox green assay.  As shown in 
Fig 1D, co- -70 exacerbated MPP+-induced 
cytotoxic cell death compared to MPP+ alone treated cells.   
Next, as a proof of concept we examined if positive pharmacological 
modulation of PKD1 can protect against oxidative damage and cell death.  
Since there are no PKD1 activators available, we screened for PKD1 
activators.  We have previously shown that in dopaminergic neurons 
proteolytically activated PKCδ phosphorylates PKD1 during the early stage, 
so we looked for drugs that can cause persistent activation of PKD1 
independent of PKCδ cleavage.  After carefully reviewing different PKD1 
activation mechanisms in various other models, we handpicked some drugs 
and screened them for their potential to activate PKD1 through these 
mechanisms.  As shown in Fig 1E primary screening of 10 µM Carbachol, 50 
µM Desmopressin, 100 µM Rosiglitazone, 100 ng/ml BMP2, and 25mM 
Glucose were peformed using western blot to screen for their potential to 
phosphorylate activation loop of PKD1 (pS744E/pS748E).  Eventhough both 
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Rosiglitazone and Desmopressin induced PKD1 activation loop 
phosphorylation, only Rosiglitazone’s mechanism of activation was 
indepenent of PKCδ cleavage.  Next, we used a genetic based FRET 
reporter optimized in a plate reader format as a secondary screening method 
to report PKD1 activity.  Previously this FRET reporter has been used to 
monitor PKD1 activity directly in cells (16-18).  As shown in Fig 1F 10 µM 
Rosiglitazone increased PKD1 activity as shown by the FRET change 
(CFP/YFP) read out.  Further, only 10 µM Rosiglitazone protected against 
100 µM 6-OHDA induced cell death in N27 cells.  Next, we examined if 
Rosiglitazone can protect against mouse primary dopaminergic neurons.  As 
showed in Fig 1G Immunoflourescence pictures of Tyrosine Hydroxylase 
(TH) positive dopaminergic neurons showed protection against 10 µM 6-
OHDA when co-treated with 10 µM Rosiglitazone.  These results 
unequivocally demonstrate that positive pharmacological modulation of PKD1 
has protective compensatory role against oxidative damage.   
 
Rational drug design 
Eventhough we showed that positive modulation of PKD1 through 
Rosiglitazone has protective function in cell culture models of PD.  We 
wanted to develop specific activators of PKD1, as rosiglitazone is not specific 
and has other known functions (16, 17).  Previously it has been shown that 
specific peptide based regulators targeting protein-protein interactions of 
PKCs have been successfully developed and advanced to clinical trials in 
cardiovascular diseases (19) (20). PKD1 has a very different structure 
compared to PKCs; it has two cysteine rich domains and a pleckstrin 
homology (PH) domain in the regulatory fragment.  It was shown that the 
regulatory fragment importantly the PH domain has an auto-inhibitory role by 
interacting with the catalytic fragment but lacks a defined pseudo-substrate 
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domain like PKCs (21, 22).  After careful analysis of PKD1 primary and 
secondary structure, we hypothesized that PKD1 region containing the 
consensus substrate-like motif (LXRXXS/T) and pseudosubstrate-like motif 
(LXRXX#, LXR##, #- serine or threonine residue replaced mostly by a 
hydrophobic/aliphatic residue) can regulate PKD1 intra-protein interactions.  
Peptides mimicking these regions can be highly specific modulators of PKD1 
activity.  As shown in Fig 2A, Alignment of distantly related PKD1 sequences 
from murine and C.elegans show the presence of highly conserved regions 
around the substrate-like and pseudosubstrate-like sequences only in the 
regulatory fragment.  Further, the regions containing the pseudo-substrate 
like sequence are highly conserved between the three PKD isoforms, 
whereas the substrate-like sequence is present only in PKD1 (Fig 2B).  We 
chose four of these regions from each domain; the highly conserved 6 aa 
peptide AK-P1 (6-11 amino acids), and 11 aa peptide AK-P2 (36-46 amino 
acids) were synthesized from the cysteine rich domain 1, 10 aa peptide AK-
P3 (295-395 amino acids) were synthesized from the cysteine rich domain 2, 
12 aa peptide AK-P4 (405-416 amino acids) were synthesized from the 
pleckstrin homology (PH) domain.  Additionally, Peptides disrupting protein-
protein interactions have also been shown to regulate kinase activity.  
Mochly-Rosen group reported that there are regions in PKC enzymes that are 
homologous to the PKC carrier protein RACK (termed pseudo-RACKS) and 
the peptides synthesized mimicking this region can facilitate PKC 
translocation and activation (23).  Using this rational, we detected similar 
regions in PKD1 that are homologus to PKD1 interaction proteins 14-3-3γ 
and Gβγ.  As shown in Fig 2C, a 5 aa peptide AK-P5 (54-58 amino acids) 
from the cysteine rich domain 1 (pseudo-14-3-3γ), a 9 aa peptide AK-P6 (79-
87 amino acids) from the pleckstrin homology (PH) domain (pseudo- Gβγ) 
and a 5 aa control peptide AK-P7 (135-139 amino acids) were synthesized.  
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Primary screening of the synthesized peptides were done using the phospho-
specific anti-bodies to detect PKD1 S744/S748 and S916 phosphorylation.  
As shown in Fig 2D, 50 µM of AK-P3 and AK-P4 induced PKD1 S744/S748 
and S916 phosphorylation in N27 cells.  Secondary screening was performed 
by monitoring PKD1 kinase activity as measured by a [32P] kinase assay 
using Syntide 2 substrate (Fig 2E).  Peptides AK-P3 and AK-P4 significantly 
increased PKD1 activity validating the results obtained from primary 
screening whereas AK-P1 significantly decreased kinase activity.  The 
specificity of the peptides in activating PKD1 was tested in a cell free system 
using a human recombinat PKD1 enzyme.  As shown in Fig 2C, AK-P4 
increase PKD1 kinase activity and directly activates PKD1.  Together these 
results confirm that peptides mimicking PKD1’s substrate-like region acts an 
inhibitor whereas peptides mimicking highly conserved PKD1’s 
pseudosubstrate-like region acts an activator.   
 
PKD1 activation by AK-P4 TAT in cell culture models of PD 
The effect of PKD1 peptide activators on cell survival was tested in N27 cells 
using toxins MPP+ and 6-OHDA.  Fig 3A shows that N27 cells treated with 
50µM AK-P3 and AK-P4 protected against 50µM 6-OHDA induced toxicity.  
But only 50µM AK-P4 not AK-P3 protected against N27 cells treated with 
300µM MPP+ (Fig 3B).  Additional validation of the role of AK-P4 was sought 
by extending these studies to animal models.  To facilitate efficient delivery of 
AK-P4 into the brain, we tagged the AK-P4 peptide with a 13 aa HIV-TAT 
transporter peptide through diglycine conjugation.  Neuroprotective effect of 
the TAT conjugated AK-P4 peptide (AK-P4T) was tested initially in N27 cells 
and mouse primary mesencephalic neuronal cultures.  As shown in Fig 3C 
AK-P4T protected against 100µM 6-OHDA induced toxicity at a concentration 
of 100 nM.  Further, primary mesencephalic neurons were co-treated with 50 
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nM AK-P4T to determine its protcetive effect against 5µM MPP+ treatment for 
48 hours. As shown in fig 3D, the number of surviving tyrosine hydroxylase 
(TH) positive neurons were almost equal to control levels whereas MPP+ 
treatment group only showed 30%.  Next, effects of AK-P4T on the functional 
efficiency of dopaminergic neurons were studied using H3 dopamine uptake 
assay.  TH neurite length in AK-P4T co-treatment group was equal to control 
levels whereas TH neurite length was reduced 3-fold in MPP+ treated neurons 
(Fig 3E).  Further, As shown in fig 3E, AK-P4T co-treatment brought back the 
dopamine uptake of MPP+ treated neurons to 80% of control, whereas MPP+ 
treatment group only showed 50% dpamine uptake.  to 80% of control, 
whereas MPP+ treatment group only showed 50% dpamine uptake.  
Visualisation of TH neuron morphology through flouresecence microscopy 
shows clear neuroprotective effect of AK-P4T (Fig 3G).   
Together, the results demonstrate the protective effect of AK-P4T 
convincingly in PD cell culture models.   
 
Intravenous Delivery of AK-P4T effectively activates PKD1 in animal 
models 
After characterizing the neuroprotective effect of the activator peptide (AK-
P4T) in cell culture models of PD, we examined the ability of AK-P4T to 
activate PKD1 in the brain.  First, we tested different methods to deliver the 
activator peptide effectively into the brain.  Different doses of AK-P4T peptide 
were delivered intra-peritoneally using different administration paradigms.  
The intra-peritoneal Ak-P4T delivery of 5mg/kg activated PKD1 in mice after 
4 h of injections but the fold increase of PKD1 in the substantia nigra was not 
significant as monitored by the activation loop phosphorylation 
(PKD1pS744/pS748) (Fig 4A).  So we pursued different routes to deliver AK-
P4T.  We used nanopolymers to deliver the peptides. As detailed in the 
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materials and methods section, we used polymer (50:50 CPTEG:CPH) to 
coat the peptides and delivered them intra-nasally. But the polymer 
conjugated Ak-P4T peptide through this delivery route in mice did not activate 
PKD1 in the substantia nigral region (Fig 4B).  So we tried the intra-venous 
injections to deliver the peptides.  We administered 5mg/kg peptide through 
the tail vein of the mice and sacrificed at 4 and 8 hr.  As shown in Fig 4C, the 
intra-venous Ak-P4T peptide delivery activated PKD1 in the substantia-nigra 
starting at 4 h.  We see a similar trend of PKD1 activation in striatum starting 
at 4h, with a (Fig 4D).  Quantification of the activation loop phosphorylation 
(PKD1pS744/pS748) at 8 h shows a 1.4 fold increase in PKD1 activation in 
the substantia nigra and a 2 fold increase in PKD1 activation in the striatum 
(Fig 4c and D).  Further, intra-venous administration of Ak-P4T also 
increased PKD1 S916 phosphorylation starting at 4h confirming the Ak-P4T  
allosteric activation of PKD1(Fig 4E).   
Collectivley, these results show that intra-venous delivery of the Ak-P4T 
peptide can actiavte PKD1 effectively. 
 
AK-P4T protects against dopaminergic degeneration in PD animal 
model 
Next, we examined the neuroprotective efficacy of AK-P4T in a sub-acute 
MPTP mouse model of PD.  Since AK-P4T activated PKD1 through intra-
venous administration, we chose this delivery route.  Animals were 
administered AK-P4T (5 mg/kg body weight) 24 h before MPTP 
administration. Animals were then cotreated with AK-P4T and MPTP (25 
mg/kg i.p.) daily for 5 days and the AK-P4T treatment was continued for 7 
more days and the animals were sacrificed.  Saline- and vehicle-injected 
animals were used as controls.  To assess the protective effect of Ak-P4T, 
we first examined whether AK-P4T could block MPTP-induced loss of striatal 
150 
 
dopamine and its metabolites.  As shown in Fig. 5A, MPTP treatment induced 
loss of dopamine (>75%) (A), DOPAC (>80%) (B), in mouse striatum.  The 
dopamine levels were determined to be 72.21 ± 16.67, 18.56 ± 2.18 and 
38.95 ± 5.365 pg/mg protein in control-, MPTP-, and MPTP + 5 mg/kg AK-
P4T treated animals, respectively.  Pretreatment with 5 mg/kg AK-P4T 
afforded more than 50% protection against MPTP-induced striatal dopamine 
loss.  Similar results were found for dopamine metabolites DOPAC and HVA 
(Fig. 5B and C). Further, the western blotting of striatal lysates for Tyrosine 
Hydroxylase (TH) shows TH levels rescued in the AK-P4T group (Fig. 5D). 
Further, immunochemical DAB staining shows the rescue of TH levels in AK-
P4T co-treatment group compared to MPTP group in both striatal and 
substantia nigra sections (Fig. 5E). Western blotting of substantia nigra 
lysates shows that PKD1 activation is preserved in AK-P4T co-treated groups 
(Fig. 5E).  Collectively, these data suggest that AK-P4T treatment could 
afford protection against MPTP-induced nigro-striatal dopamine and 
dopamine metabolite loss in animal PD models by persistent activation of 
PKD1.   
 
AK-P4T attenuates motor deficits 
With evidence suggesting that AK-P4T protects against MPTP-induced 
dopamine and TH neuronal loss, we next determined whether AK-P4T 
treatment could also afford protection against MPTP-induced motor deficits.  
We compared the motor activity of vehicle plus control peptide, MPTP plus 
control peptide, and MPTP plus AK-P4T-treated animals, using a VersaMax 
computerized activity monitoring system (Accuscan, Columbus, OH). This 
system uses infrared sensors to measure repetitive movements both in the 
horizontal and vertical planes in real time, and it provides color-coded output. 
Representative activity maps of the animals are presented in Fig. 6A. The 
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cumulative behavioral activities are monitored and expressed as percentage 
of the vehicle-treated group, and they were obtained at day 9 of the sub-
acute MPTP treatment paradigm.  Statistical analyses of both raw data and 
percentage of control showed significant differences in various behavioral 
activities.  The data indicate that the horizontal motor activity (>20% 
reduction), number of movements (>20% reduction), vertical motor activity 
(>40% reduction), vertical movement time (>50% reduction) total distance 
travelled (>20% reduction), ), vertical number of movements (>40% 
reduction), movement time (>20% reduction), stereotypy count (>20% 
reduction), margin distance (>20% reduction), margin time (>20% reduction), 
stereotypy time (>20% reduction),  rearing activity (>40% reduction), rearing 
time (>50% reduction), were significantly reduced in MPTP-treated animals 
compared with the vehicle-treated group (Fig 6B-N).  However, administration 
of AK-P4T almost completely restored all the behavioral and locomotory 
patterns of MPTP-treated animals to the levels observed in control animals 
(Fig 6B-N).  These results demonstrate AK-P4T treatment attenuates MPTP-
induced locomotor deficits in pre-clincial models of mice. 
 
Discussion 
The present study demonstrates that a rationally designed allosteric activator 
peptide of PKD1 protects against dopaminergic neurodegeneration in pre-
clinical models of Parkinson’s disease.  Extensive characterization of PKD1 
signal transduction in pre-clinical models of PD showed that, positive 
modulation of PKD1 can be a novel therapeutic strategy against PD.  Herein, 
we report for the first time some key findings pertinent to neuroprotection 
against Parkinson’s disease: (i) rationally designed peptide modulators based 
on the substrate-like and pseudo-substrate like sequences present in the 
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regulatory fragment activate or inhibit PKD1 allosterically by mimicking and 
disrupting the native intra-protein interactions  (ii) one of the peptide 
activators AK-P4 protected against both 6-OHDA and MPP+ induced toxicity 
in N27 dopaminergic cells (iii) TAT47-57 peptide conjugated AK-P4 (AK-P4T) 
rescued TH+ neurons against MPP+ and prevented dopaminergic 
neurodegeneration in primary mesencephalic cultures (iv) effective delivery of 
AK-P4T through intravenous administration activated PKD1 and protected 
against MPTP-induced motor deficits, striatal dopamine depletion, and nigral 
dopaminergic neuronal loss in a sub-acute MPTP animal model.  To our 
knowledge, this is the first demonstration of a novel neuroprotective strategy 
against PD by positivley modulating an anti-apoptotic kinase PKD1 using a 
rationally designed allosteric activator.    
 
Based on these findings we hypothesized that prolonging the activation of the 
survival switch PKD1 through a specific activator can prevent or delay PD 
progression.  Recently, Peptide based drugs have successfully entered 
clinical trials or approved as a treatment for many disorders.  Additionally, 
they are specific with fewer side effects compared to small molecule drugs 
(24).  We utilised the vast protein databases and developed a new approach 
to find PKD1 modulators.  We began with our hypothesis that interfering with 
intra-protein interactions of PKD1 can modulate PKD1.  PKD1 in native state 
is auto-inhibited by its regulatory fragment consisting of the cystine rich 
domains and pleckstin homology (PH) domain but do not have a pseudo-
substrate region like some PKC family members.  Careful analysis of PKD1 
protein sequence revealed highly conserved regions similar to the consensus 
substrate sequence.  Our results suggest that peptides synthesized 
mimicking the pseudo-substrate like region activates the kinase, while 
peptide mimicking the substrate like region inhibits the kinase.  Particulary, 
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the peptide AK-P4 mimicking the highly conserved pseudo-substrate like 
region in the PH domain protected against both 6-OHDA and MPP+ mediated 
toxicity.   
Previous studies have shown that the cell penetrating peptides derived from 
the trans-activating transcriptional activator (TAT) from HIV can be used to 
deliver therapeutic peptides (25) (26).  AK-P4 Peptide was conjugated with 
the TAT47-57 (AK-P4T) to facilitate effective delivery across the blood-brain 
barrier.  Even though, progress has been made to deliver therapeutic 
peptides for neurodegenerative disorders, effective peptide drug delivery 
remains as an area for improvement (27).  We tested different routes and 
methods to effectively deliver the peptide; inta-peritoneal administration, intra-
nasal administration of peptides coated with nanopolymers, intra-venous 
administration.  Our results indicate that only AK-P4T peptide administered 
through intra-venous route can activate PKD1 in the nigro-striatal pathway 
after effectively crossing the blood-brain barrier.  We used intra-venous route 
for all our studies, even though exploration of other methods are underway.   
Our findings in pre-clinical models using MPTP demonstrate that AK-P4T 
delieverd through intra-venous route activates PKD1, and rescues 
dopaminergic neurons from succumbing to cell death.  Further the nigro-
striatal dopaminergic neuronal loss is reduced improving the neuro-
tansmission function of dopaminergic neurons.  This considerably improves 
the motor function as the mice behave like the control group.   
 In conclusion, we demonstrate that activation of the novel protective 
signaling mechanism mediated by PKD1 in dopaminergic neurons by a 
peptide based PKD1 activator offers neuroprotection in pre-clincal models of 
PD by slowing down or stopping dopaminergic degeneration. This drug offers 
therapeutic promise for PD.   
154 
 
Abbreviations   
PD, Parkinson’s disease; PKD1, Protein kinase D1; MAPK, Mitogen-activated 
protein kinases PKCδ, Protein kinase C delta; CAMK, Ca 2+ /Calmodulin-
Dependent Protein Kinase II; JNK, c-Jun N-terminal kinases; LRRK2, 
Leucine-rich repeat kinase 2 (LRRK2);MLK, Mixed-lineage kinase; ROS, 
Reactive oxygen species; MnSOD, Manganese superoxide dismutase; WB, 
Western Blot; PKC,  Protein kinase C; PKCα, Protein kinase C alpha. 
Competing interests 
The authors declare the have no competing interests. 
Authors' contributions 
All authors read and approved the final manuscript.  
Acknowledgements  
The authors also acknowledge Ms. Mary Ann deVries for her assistance in 
the preparation of this manuscript. This work was supported by National 
Institutes of Health (NIH) [Grants NS 38644, ES10586, NS65167 and ES 
19267]. The W. Eugene and Linda Lloyd Endowed Chair to A.G.K. is also 
acknowledged.  
 
References 
1. T. M. Dawson, V. L. Dawson, Science 302, 819 (Oct 31, 2003). 
2. S. Przedborski, Parkinsonism Relat Disord 11 Suppl 1, S3 (Jun, 
2005). 
3. W. Dauer, S. Przedborski, Neuron 39, 889 (Sep 11, 2003). 
4. D. A. Di Monte, Lancet Neurol 2, 531 (Sep, 2003). 
155 
 
5. A. Kanthasamy, Kitazawa M, Kaul S, Anantharam V, Kanthasamy 
A.G., J Neurochem 81(suppl): 76.  (2002). 
6. G. Veurink, S. J. Fuller, C. S. Atwood, R. N. Martins, Ann Hum Biol 
30, 639 (Nov-Dec, 2003). 
7. K. A. Malkus, E. Tsika, H. Ischiropoulos, Mol Neurodegener 4, 24 
(2009). 
8. J. K. Andersen, Nat Med 10 Suppl, S18 (Jul, 2004). 
9. P. Jenner, Parkinsonism Relat Disord 9, 131 (Jan, 2003). 
10. S. Tan, M. Wood, P. Maher, J Neurochem 71, 95 (1998). 
11. S. Przedborski, M. Vila, Ann N Y Acad Sci 991, 189 (Jun, 2003). 
12. S. Kaul et al., J Biol Chem 280, 28721 (Aug 5, 2005). 
13. Neurology 69, 1480 (Oct 9, 2007). 
14. A. Asaithambi, A. Kanthasamy, H. Saminathan, V. Anantharam, A. G. 
Kanthasamy, Mol Neurodegener 6, 43 (2011). 
15. P. Storz, H. Doppler, A. Toker, Mol Cell Biol 24, 2614 (Apr, 2004). 
16. J. S. Wu, T. N. Lin, K. K. Wu, J Cell Physiol 220, 58 (Jul, 2009). 
17. C. Yang et al., Diabetes 50, 2598 (Nov, 2001). 
18. M. T. Kunkel, A. Toker, R. Y. Tsien, A. C. Newton, J Biol Chem 282, 
6733 (Mar 2, 2007). 
19. G. R. Budas, E. N. Churchill, D. Mochly-Rosen, Pharmacol Res 55, 
523 (Jun, 2007). 
20. G. R. Budas, T. Koyanagi, E. N. Churchill, D. Mochly-Rosen, Biochem 
Soc Trans 35, 1021 (Nov, 2007). 
21. K. Nishikawa, A. Toker, F. J. Johannes, Z. Songyang, L. C. Cantley, J 
Biol Chem 272, 952 (Jan 10, 1997). 
22. T. Iglesias, E. Rozengurt, J Biol Chem 273, 410 (Jan 2, 1998). 
23. E. N. Churchill, N. Qvit, D. Mochly-Rosen, Trends Endocrinol Metab 
20, 25 (Jan, 2009). 
156 
 
24. S. Lien, H. B. Lowman, Trends Biotechnol 21, 556 (Dec, 2003). 
25. R. Begley, T. Liron, J. Baryza, D. Mochly-Rosen, Biochem Biophys 
Res Commun 318, 949 (Jun 11, 2004). 
26. L. Chen et al., Chem Biol 8, 1123 (Dec, 2001). 
27. I. Brasnjevic, H. W. Steinbusch, C. Schmitz, P. Martinez-Martinez, 
Prog Neurobiol 87, 212 (Apr, 2009). 
28. V. Anantharam, M. Kitazawa, J. Wagner, S. Kaul, A. G. Kanthasamy, 
J Neurosci 22, 1738 (Mar 1, 2002). 
29. Y. Yang, S. Kaul, D. Zhang, V. Anantharam, A. G. Kanthasamy, 
Molecular and Cellular Neuroscience 25, 406 (2004). 
30. A. G. Kanthasamy et al., Free Radic Biol Med 41, 1578 (Nov 15, 
2006). 
31. F. Sun et al., J Cell Mol Med 12, 2467 (Dec, 2008). 
32. D. Zhang, A. Kanthasamy, Y. Yang, V. Anantharam, J Neurosci 27, 
5349 (May 16, 2007). 
33. M. Kitazawa, V. Anantharam, A. Kanthasamy, A. G. Kanthasamy, 
Neurotoxicology 25, 589 (Jun, 2004). 
34. H. Afeseh Ngwa et al., Toxicol Appl Pharmacol 240, 273 (Oct 15, 
2009). 
 
 
 
 
 
 
 
 
 
157 
 
 
 
 
 
 
 
 
 
158 
 
 
 
 
 
 
 
 
 
159 
 
 
 
 
 
 
160 
 
 
 
 
161 
 
 
 
 
 
162 
 
 
163 
 
 
 
 
 
 
 
 
 
 
 
164 
 
Figure legends 
Figure1. Pharmacological activation of PKD1 by Rosiglitazone shows  
neuro-protection  in  N27 cells and primary neurons 
N27 dopaminergic cells were treated with MPP+ (300 µM) for 0-20 h and 6-
OHDA (100 µM) for 0-4 h and blotted for PKD1 activation loop 
phosphorylation pS744/pS748 (A & B). N27 dopaminergic cells transiently 
transfected with 5 μM  PKD1 S744E/S748E and 5 μM vector plasmid were treated 
with or without 300 μM MPP+ and monitored for cytotoxicity at various time 
points using sytox green. (C). N27 cells were co-treated with or without 50 
µM PKD1 inhibitor kb-NB 14270 and monitored for cell death during MPP+ 
treatment (D). N27 cells were treated with 10 µM Carbachol, 50 µM 
Desmopressin, 100 µM Rosiglitazone, 100 ng/ml BMP2, and 25mM Glucose 
and probed for PKD1 (pS744E/pS748E)  and PKCδ cleavage (E). N27 cells 
transfected with 5μM PKD1 kinase activity reporter (PKD1-KAR) plasmid and 
5 μM vector plasmid were treated with Rosiglitazone and monitored for 
CFP/YFP FRET change in a high-throughput format (F). N27 cells were co-
treated with or without 10 µM Rosiglitazone and monitored for cell death 
during 6-OHDA treatment (G). Tyrosine Hydroxylase (TH) positive primary 
mesencephalic neurons treated with co-treated with or without 10 µM 
Rosiglitazone were monitored for changes in neuronal morphology and 
neuroprotection using immune-flourescence (H). p<0.001 denotes significant 
difference between treatment groups from n≥6. (n= 6-8).  
Figure 2. Rationally designed peptide activates PKD1  
Alignment of amino acid sequences of PKD1 regulatory fragment between 
distantly related different organisms rat, mouse and C.elegans, shows the 
presence of the consensus substrate-like motif (LXRXXS/T) and 
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pseudosubstrate-like motif (LXRXX#, LXR##, #- serine or threonine residue 
replaced mostly by a hydrophobic/aliphatic residue) (A). Alignment of mouse 
PKD isoforms PKD1, PKD2, PKD3 amino acid sequences containing the four 
(AK-P1, AK-P2,AK-P3, AK-P4) substrate-like (LXRXXS/T) and 
pseudosubstrate-like region shows high level of conservation (B).  5 aa 
peptide AK-P5 (54-58 amino acids) from the cysteine rich domain 1 (pseudo-
14-3-3γ), a 9 aa peptide AK-P6 (79-87 amino acids) from the pleckstrin 
homology (PH) domain (pseudo- Gβγ) and a 5 aa scramble control peptide 
AK-P7 (135-139 amino acids) were synthesized (C). Primary screening: N27 
cells were treated with the peptides were probed for PKD1 (pS744E/pS748E) 
at 60 min (D). Secondary screening: N27 cells were treated with the peptides 
and PKD1 kinase activity was measured using [32P] kinase assay; the bands 
were quantified for the graph *, p<0.05, **, p<0.01, ***, p<0.001 denotes 
significant difference between the control peptide and activator/inhibitor 
peptide groups (E). [32P] kinase assay was performed using recombinant 
human PKD1 protein in a cell-free system to test the specific and direct role 
of AK-P4 peptide (F). N27 cells transfected with 5μM PKD1 kinase activity 
reporter (PKD1-KAR) plasmid and 5 μM vector plasmid were treated with AK-
P4 and monitored for CFP/YFP FRET change (G).  
Figure  3. AK-P4 protects against neuronal death in  dopaminergic 
neurons 
N27 dopaminergic cells were treated with 6-OHDA (100 μM) and MPP
+ (300 
μM) with or without control peptide, AK-P3, AK-P4 and probed for cytotoxicity 
(A, B). N27 cells were treated with 6-OHDA (100 μM) and co-treated with 
different doses (0-10 μM) AK-P4T (AK-P4 was tagged with aa HIV-TAT 
transporter peptide) and probed for cytotoxicity (C). Mouse primary 
mesencephalic neurons were co-treated with or without 50 nM AK-P4T and 
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monitored for number of protected TH  neurons (D), TH neurite length (E), 
neurotransmission function (F), length viability during MPP+ treatment using 
3H dopamine uptake assay (G), TH neuronal morphology (G). *, p<0.05, **, 
p<0.01, ***, p<0.001 denotes significant difference between the control  and 
treatment groups. 
Figure 4. In-vivo delivery of AK-P4T  
C57Bl/6 mice was administered AK-P4T through inta-peritoneal injections 
(A), intra-nasal administration of peptides coated with nanopolymers (B), 
intra-venous administration (C) and monitored for PKD1pS744/pS748 in the 
substantia nigra and striatum (D). C57Bl/6 mice was administered AK-P4T 
through intra-venous injections and monitored for PKD1pS916 in the 
substantia nigra.   
Figure 5. AK-P4T mediated PKD1 activation rescues neurotransmitter 
levels and dopaminergic function in pr-clinical model  of PD   
Neuroprotective efficacy of AK-P4T was examined in a sub-acute MPTP 
mouse model of PD.  Animals pre-treated and co-treated with AK-P4T and 
control peptide (5 mg/kg body weight) were sacrificed at the end of the study 
and the following analyses were performed: Striatal brain lysates were 
analysed for Dopamine (A), DOPAC (B), HVA (C) levels were measured 
using HPLC. Striatal lysates were blotted for Tyrosine Hydroxylase (TH) (D). 
Immunohistochemical analysis of dopaminergic neurons staining for tyrosine 
hydroxylase (TH) DAB staining were performed from Mouse brain slices cut 
at the level of the striatum (E) and substantia nigra (F). Substantia nigral 
lysates were blotted for Tyrosine Hydroxylase (TH) and PKD1 pS744/S748 
(G). 
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Figure 6. AK-P4T completely attenuates behavioral and locomotory 
deficits in pre-clinical PD model 
Behavioral and locomotory changes were measured after AK-P4T and control 
peptide (5 mg/kg body weight) co-treatment in the sub-chronic MPTP mouse 
model of PD.  Following parameters were measured using versamex: 
horizontal motor activity, number of movements, vertical motor activity, 
vertical movement time, total distance travelled, vertical number of 
movements, movement time, stereotypy count, margin distance, margin time, 
stereotypy time, rearing activity, rearing time, were significantly reduced in 
MPTP-treated animals compared with the vehicle-treated group (Fig 6B-N). 
Figure 7. Working Model for AK-P4T activation mechanism  
1. Regulatory fragment auto-inhibits catalytic fragment through inhibitory 
pockets containing the pseudo-substrate like sequences. 2. Peptide 
regulators (AK-Series) mimics the inhibitory pockets, interacts with the 
catalytic fragmnet and release the auto-inhibition. 3. Persistent activation of 
PKD1 promotes neuronal survival and neurodegeneration 
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Chapter VI: GENERAL CONCLUSIONS 
The major findings of each research chapter included in this dissertation have 
been described and the implications for dopaminergic degeneration have 
been interpreted in the discussion section of each individual chapter. This 
section presents an overview of the results and findings of this dissertation, 
with special emphasis on the role of the survival switch, protein kinase D1 
signal transduction, with respect to dopaminergic degeneration and 
development of a PKD1 activator for neuroprotection. 
A novel oxidative signal transduction circuit controlling neuronal survival and 
death during oxidative stress in the dopaminergic system.  
Our results demonstrate that the PKD1-mediated protective mechanism is a 
novel signal transduction pathway that regulates cell survival and cell death 
during various stages of oxidative stress in dopaminergic neuronal cells. In 
the early stages of oxidative insult, PKCδ acts as an oxidative stress 
sensor/regulator and activates PKD1, which serves as a key compensatory 
protective mechanism against oxidative damage.  However, prolonged 
oxidative insult creates a homeostatic imbalance, causing deactivation of 
extensive neuronal damage.   We report that cleaved active PKCδ (PKCδ-
CF) phosphorylates the activation loop (Ser744/Ser748) of PKD1 and 
activates the kinase during the early stages of H2O2- and 6-OHDA-induced 
oxidative stress in dopaminergic neuronal cells.  Multiple phosphorylation 
sites on PKD1 seem to be important for its activation loop phosphorylation, 
depending on the cell types and stimuli.  Our data suggest that Ser 916 
phosphorylation in the C-terminal of PKD1 may open the conformation for full 
activation of the kinase through activation loop phosphorylation during 
oxidative stress in dopaminergic neurons. When the constitutively active 
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PKD1 mutant (PKD1S744E/S748E) is overexpressed, dopaminergic cells are 
resistant to H2O2- and 6-OHDA-induced neurotoxicity, even during the late 
stages of oxidative stress, which demonstrates that PKD1 activation protects 
against oxidative damage.   
The anti-apoptotic PKD1 signal transduction is regulated by Fyn kinase- 
PKCδ in in vitro and in vivo models of PD. 
Using the classic MPTP disease model to induce dopaminergic degeneration 
and the powerful transgenic mouse models as tools, we further investigated 
the biomedical importance of this novel survival signaling pathway in 
dopaminergic degenerative processes. Our current results show that the 
parkinsonian specific toxicant MPP+ induced PKD1 activation in a PKCδ 
dependent mechanism.  Results from N27 cells and primary mesencephalic 
neurons show that PKCδ inhibition prevents PKD1 activation during MPP+-
induced oxidative damage.  Our findings were strengthened by using PKCδ (-
/-) (PKCδ knockout) mice subjected to acute MPTP treatment.  Dopaminergic 
neurons from PKCδ (-/-) mice exposed to MPTP/MPP+ treatment do not 
show PKD1 activation.  Following this observation, we also looked at the key 
upstream regulator of PKCδ-PKD1 signaling.  Fyn kinase has recently been 
shown to regulate PKCδ proteolytic activation in both cell culture and animal 
models of PD(95).  We examined whether Fyn kinase acts as an upstream 
regulator of PKD1 activation via PKCδ.  Dopaminergic neurons from Fyn (-/-) 
(Fyn kinase knockout) mice treated with MPTP do not show PKD1 activation, 
which is in agreement with the results obtained in cell culture models treated 
with MPP+. Our examination of samples obtained from post-mortem human 
PD patients showed high levels of PKD1 activation compared to age matched 
controls.  Put together, we suggest that the anti-apoptotic PKD1 signaling 
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controlled by Fyn-PKCδ is activated as an early protective compensatory 
mechanism in Parkinson’s disease. 
Rationally designed peptide activates PKD1, protects against dopaminergic 
degeneration and rescues normal neurochemical and behavioral patterns in 
pre-clinical models of PD. 
Based on these findings, we hypothesized that prolonging the activation of 
the survival switch PKD1 through a specific activator can prevent or delay PD 
progression.  PKD1 in its native state is auto-inhibited by its regulatory 
fragment consisting of the cysteine rich domains and pleckstin homology 
(PH) domain. We rationally designed peptide mimics to interfere with intra-
protein interactions and modulate PKD1. We screened the peptides to 
activate PKD1 using different strategies, including the radioactive kinase 
assay and the genetic reporter based assay. We developed the genetic 
reporter assays in high throughput format for monitoring PKD1 kinase activity. 
The peptide AK-P4, mimicking the highly conserved pseudo-substrate like 
region in the PH domain, activated and protected against both 6-OHDA and 
MPP+ mediated toxicity.   
Previous studies have shown that the cell penetrating peptides derived from 
the trans-activating transcriptional activator (TAT) from HIV can be used to 
deliver therapeutic peptides (96).  AK-P4 Peptide was conjugated with the 
TAT47-57 (AK-P4T) to facilitate effective delivery across the blood-brain 
barrier.  Although progress has been made in delivering therapeutic peptides 
for neurodegenerative disorders, effective peptide drug delivery needs to be 
improved.  We tested different routes and methods to effectively deliver the 
peptide; our results indicate that only AK-P4T peptide administered through 
the intravenous route can activate PKD1 in the nigrostriatal pathway after 
crossing the blood-brain barrier.  Our findings in the subchronic MPTP model 
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demonstrate that AK-P4T delivered intravenously activates PKD1, and 
rescues dopaminergic neurons from death.  Further, the nigrostriatal 
dopaminergic neuronal loss is reduced, and neurotansmission and motor 
function are considerably improved to control levels.   
In summary, proteolytically activated catalytic PKCδ fragment (PKCδ-CF) 
phosphorylates protein kinase D1 (PKD1), resulting in PKD1 activation, which 
further counteracts early stage oxidative damage and protects dopaminergic 
neurons.  Positive modulation of PKD1 using genetic or pharmacological 
methods protects against oxidative damage, whereas negative modulation of 
PKD1 exacerbates oxidative damage. PKD1 signaling is biomedically 
important for survival, as shown in MPTP models. Fyn Kinase acts as an 
upstream regulator of PKCδ – PKD1 signaling both in vitro and in vivo.  The 
activation of the PKD1 protective signaling mechanism mediated by a 
rationally designed peptide activator offers neuroprotection in preclinical 
models of PD.  The development of our translational strategy shows 
therapeutic promise for PD. 
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